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“Bones can break, muscles can atrophy, glands can loaf, even the brain can go to sleep, without 
immediately endangering our survival, but when the kidneys fail to manufacture the proper kind 
of blood neither bone, muscle, gland nor brain can carry on”. 
Homer Smith, From Fish to Philosopher (1).
It is probably of limited value to ascribe the kidney a function superior to that of other organs; 
this quote merely indicates the importance of the kidney for the maintenance of the harmoni-
ous composition of body fluids – a function the kidney performs in a way that joins efficacy with 
elegance. Some of these processes will be lined out in this introductory chapter. The first section 
gives an overview of kidney development, anatomy and function. This is followed by a descrip-
tion of malfunction of the kidney and its consequences in the second part, which focuses on the 
development of proteinuria. Complete failure of the kidneys necessitates kidney replacement 
therapy or transplantation. The third section gives an overview of long-term problems that limit 
the success of transplantation as a treatment modality. This is followed by an outline of the thesis.
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THE KIDNEY: DEVELOPMENT, 
ANATOMY AND FUNCTION
Overview of kidney anatomy and function
The kidney is a bean-shaped organ with a length of about 11 cm and a weight of approximately 
150 grams. The kidneys are located in the retroperitoneal space at either side of the vertebral 
column, just below the diaphragm. The concave part of the kidney forms the renal sinus that 
contains the renal vessels, nerves, and the renal pelvis. The arterial blood supply sprouts directly 
from the aorta; the renal veins drain into the vena cava. Via the ureter the renal pelvis is continu-
ous with the bladder and the outside world. The functional tissue of the kidneys surrounds the 
renal sinus, and is divided into cortex and medulla. 
The human kidney contains about one million functional units or nephrons (30,000 in rats). A 
nephron consists of a filtration body – a tuft of anastomosing capillaries called glomerulus – 
connected to a long, tortuous tubule. The glomerular capillaries function as a microfilter that 
restricts passage of blood cells and proteins, but is permeable for smaller plasma components 
and waste products dissolved in the plasma water. Some ten percent of the blood that flows into 
the glomerulus is filtered, and the ultrafiltrate is delivered into the tubule (see below for a more 
comprehensive description of glomerular filtration). The blood that escapes filtration flows into 
the capillary network in the tubular compartment. Here, the tubular epithelial cells exchange 
substances between the fluids in the tubular lumen and the blood, thus gradually converting 
the ultrafiltrate into urine. Most of the exchange is from tubular lumen to the blood: the tubular 
epithelial cells reabsorb almost all water filtered in the glomerulus, together with salts, glucose, 
amino acids, vitamins, and other small molecules. But there is also active excretion of substances 
from the blood into the tubular lumen. When the urine via the collecting ducts flows into the 
renal pelvis, it is a concentrated solution of dissonants that the nephron has produced to maintain 
the harmonious composition of the blood.
In the next paragraphs, the microscopic anatomy of the nephron is described in some more detail, 
along with an overview of glomerular filtration. First, a brief overview of kidney development is 
provided. 
PART 1
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Development
Pathophysiologic processes sometimes recapitulate mechanisms that play a role in embryonic 
development (2). It is therefore of importance to understand some of the processes that take 
place during the organogenesis of the kidney. This paragraph describes the development of the 
kidney, with a focus on the development of the glomerulus. For more extensive overview of the 
developmental processes and their molecular regulation the reader is referred to several reviews 
on the topic (3-7).
The kidneys develop from the intermediate mesoderm of the embryo. The intermediate meso-
derm is made up of two tissue compartments, 
the nephric duct and the nephrogenic cord, that 
form the different structures of the kidney. Deri-
vates of the nephric duct form the collecting sys-
tem of the kidney. The glomerular and tubular 
parts of the nephron arise from the nephrogenic 
cord.
During embryonic development, a sequential de-
velopment of three more or less separate excre-
tory systems, referred to as the pro-, meso-, and 
metanephros, takes place through interaction 
between the nephrogenic cord and the nephric 
duct. The pronephros is formed first and most 
cranial. It is a transient, non-functional structure 
that consists of a few tubules that connect to 
the nephric duct. Caudal to the pronephros the 
nephric duct induces the formation of the me-
sonephros, a structure consisting of a glomeru-
lus and a relatively simple tubule. Though also 
transient, the mesonephron forms a functional 
excretory organ (8). The blood supply to each 
glomerulus sprouts directly from the aorta, while 
the tubules drain into the nephric duct that at 
this stage of development is called the meso-
nephric or Wolffian duct. 
Subsequent to the development of the me-
sonephros, and again more caudally, the 
Figure 1. Embryonic development of the glomerulus. In the 
S-shaped body, the presumptive podocytes form a columnar 
epithelium that is continuous with the tubular epithelial cells. 
Endothelial and mesangial cells migrate into the vascular cleft 
(a). In the capillary loop stage, further differentiation of podo-
cytes takes place (b). The presumptive podocytes start to form 
foot processes that interdigitate with those of neighboring 
cells (d). Differentiation of podocytes stimulates further de-
velopment of endothelial and mesangial cells (c). See text for 
further details. Adapted from (152), with kind permission from 
S. Karger AG and the author.
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development of the permanent kidney or metanephros starts. The metanephros develops through 
reciprocal interactions between the mesonephric duct and a condensed part of mesenchyme re-
ferred to as the metanephric blastema. The metanephric blastema induces the formation of a 
bud from the mesonephric duct. This ureteric bud grows into the metanephric blastema, and 
induces it to form a cap on the ureteric bud. The mesenchymal cap in turn induces dichotomous 
branching of the ureteric bud. The close apposition of the tips of the ureteric bud and the prolif-
erating mesenchyme leads to continuous branching of the ureteric bud (a movie of ureteric bud 
branching will play in the upper right corner when quickly thumbing through the pages of this 
book from back to front. Courtesy of dr. Frank Constantini, Columbia University Medical Center). 
This reciprocal stimulation eventually produces an arborized system of ducts, of which each final 
branch is in close proximity to a mesenchymal condensate. Remodeling, ie, coalescence of the 
branched ducts shapes a system of collecting ducts that via the renal calyces, renal pelvis and 
ureter drains into the bladder; the mesenchymal condensate undergoes a sequence of events that 
transforms it into a functional nephron that connects to the collecting duct. 
The invasion of the ureteric bud into the metanephric mesenchyme rescues the mesenchymal 
cells from apoptosis, and induces expression of the genes paired box 2 (PAX2) and Wilms Tumor 1 
(WT1). In the presence of PAX2 and WT1 expression, and through stimulation by Wnt-4 and Bone 
morphogenetic protein 7 (BMP-7), mesenchymal cells acquire an epithelial phenotype, a process 
called mesenchymal-to-epithelial transition (MET) (9-12). After completing MET, the condensed 
cells start to form a vesicle. The renal vesicle then undergoes a series of morphologic changes: 
it first changes into a comma-shaped body that then elongates and folds back on itself to form 
an S-shape (figure 1a). The molecular mechanisms that regulate this process are not completely 
known. From this stage onward, epithelia in different parts of the S-shaped body start to dif-
ferentiate, thus forming the at least 15 different epithelial cell lineages of the future nephron 
(5). During differentiation, expression of PAX2 is downregulated, probably through increasing 
expression of WT1 (13). This occurs most prominently in the proximal part of the S-shaped body, 
where the future podocytes show high expression of the WT1 protein, which continues to be a 
marker of podocytes throughout differentiation and in the mature glomerulus (14,15). The pre-
sumptive podocytes that surround the capillary tuft are first organized as a columnar epithelium, 
but progressively lose their lateral cell-cell adhesions and begin to form cellular extensions called 
foot processes. Eventually, the cell bodies of the podocytes float freely in the urinary space, and 
the adhesion between two adjacent podocytes is restricted to the slit diaphragm between the in-
terdigitating foot processes (figure 1d) (16,17). Exactly which signals drive foot process formation 
is currently unknown, although the interaction with the GBM seems to be of crucial importance 
(17).
In the S-shaped stage of glomerular development, the presumptive podocytes express vascular 
endothelial growth factor A (VEGF-A) (18). This, either through stimulation of local angioblasts or 
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through incorporation of endothelial cells sprouting from nearby vessels (19,20), leads to the re-
cruitment of endothelial cells into the cleft of the S-shaped body adjacent to the future podocytes 
(figure 1a,b) (14,21). In turn, endothelial cells of the capillaries express platelet-derived growth 
factor-B (PDGF-B), thus recruiting mesangial cells – of which the origin remains elusive (22) – that 
express PDGF receptor-β (figure 1c) (23). Through further branching of capillaries, differentiation 
of epithelial cells, and deposition of extracellular matrix, the three glomerular cell types shape the 
glomerulus (17,23).
The tubules elongate and differentiate and the most distal part of the S-shaped body connects 
with the branch of the ureteric bud that has developed into the collecting duct. By week 34 of 
fetal development, the formation of nephrons is complete. Further differentiation of the renal 
tissues continues postnatally (24).
The glomerulus
As the renal artery enters the kidney, it subdivides in smaller arteries and arterioles. The last 
branch, the afferent arteriole, gives rise to a tuft of anastomosing capillaries called the glomeru-
lus. Like all capillaries, the glomerular capillary lumen is lined by endothelial cells. At the inside, 
the tuft of capillaries is held together by mesangial cells, while the outer aspect of the capillaries 
is covered by the visceral epithelial cells or podocytes. The glomerulus is surrounded by Bowman’s 
capsule and its parietal epithelial cells. Bounded by the visceral and parietal epithelial cells is the 
urinary space, which is continuous with the lumen of the tubuli. The different glomerular cell 
types will be discussed, followed by an overview of podocyte cell biology and glomerular filtra-
tion. 
Glomerular cell types
The endocapillary lumen is lined with endothelial cells that are fenestrated. The cells rest on the 
glomerular basement membrane (GBM). With special staining techniques, a thick layer of gly-
cocalyx has been visualized on glomerular endothelial cells, a finding that may shed light on the 
contribution of endothelial cells to glomerular filtration (25-27). 
Mesangial cells are located between the glomerular capillaries, and reinforce the structure of the 
glomerulus. Contractile extensions of the mesangial cells bridge opposing portions of the GBM, 
and balance the outward forces of the blood pressure (28). Additionally, contraction of the me-
sangial cell myosin filaments provides a mechanism for control of glomerular blood flow. In this 
regard, mesangial cells resemble smooth muscle cells. Mesangial cells also have macrophage-like 
15the glomerulus > glomerular extracellular matrix
functions, through which they are able to clear macromolecules and immune complexes from 
the glomerulus. 
The outer aspect of the GBM is covered by visceral epithelial cells, or podocytes. These are highly 
differentiated cells with a complex, arborized phenotype. The podocyte cell body floats in the 
urinary space and gives rise to primary processes. The podocyte attaches to the GBM by means of 
foot processes, further cellular extensions that sprout perpendicularly from the major processes. 
Foot processes of two adjacent primary processes interdigitate, leaving a 40 nm space or ‘slit 
pore’ between them that is bridged by the slit diaphragm. In this way, the podocyte foot pro-
cesses and the interposed slit diaphragm completely enwrap the glomerular capillaries. Recent 
three-dimensional ultrastructural analysis of the podocyte revealed an even further complexity. 
The space between the foot processes and the overlying cell body and primary processes ap-
peared to be more restricted than previously appreciated, delineating a so-called sub-podocyte 
space. The finding that this space covers as much as 60 percent of the glomerular surface may 
bring important insights into the mechanisms of glomerular filtration (29,30).
Apart from its role in glomerular filtration, the podocyte probably also functions as a structure-
stabilizing cell, providing forces to counteract capillary distension (31). Additionally, podocytes 
produce the extracellular matrix components that make up the GBM, and they provide growth 
factors like TGF-β and VEGF. The latter plays a role in the maintenance of the glomerular endo-
thelium. The cell biology of the podocyte will be discussed in more detail in the next paragraph.
In contrast to the elaborately shaped podocytes and not reminiscent of their common embryonic 
origin, parietal epithelial cells (PECs) appear as a simple flat epithelium that lines Bowman’s cap-
sule. Recent reports have made clear that occasionally podocyte-like cell types can be found at 
parietal cell positions (32). These cells may be PECs that transdifferentiate to become podocytes 
(33). PECs themselves have long been regarded as relatively inert cells that, although they may 
show secondary reactivity in response to glomerular pathology, play no crucial role in glomerular 
diseases. Recent studies have changed this view (34). Several reports have indicated that PECs 
do play a role in animal models of focal segmental glomerulosclerosis (35,36) and HIV-associated 
nephropathy (37), as well as in human glomerular diseases (38,39).
Glomerular extracellular matrix
During the development of the glomerulus, endothelial cells and podocytes together produce the 
extracellular matrix they rest on and that separates the two cell types: the 300 nm thick GBM. In 
the mature glomerulus, all three glomerular cell types synthesize components of the GBM (40-42)
Ultrastructurally, the GBM consists of three layers: the laminae rara interna, densa and rara exter-
na, but it is not known whether these different layers also represent different molecular composi-
tions, or are a reflection of a fixation artifact (43). The molecular constituents of the GBM include 
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laminin (isoform α5β2γ1), collagen IV (isoform α3α4α5), heparan sulphate proteoglycans agrin, 
perlecan, collagen XVIII, syndecan, fibronectin, and nidogen/entactin. The collagen IV and laminin 
chains are crosslinked by nidogen, and form a strong, porous, network. The GBM proteoglycans 
are responsible for the negative charge of the GBM, thought to be instrumental in glomerular 
ultrafiltration (see below). 
Mesangial cell extensions and mesangial ECM fibers are continuous with the GBM, and are 
thought to reinforce the glomerular structure (44). The mesangial matrix is composed of fibronec-
tin, collagen IV (isoform α1α1α2), laminins (isoform α5β1γ1) and proteoglycans, with – similar 
to the GBM – heparansulphate as the major glycosaminoglycan (45). Many glomerular diseases 
result from an imbalance between mesangial matrix synthesis and degradation. For example, 
expansion of mesangial matrix is an important feature of diabetic nephropathy.
Cell biology of the podocyte
The molecular processes that support the podocyte’s complex architecture and provide the basis 
for its function have received much attention in recent years. The elucidation of genetic causes 
of rare hereditary disorders, the generation of conditional and inducible knock-out mice, and the 
possibility to culture human and rodent podocytes have been instrumental in the advancement 
of understanding the cell biology of the podocyte. 
Cytoskeleton
An elaborate cytoskeleton that combines strength with flexibility is indispensable for the correct 
shape and function of the podocyte. In the foot processes all membrane domains are physically 
linked to the cytoskeleton, and at the functional level the establishment of a connection between 
membrane associated molecules and the cytoskeleton has become a common theme. 
The cytoskeleton of the cell body and primary processes is composed of microtubules and in-
termediate sized filaments such as vimentin. Foot processes lack these filament types; their cy-
toskeleton instead consists of actin filaments. Ichimura et al showed that there are two distinct 
populations of these actin filaments in the foot processes: a dense bundle that runs along the 
longitudinal axis of the foot processes, and a cortical actin network beneath the plasma mem-
brane (46). At the base of the foot processes the bundle of actin filaments connects to that of 
the adjacent foot process as well as to the cytoskeleton of the major processes (figure 2). At the 
tip of the foot process the filaments are attached to the GBM via various linker molecules. Apart 
from actin, the foot process cytoskeleton contains several actin-associated molecules, including 
myosin and α-actinin-4. This suggests that the cytoskeleton has contractile capacities, and may 
serve to counteract the capillary pressures (14,31,47), although such contractions have until now 
not been observed in vivo (48).
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In response to damage, the 
podocyte ultrastructure and 
organization of the actin cyto-
skeleton are severely altered: 
foot processes are typically lost 
– a process called foot process 
effacement – and the highly 
organized actin fibers are rear-
ranged to form a dense mat 
of interconnected fibers at 
the base of the effaced foot 
processes (14,49,50). This ex-
tensive and sometimes quickly 
reversible rearrangement of 
cytoskeletal elements has stim-
ulated research into the regu-
lation of actin and actin associ-
ated proteins in the podocyte. 
Actin filament elongation is 
regulated by Rho GTPases such as RhoA, rac, and cdc42, and these molecules probably have an 
important role in the formation of the cytoskeleton of the podocyte (51). Indeed, mice that lack 
an inhibitor of Rho GTPases, ie, in which these proteins are more active, develop heavy protein-
uria and foot process effacement (52). Others have shown that the deleterious effect that plasma 
Figure 2. Organization of the podocyte 
cytoskeleton. A cross section through a 
capillary loop shows that the capillary is 
surrounded by podocyte foot processes. 
At the base of the capillary, contractile 
mesangial cell filaments are attached (a). 
A schematic view from above shows that 
the foot processes sprout perpendicular 
to the major processes. The cytoskeleton 
of the major processes is composed of 
microtubuli, to which the actin-based 
cytoskeleton of the foot processes is at-
tached (b). In (c) and (d) the lateral view 
capillary wall is depicted, corresponding 
to the w-x and y-z line in (b), respec-
tively. Adapted from (14), used with per-
mission from The American Physiological 
Society and the author.
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proteins have on podocytes is regulated in a RhoA dependent manner (53). Other actin regulating 
molecules including cortactin, Ena/VASP, and Arp2/3 are expressed in podocytes, illustrating the 
wide range of actin cytoskeleton activity displayed by podocytes (48).
The crucial role of the actin cytoskeleton is underscored by the fact that dysregulation of actin 
associated molecules results in a loss of adequate glomerular function. For example, MYH9, the 
gene coding for myosin heavy chain IIA, is related to the development of Fechtner syndrome 
that includes podocyte abnormalities (54). An upregulation of α-actinin-4 was shown to precede 
proteinuria and development of foot process effacement in PAN nephrosis (55). Later, mutations 
in ACTN4, the gene coding for α-actinin-4, were shown to be the cause of a hereditary form of 
late-onset focal segmental glomerulosclerosis (56). These mutations lead to an increased affinity 
of α-actinin-4 for actin, probably reducing cytoskeletal dynamics (56). At the same time, these 
mutations increase the protein degradation rate (57), and mice that lack α-actinin-4 also have 
glomerular disease (58), showing that both gain- and loss-of-function mutations in ACTN4 impair 
correct podocyte function.
Heat shock protein 27 has been reported to play a role in actin polymerization, and has been 
implicated in foot process effacement (59-61). Synaptopodin, also called pp44, was identified 
by Mundel et al to be an actin binding protein which expression is restricted to podocytes and 
neurons (62,63). Disruption of synaptopodin does not lead to glomerular disease, but seems to 
lower the threshold for development of glomerular abnormalities (64,65). This may relate to the 
involvement of synaptopodin in actin dynamics: synaptopodin regulates the actin bundling activ-
ity of α-actinin-4 (64) and prevents the proteasomal degradation of RhoA (66).
Apical membrane
Mature podocytes are polarized cells, and the apical membrane of the foot processes is funda-
mentally different from the basal and baso-lateral parts (see figure 3 for a schematic representa-
tion of the molecular organization of the podocyte foot process). A long-known characteristic 
of the apical membrane is that it is highly negatively charged (67). Kerjaschki et al identified the 
sialomucin podocalyxin as the molecule that provides this negative charge by means of several 
sialic acid residues (68). It has been suggested that the extracellular domain of podocalyxin serves 
as a ‘spacer molecule’ with anti-adhesive characteristics, preventing a connection between two 
adjacent foot processes (69,70). In keeping with the importance of podocalyxin for the integrity 
of the podocyte, podocalyxin knock-out mice show an impaired kidney development, with failure 
of podocytes to form foot processes (71). In vivo, interference with podocalyxin, for example 
through infusion of the polycation protamine sulfate, leads to proteinuria and foot process ef-
facement (72). Such a change in foot process architecture would require a reorganization of the 
actin cytoskeleton, suggesting that podocalyxin interacts with this structure. Indeed, Farquhar’s 
group showed that podocalyxin is physically linked to actin via a complex including NHERF2 
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and ezrin, and that this linkage is disrupted in foot process effacement (72). Follow-up studies 
showed that podocalyxin may also directly bind ezrin and activate RhoA, showing additional 
actin-modulating properties (73).
Recently, the heavily glycosilated negatively charged α-subunit of dystroglycan has been sug-
gested to perform a function similar to that of podocalyxin (74). Loss of dystroglycan from the 
apical membrane may result in foot process effacement, in addition to a pathogenic role that loss 
of dystroglycan from the basal site of the foot process may have (discussed below) (75).
The transmembrane glycoprotein podoplanin adds further negative charge to the apical mem-
brane (76-78). Little is known about the intracellular connections of podoplanin in the podocyte, 
although in other cell types this protein has been shown to interact with ezrin (79,80).
GLEPP-1 (protein tyrosine phosphatase receptor type O) is a phosphatase expressed in the apical 
membrane of the podocyte. As demonstrated in knock-out mice, the protein has a role in the 
correct shaping of the actin cytoskeleton (81), but the substrates of its phosphatase function 
remain undefined (14). 
Slit diaphragm region
The slit diaphragm that spans the space between two adjacent foot processes is inserted in the 
basolateral membrane of the foot process. The multitude of proteins and protein-lipid complexes 
that make up and support the slit diaphragm and both physically and functionally link the struc-
ture to other parts of the cell, make this a highly specialized cell compartment. 
Molecular architecture of the slit diaphragm
Although the slit diaphragm and some of its morphological characteristics have been recognized 
since the application of electron microscopy in kidney research (82,83), its molecular constituents 
have long remained obscure. The tight junction protein zonula occludens-1 (ZO-1) was one of 
the first molecules described to be associated with the slit diaphragm. Reiser et al showed that 
P-cadherin and ZO-1 co-localize at the slit diaphragm region, suggesting that the slit diaphragm 
is a modified adherens junction (84). 
In 1988, Shimizu’s group showed that the injection of monoclonal antibody raised against a 
component of rat glomeruli (mAb 5-1-6) in rats produced massive and transient proteinuria. The 
epitope recognized by this antibody localized almost exclusively to the slit diaphragm (85). Pro-
teinuria, induced through infusion of the antibody or through protamine sulfate, caused an apical 
dislocation and internalization of the protein (86,87).
A breakthrough in podocyte biology was the finding that mutations in NPHS1, coding for neph-
rin, cause the congenital nephrotic syndrome of the Finnish type (CNF) (88), a syndrome char-
acterized by proteinuria in utero and rapid development of end-stage renal disease requiring 
kidney transplantation (89). Nephrin was found to have a restricted expression, and in the kidney 
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localized to the slit diaphragm (90-92). In retrospect, the epitope recognized by mAb 5-1-6 ap-
peared to be identical to rat nephrin (93). Because nephrin, a member of the Ig protein superfam-
ily, has a large extracellular domain and could form homodimers in vitro (94), it was suggested 
that nephrin strands from opposing foot processes may form the actual slit diaphragm through 
nephrin-nephrin interactions (95). This hypothesis was tested in an extensive study using electron 
tomography in combination with immuno-gold labeling of nephrin in glomeruli from various 
mammalian species, both in health and disease (96). From this study, it was concluded that 
nephrin, together with other proteins that were not molecularly identified, contributes to the slit 
diaphragm. In CNF patients the slit pore was much smaller and did not contain a slit diaphragm. 
Confirming these findings, different reports on nephrin knockout mice consistently showed heavy 
proteinuria and early death of the mice, with absence of the slit diaphragm (97-99), although 
foot processes were assembled normally (17). These studies established nephrin as an important 
structural component of the slit diaphragm. 
Figure 3. Molecular organization of the podocyte foot process. Two podocyte foot processes with the bridging slit diaphragm 
are depicted, resting on the glomerular basement membrane (GBM). The central part of the foot process is the actin cytoskeleton 
(indicated with grey lines and dots), which is reinforced by synaptopodin and α-actinin-4, and has contractile properties as a 
result of myosin fibers (M). Connected to the cytoskeleton are several molecules that reside in the negatively charged apical 
membrane, including podocalyxin (PC) via NHERF2 (N) and ezrin (Ez), and podoplanin (not depicted). At the basal membrane, the 
actin cytoskeleton is connected to the GBM via dystroglycan (linking utrophin (U) to agrin), and the integrin-complex (integrin, 
talin-paxillin-vinculin (TPV), integrin linked kinase (ILK), focal adhesion kinase (FAK)). The slit diaphragm is composed of nephrin, 
NEPH-proteins, P-cadherin, and FAT, and the slit diaphragm domain contains several molecules that play a role in the anchor-
ing and signaling of the slit diaphragm (TRPC6, podocin, CD2AP (CD), β-catenin (cat), and ZO-1 (Z)). The podocyte has several 
receptors, including the angiotensin II receptor AT1. See text for further details. Adapted from (505) and (506), with permission 
from Elsevier, Lippincott Williams & Wilkins, and the author.
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Since the discovery of nephrin several other molecular components of the slit diaphragm have 
been identified. The nephrin homologues NEPH1-3 were identified in the mouse. As is the case 
with nephrin, NEPH1 deficient mice show proteinuria and neonatal death (100). Several groups 
subsequently showed that NEPH1 and nephrin form homo- and heterodimers, suggesting a 
shared role in formation of the slit diaphragm (101,102). Injection of individually subnephrito-
genic doses of antibodies against nephrin and NEPH1 induced proteinuria (103), underscoring the 
functional link between these two molecules. NEPH3 (syn. filtrin, KIRREL2) is expressed at the slit 
diaphragm region, and its expression was found to be reduced in acquired proteinuric diseases, 
both at the protein and the mRNA level (104,105).
In a search for other cell-cell adhesion proteins that may be of relevance, Inoue et al found that 
the protocadherin FAT1 is expressed at the site of the slit diaphragm (106). Mice that lack FAT1 
develop, among other abnormalities, proteinuria and foot process effacement (107). 
Anchoring to the actin cytoskeleton
The slit diaphragm is inserted in a highly organized membrane region modified by lipid rafts. 
Podocin is one of the proteins that localizes to this region, and like nephrin is present in lipid rafts 
(108-110). The protein has a hairpin structure, with both the N- and C-terminus ending in the 
cytoplasm. Mutations in NPHS2, the gene encoding podocin, lead to a steroid-resistant form of 
nephrotic syndrome (111). Podocin interacts with several components of the podocyte foot pro-
cess, including nephrin and CD2-associated protein (CD2AP). TRPC6, coding for a cation channel 
with a preference for Ca2+, was recently found to be mutated in patients with a late-onset form 
of FSGS (112). Subsequent analysis showed that TRPC6 localizes to the slit diaphragm region, and 
associates with other components such as nephrin and podocin (113,114).
As pointed out before, the different membrane compartments of the podocyte are linked to the 
subcortical actin cytoskeleton. This is also true for the slit diaphragm region. FAT1, for example, 
was shown to recruit Ena/VASP proteins that play a role in actin polymerization (115). P-cadherin 
forms a multimolecular complex with α-, β-, and γ-catenin and ZO-1, both ZO-1 and β-catenin 
could link this complex to the actin cytoskeleton (84). Nephrin interacts with a wide array of 
intracellular molecules that relate to actin dynamics. One of the first intracellular linkers to be dis-
covered was CD2AP (116), a protein that directly connects to the actin cytoskeleton (117). Study-
ing the role of this protein in the immunological synapse, it was serendipitously discovered that 
absence of CD2AP in mice leads to heavy proteinuria (118), which brings functional relevance to 
the nephrin-CD2AP-actin interaction. Other actin-associated molecules that interact with nephrin 
include IQGAP1, spectrins, and α-actinin-4, while nephrin also connects to MAGUK family pro-
teins that link it to other signaling and cell-junction molecules (119).
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Signaling at the slit diaphragm
The studies mentioned so far have established numerous structural components of the slit dia-
phragm and their intracellular connections; a major finding was that several of the proteins lo-
cated in the slit diaphragm region participate in signaling pathways. Signal transduction in cells is 
mostly regulated by the attachment or detachment of phosphate groups on serine, threonine, or 
tyrosine residues of proteins, enabling the binding of other proteins (120). Both the intracellular 
(C-terminal) part of nephrin and NEPH1 contain tyrosine residues that can be phosphorylated by 
kinases such as Fyn; the importance of this is underscored by the fact that Fyn knockout mice 
show foot process effacement and proteinuria (121). Nephrin tyrosine phosphorylation results 
in activation of AP1, an effect that is enhanced by binding of nephrin to podocin (122). Later 
experiments showed that in vivo, phosphorylated nephrin in conjunction with CD2AP activates 
PI3 kinase. This in turn initiates a series of phosphorylations that may lead to intracellular re-
sponses including cell survival, actin dynamics, proliferation, metabolism, and endocytosis. Two 
examples that give some insight in the importance of signaling for podocyte integrity are listed 
here; more in-depth reviews are provided in references (120) and (123). One specific response 
is the regulation of apoptosis: nephrin and CD2AP induced PI3 kinase activity may increase AKT 
expression, thus suppressing TGF-β signaling and preventing podocyte apoptosis (124,125). As 
will be discussed in a later paragraph, loss of podocytes is linked to the progression of renal dis-
ease (126). Secondly, two different groups showed that nephrin phosphorylation by Fyn is crucial 
for its binding to the adaptor protein nck (127-129). Nck is able to recruit a protein complex that 
regulates actin polymerization. This suggests that the phosphorylated nephrin – nck interaction 
may be of importance in states with high dynamic activity such as development and foot process 
effacement or rearrangement (128-130).
The different interactions between the proteins in the slit diaphragm region, both in physical 
attachments of proteins and in signaling, make clear that protein complexes rather than single 
molecules are responsible for a correct podocyte and slit diaphragm function. And not only pro-
teins, but also lipids may be involved. The role of lipid rafts in the cell membrane has already been 
alluded to; in addition, recent studies by Huber et al indicate that the regulation of TRPC6 by 
podocin requires binding of cholesterol by podocin (114). 
Interaction with the GBM
At the basal site, the ‘sole’ of the foot process, the podocyte attaches to the matrix they have in 
part themselves produced: the GBM. This interaction is accomplished by several transmembrane 
matrix binding proteins, including integrins and dystroglycan.
Integrins are heterodimers, consisting of an α and β subunit, that attach to extracellular matrix 
molecules. The podocyte’s integrin is made up of the α3 and β1 integrin subunit that attach to 
collagen, fibronectin, and laminins in the basement membrane (131). Blocking the β1 integrin 
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in animal models leads to proteinuria. α3 integrin knockout mice die in the neonatal period and 
show defects in lung maturation and kidney development, including a disorganization of the 
GBM and a failure to form podocyte foot processes (132). Upon extracellular ligand binding, 
integrins cluster to form so-called focal adhesions. At the intracellular side these focal adhesions 
recruit several adapter molecules, including talin, paxillin, and vinculin, which attach the integ-
rins to the cortical actin network. As with the slit diaphragm, these interactions serve not only a 
structural function, but are also involved in signaling pathways. Integrins are able to mediate both 
inside-out and outside-in signaling, an action in other cells frequently mediated by phosphoryla-
tion through focal adhesion kinase (Fak). In podocytes, this route has not been unequivocally 
demonstrated. Another candidate for mediating the signaling by integrins could be integrin-
linked kinase (ILK). Using differential display analysis, the groups of Holthofer and Kretzler found 
an increase of – among other molecules – ILK mRNA expression in glomeruli of patients with CNF 
(133). Subsequent experiments showed that ILK mRNA expression was increased in several pro-
teinuric kidney diseases in vivo (134), and that increased ILK activity was related to reduced matrix 
adhesion in vitro (135). Also, clustering of integrin receptors by ECM molecules leads to a de-
crease in ILK activity, the outside-in route. Further studies identified several molecules interacting 
with ILK, linking this complex to actin cytoskeleton dynamics, hypoxia signaling (via HIF-1α and 
VEGF), the wnt signaling pathway, and proliferation (136-138). ILK activity also induces expres-
sion of matrix metalloproteinase 9 (MMP-9) that has a role in GBM remodeling. Podocyte-specific 
ILK knockout mice showed a normal development, but after three weeks started to become 
proteinuric. The initial changes were primarily found in the GBM, indicating a possible role for ILK 
in integrin mediated GBM organization (139). Using a comparable mouse model, another group 
showed that disruption of ILK signaling also resulted in changes at the slit diaphragm (140).
Apart from integrins, dystroglycans have been implicated in the embedding of the podocyte foot 
processes in the GBM. Indeed, dystroglycan seems to be well-adapted to such a function: the 
extracellular domains bind ligands including laminin, agrin, and perlecan – all present in the GBM; 
the intracellular domain (the transmembrane β subunit) is linked to the actin cytoskeleton via 
the adapter protein utrophin (50,141). Reports on the localization of dystroglycan in the podo-
cyte have been controversial; some studies reported an expression limited to the basal foot pro-
cess membrane (142), while others also found dystroglycan expression at the apical membrane 
(74,141). Raats et al found utrophin expression only at the basal membrane (141), suggesting 
this to be the place of a dystroglycan-mediated GBM-actin association. Loss of dystroglycan ex-
pression at the basal part of the foot processes has been reported in minimal change disease (as 
opposed to FSGS) that was reversible after steroid treatment (142). A similar finding was reported 
in a patient with proteinuria but otherwise with no glomerular abnormalities (143). Raats et al 
instead reported an increase in basal membrane dystroglycan expression in adriamycin nephropa-
thy (141). Later studies have added to the notion that the dystroglycan-GBM connection is of 
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importance for the correct function of the glomerular filtration barrier: reactive oxygen species 
were found to decrease the adherence of dystroglycan to agrin, possibly leading to podocyte 
detachment (75). In a comparable study, Kojima et al found that protamine as well as reactive 
oxygen species disrupted the link between dystroglycan and its ligands (144). This resulted in 
a disorganization of the lamina rara externa of the GBM, substantiating the hypothesis, as put 
forward by Kerjaschki (50,142), that via dystroglycan the actin cytoskeleton of the podocyte may 
function as a blueprint for the organization and spacing of GBM proteins.
Other proteins that are located at the basal membrane include megalin/gp330 (in rats) and neu-
tral endopeptidase/CD10 (in humans). These proteins have been discovered to be the pathogenic 
antigens in Heymann nephritis and neonatal membranous nephropathy, respectively (145-148). 
Megalin may be linked to the cytoskeleton via the adaptor protein MAGI-1 (149).
Podoplanin has also been reported to be present in the basal membrane of the foot processes, 
its predominant localization being at the apical membrane domain. As discussed above, the 
intracellular linkers of podoplanin in the podocyte have not been identified, nor is the function 
of podoplanin at this location clear. In lymphatic endothelial cells podoplanin has been reported 
to play a role in the shaping of a gradient of the chemokine SLC/CCL21 (150), which is also 
expressed in podocytes, and which is important for mesangial function (151). It is tempting to 
speculate that podoplanin is important for the mediation of this cross-talk between podocytes 
and the mesangium.
Exocytosis of ECM molecules and matrix modifying enzymes such as metalloproteinases takes 
place at the basal membrane of the podocyte. Also, growth factors such as VEGF are excreted 
at the basal site of the podocyte, although little is known about the kinetics and precise mecha-
nisms by which this occurs (152). But interactions at the basal membrane of the podocyte are not 
restricted to binding and modifying the GBM, several other interactions take place. For example, 
there is extensive endocytosis in this membrane compartment, as can be inferred from the wide-
spread presence of clathrin-coated pits and vesicles (14,153). In vitro, podocytes were shown to 
endocytose albumin, possibly important in clearing the glomerular filter from macromolecules 
(154). Others have also found that the podocyte is able to perform transcytosis, yielding a tran-
scellular rather than paracellular, ie, slit diaphragm, route between the intracapillary lumen and 
Bowman’s space (155).
Receptors and signaling pathways 
Numerous receptors and coupled signaling pathways that are involved in podocyte function have 
been investigated, but will not be discussed in detail here. For further details on this subject the 
reader is referred to an extensive review (14). The bottom-line of the different receptors is the 
notion that intracellular second messengers, including cyclic AMP, cyclic GMP, and Ca2+ and their 
related pathways in the podocyte are modifyable by a wide range of extracellular and circulating 
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molecules. These include vasoactive compounds as nitric oxide, atrial natriuretic peptide, hor-
mones (156), and medication (including dexamethason (157) and cyclosporine (158)). Of some 
importance, also from a clinical point of view, is the fact that podocytes carry both types of the 
angiotensin II receptor, AT1 and AT2, suggesting podocytes have a local renin-angiotensin system 
(RAS) (159). It is well known that ACE inhibitors or AT1 antagonists have a beneficial effect on the 
kidney, which is not completely explained by their blood pressure lowering properties (152). The 
inhibition of angiotensin II receptor mediated effects may be the explanation for these observa-
tions. Indeed, hypertrophy in podocytes was prevented by ACE inhibition (14), and several other 
studies have shown a ‘podoprotective’ effect of RAS inhibition (160-163). Conversely, transgenic 
rats that overexpress the human AT1 receptor specifically in podocytes develop albuminuria, 
podocyte foot process effacement, and eventually FSGS (164).
Rastaldi et al found that podocytes express several molecules associated with neuronal synaptic 
vesicles, and showed that in podocytes these molecules also associate with vesicles (165). These 
findings expand the extent of similarities between neurons and podocytes. Indeed, the branched 
appearance, cell cycle quiescent phenotype, cytoskeletal organization (166), and gene expression 
pattern (167) of these cells are strikingly similar. Moreover, these findings could indicate that 
apart from intracellular signaling, also an intercellular communication by means of synaptic-like 
exocytosis of glutamate may take place in podocytes (168).
Cell cycling and transcription factors
During the capillary loop stage of glomerular development, podocytes start to differentiate, they 
form foot processes and express typical podocyte markers. At the same time these cells stop to 
proliferate. In the mature glomerulus, podocytes are considered to be terminally differentiated, 
post-mitotic cells. Proliferation, or progression through the cell cycle, is regulated by a complex 
set of stimulatory and inhibitory proteins. Cyclins and their respective cyclin dependent kinases 
(CDKs) promote proliferation, while CDK inhibitors such as p21, p27, and p57 inhibit prolifera-
tion. In podocytes, an upregulation of CDK inhibitors is seen in the capillary loop stage, promot-
ing a quiescent podocyte phenotype. Also in response to injury, podocytes, in contrast to other 
glomerular cells such as mesangial cells, do not divide, although they do show hypertrophy and 
sometimes multi-nucleation. Petermann et al found that in response to injury, podocytes do enter 
the cell cycle: they show (limited) DNA amplification and upregulate proteins that mark the start 
of the cell cycle. However, there was no proliferation of podocytes, suggesting that they do not 
have the ability to complete the cell cycle and perform cytokinesis (169). Others have suggested 
that the complex cellular architecture of podocytes prohibits cytokinesis (14). Consequently, there 
must be cell cycle inhibitory molecules that prevent cell division. Loss of such inhibitory regula-
tors, as exemplified by the p21 and p27 knockout mice, results in podocyte proliferation in re-
sponse to damage (170,171). While loss of podocytes is considered to be the initial step towards 
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nephron loss, also certain glomerular diseases have been associated with a proliferating podocyte 
phenotype. Almost all of these diseases show a detrimental course when left untreated. Moeller 
et al studied transgenic mice with tagged podocytes and showed that podocytes contribute to 
cellular crescents, seen in some forms of glomerulonephritis (172). In HIV-associated nephropathy 
podocytes are presumed to be able to escape their cell-cycle control and re-proliferate, leading 
to FSGS of the collapsing type with a rapidly progressive clinical course (173-175). It has been 
difficult to prove that these cells are really podocytes – the cells are dedifferentiated, they have 
lost their typical markers and they are allegedly podocytes merely on the basis of their localization 
in the glomerulus. Studies by Dijkman and Smeets et al brought evidence for the role of parietal 
epithelial cells in proliferative glomerular diseases (34,39).
Transcription factors that regulate podocyte development and maintenance include PAX2, pod1, 
Kreisler, Lmx1b, and WT1 (176). WT1 has been linked to the expression of several podocyte mark-
ers, including nephrin and podocalyxin (177-180). The crucial role for WT1 is underscored by the 
fact that mutations in the gene cause syndromes (Denys-Drash, Frasier, and WAGR syndrome, 
OMIM 607102) that frequently involve podocyte and glomerular abnormalities.
Mutations in the gene that encodes the transcription factor Lmx1b cause nail-patella syndrome, 
characterized by the absence of the patella and nails and by the occurrence of nephropathy. Two 
groups of investigators studied Lmx1b knockout mice and found that this transcription factor 
is important for the expression of collagen α3(IV) and α4(IV), and the slit diaphragm associated 
proteins podocin and CD2AP (181,182), indicating a role for this transcription factor in both GBM 
formation and slit diaphragm function.
Glomerular filtration: characteristics and theoretical models
How exactly the kidneys produce urine has been investigated for over 150 years and remains 
unresolved. Initially, the question was whether the glomerulus takes at all part in formation of 
urine. At that time, tubular secretion probably was a more plausible option, as secretive epithelia 
in salivary, gastrointestinal, lactating glands etc. had just been extensively studied. The notion 
that urine is formed by glomerular filtration and tubular resorption and excretion was only proven 
through micropuncture studies in the 1920-60s (183-185). Still, the molecular mechanism of 
glomerular filtration remains incompletely understood.
In this paragraph, the characteristics of the glomerular filtration barrier are described: the amount 
and concentration of fluids, small solutes, and macromolecules involved, the forces that drive 
filtration, and the biochemical and biophysical properties of the filter. This is followed by a de-
scription of several theories on how glomerular permselectivity is accomplished at subcellular and 
molecular levels.
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Characteristics of glomerular filtration
Amounts and concentration of fluids
The kidney receives about 20 percent of the cardiac output, ~1.2 liters of blood per minute. Some 
ten percent of this total volume is filtered in the glomerulus, and enters the tubular system as pre-
urine; the total volume of pre-urine thus amounts to 180 liters per day. Most of the pre-urine is 
reabsorbed in the tubules, leaving an average of 1.5 liters of urine each day for excretion (range 
0.8 – 20 liters). The ultrafiltrate has almost the same composition as plasma-water, it is acellular 
and contains a low amount of protein. It is generally agreed upon that the concentration of albu-
min in the pre-urine is about 25 µg/ml, compared to a plasma albumin concentration of 45mg/ml. 
This indicates that the glomerular filter is restrictive for proteins, a feature referred to as glomeru-
lar permselectivity. The extent of restriction differs for each protein (see below), and is expressed 
as the glomerular sieving coefficient (Bowman’s space-to-plasma concentration ratio) θ, theta.
Forces that drive filtration
There are different forces that drive transport of fluids through the glomerular capillary wall. 
These so-called Starling forces include the hydrostatic and colloid osmotic pressure, determined 
by the fluid-pressures and the colloid osmotic value of the fluids, respectively. These two forces 
work in opposite directions: the hydrostatic pressure in the glomerular capillaries is higher than 
that in Bowman’s space, providing an outward force. Instead, the colloid osmotic pressure within 
the capillaries exceeds that in Bowman’s space, and this will drive transport of fluids inwards. 
In the upstream part of the glomerular capillaries, the hydrostatic outward force is higher than 
the colloid osmotic inward force, resulting in filtration. Since the filtration barrier is restrictive to 
proteins, the extraction of fluids from inside the capillaries will increase the intracapillary protein 
concentration, and thus the colloid osmotic pressures. Eventually, in the downstream part of 
the glomerular capillaries this will lead to an osmotic inward force that equals the hydrostatic 
outward force, the so-called filtration pressure equilibrium. Downstream of the point where the 
filtration pressure equilibrium is reached, there is no filtration. 
The amount of filtration is further influenced by the characteristics of the filter, represented in the 
ultrafiltration coefficient Kf, the constant that indicates the resistance to fluid flow through a bar-
rier. Higher levels of Kf indicate a higher permeability. Both the GBM and the cellular constituents 
of the filter contribute to the resistance to flow. 
Small molecules are mainly transported by convection, and thus hold pace with the transport of 
the fluids over the capillary wall, while macromolecular transport is determined by both convec-
tion and diffusion. 
Biochemical and biophysical properties of the glomerular filter
The general view is that the glomerular filter restricts passage of macromolecules on the basis of 
their size, shape, and charge. The influence of these factors determines the sieving coefficient θ 
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for each macromolecule. Because macromolecular transport is passive, θ varies between 1 (free 
passage through the filtration barrier) and 0 (complete restriction). The different determinants of 
glomerular permeability will be discussed here.
Size selectivity – The size of a molecule, commonly indicated by its Stokes-Einstein radius (SE 
radius), is influenced by the compactness of the molecule and its molecular weight. For albumin 
(molecular weight 3000 kDa, SE radius 36 Å) the sieving coefficient θ is about 6∙10-4 (25 µg/
ml, the albumin concentration in Bowmans’ space divided by 45 mg/ml, the plasma albumin 
concentration). The θ for smaller proteins is considerably larger, and proteins smaller than 14 
Å have a θ that is 1, indicating that these molecules are not restricted by the glomerular filtra-
tion barrier. For larger proteins such as IgG (molecular radius 55 Å) or IgM (molecular radius 
120 Å), the θ is considerably smaller; these molecules may even be completely absent from the 
ultrafiltrate in Bowman’s space. The exact size selectivity of the glomerulus has been difficult to 
determine: direct measurement of proteins should be performed in the glomerular ultrafiltrate, 
before reabsorption in tubules may occur. This requires micropuncture techniques that have been 
criticized because they may measure proteins released as a result of the tubular damage associ-
ated with the measurement itself, or by contamination of peritubular capillary blood proteins. 
The most reliable direct measurements of protein concentrations are probably experiments by 
Tojo and Endou (186), who used sophisticated techniques to circumvent the problems associ-
ated with micropuncture techniques. These studies have established the before mentioned θ for 
albumin of 6∙10-4. Furthermore, patients with Fanconi syndrome have been used for estimations 
of the glomerular filtration selectivity. These patients have an impaired tubular protein uptake, 
and the protein concentration in urine is thus a reflection of their glomerular protein filtration. 
In these studies, the θ for albumin was found to be ~8∙10-5, which is even lower than that of 
rodents (187). Probes of different sizes, such as the polysaccharides dextran and Ficoll as well 
as different proteins, have been used to get insight in the exact size characteristics of the filter. 
Results from these experiments have been used in models of glomerular size selectivity, in which 
the glomerular filtration barrier is considered to be perforated by pores with a certain diameter. 
In most models, there are two ‘pore-populations’: a large number of restrictive small pores with 
a radius between 37 and 55 Å, and far less frequent unrestrictive large pores or ‘shunts’, with a 
radius of 80 – 100 Å (43,188-191).
Macromolecular shape – Uncharged probes with a similar SE radius may show a divergent filtra-
tion behavior. For example, the polysaccharide dextran has a θ that is about 7-fold higher than 
that of an uncharged protein of the same size, and is also larger than Ficoll with the same radius. 
This is attributed to the fact that dextran may change its conformation from a sphere to a more 
elongated molecule, and thus pass through the capillary wall more easily. Also for Ficoll, although 
more spherical than dextran, the glomerular filtration barrier was found to be to some extent 
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hyperpermeable, probably due to the compressibility of Ficoll (188). This indicates that the form, 
globular or linear, and deformability of a molecule is of importance for its sieving characteristics.
Charge selectivity – Several studies have demonstrated that the capillary wall restriction for an-
ionic proteins is higher than that for neutral or cationic proteins, indicating the presence of 
charge selectivity (192-194). The extent of this charge selectivity has, however, been difficult to 
quantify. This relates in part to the use of tracers that may not truly mimic the behavior of pro-
teins in the capillary wall: negatively charged sulfated dextrans may more rapidly interact with the 
components of the glomerular filter, thus retarding their passage (188). As pointed out before, 
the capillary wall seems to be hyperpermeable for Ficoll in comparison to albumin of the same 
size. This has led to the suggestion that the negative charge of albumin accounts for the appar-
ent restriction, which would fit with an important charge barrier (195), although the divergent 
behavior may in fact be related to the compressibility of Ficoll. Furthermore, comparison of tracers 
such as sulfated dextrans and carboxymethyl Ficoll (tracers that have been rendered negatively 
charged) with their neutral counterparts even showed an increased permeability of negatively 
charged tracers (196). Removal of molecular constituents of the negative charge in the GBM – 
using enzymatic and genetic methods – failed to induce proteinuria, further questioning the role 
of the GBM in charge selectivity (197-201). It has been suggested that the actual charge barrier 
may reside in the endothelium rather than in the GBM (see below). Also, a charge effect could 
be built up by negatively charged components of the blood, such as albumin, which accumulate 
during filtration or interact with the endothelial cell glycocalyx (202). An indirect proof for this 
is the observation by Ryan and Karnovsky, that a continuous blood flow is needed to maintain 
a normal filtration barrier (203). Direct proof for this mechanism is lacking. Thus, although most 
authors acknowledge the presence of charge selectivity, at least with regard to the filtration of 
proteins, its relative contribution to permselectivity remains controversial. 
Different explanations for permselectivity
The description of the functional characteristics of glomerular filtration directly relates to the 
question how filtration is accomplished on a structural level. In the literature, the different struc-
tural components of the glomerular filter have all been given attention, with a recent skewing 
towards the contribution of the podocyte. An overview of the different explanations and hypoth-
esis is lined out below.
The GBM as the main filter for plasma proteins
In 1975, Farquhar in a review on glomerular filtration concluded that ‘the bulk of the evidence 
available at present favors the basement membrane as the primary filtration barrier in the glom-
erulus’ (204). Indeed, in most tracer studies, an accumulation of tracer molecules at the suben-
dothelial rather than at the subepithelial side has been observed. On the molecular level, the 
GBM contains proteins that permit the formation of sieve-like structures, for example through 
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cross-linked collagen IV networks, and removal of some essential components leads to the devel-
opment of proteinuria. Localization of the charge restriction in the GBM has been inferred from 
the observation of regularly spaced anionic sites demonstrated using for example polyethylenei-
mine, and the corresponding molecules have been identified as the glycosaminoglycan sidechains 
of proteoglycans such as agrin, perlecan, and collagen XVIII. In conclusion, charge and size selec-
tivity can both be explained by the structural and molecular properties of the GBM. Yet, this view 
leaves several observations unexplained. For example, while IgG is mostly absent from the glo-
merular ultrafiltrate, injection of IgG directed against nephrin and megalin binds these antigens 
expressed on the podocyte membrane (85,145), indicating that these IgGs have passed through 
the GBM. The contribution of GBM proteoglycans to the charge selectivity has been criticized by 
investigators pointing out that in other tissues such as cartilaginous tumors albumin is found in 
the stroma, which is even more rich in proteoglycans than the GBM (205,206).
Furthermore, fitting data obtained from experiments with isolated GBM into a theoretical model 
of glomerular filtration, Deen et al concluded that the contribution of the GBM to permselectiv-
ity is relatively small in comparison to that of the cellular components of the filter (26,207,208). 
These could then either be the endothelial or the epithelial cells. Over the last decade, the contri-
bution of the podocyte to the permselectivity of the glomerular filter has received most attention.
The podocyte slit diaphragm is the main barrier for plasma proteins
Tryggvason and coworkers, after the discovery of nephrin, argued that the podocytes and espe-
cially the slit diaphragm would be the main site of ultrafiltration (95,209-211). This hypothesis 
was supported by observations by Rodewald en Karnovsky in the 1970’s, who observed that the 
slit diaphragm had a zipper-like ultrastructure and suggested that this could explain the glomeru-
lar size selectivity (83). Using electron tomography, Wartiovaara et al visualized nephrin strands 
spanning the slit pore and leaving lateral pores of about the size of an albumin molecule (96). The 
fact that absence or abnormal function of many other slit diaphragm-associated proteins leads 
to proteinuria brings additional evidence for the importance of the slit diaphragm in glomerular 
permselectivity, and possibly for its dominant role in ultrafiltration.
If, however, the most selective barrier is indeed localized downstream in the filter, one would 
expect that proteins that pass through the upstream layers would ‘pile up’ in the sub-epithelial 
part of the GBM, a phenomenon called concentration polarization (202). In other words, the 
filter would clog (152,202,211,212). Several mechanisms that prevent such a clogging of the 
filter have been put forward. For example, the characteristics of the previously mentioned sub-
podocyte space theoretically leave open the possibility of an inversion of the direction of the 
fluid flow in the capillary wall, and could thus play a role in the unclogging of the filter (29,30). 
Another recently pursued hypothesis is that the proteins that accumulate at the basal membrane 
of the podocyte are transported to Bowman’s space by transcytosis (155). Indeed, coated pits 
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are frequently observed at the basal membrane, and in vitro podocytes have been shown to be 
capable of large scale endocytosis (154). 
Alternatively, the restrictive properties of the glomerulus could be localized to the other cellular 
component, the endothelium. 
The endothelial cells restrict passage of proteins
Deen showed that theoretically the endothelial layer is able to contribute notably to the glomeru-
lar filtration barrier (208). Early studies of glomerular permselectivity had ruled out a contribu-
tion of the glomerular endothelium, as it was recognized that the fenestrations would be too 
large to restrict passage of macromolecules (204). Later studies, however, have changed this 
view. Rostgaard and Qvortrup used special fixation and staining techniques that allowed them to 
study the ultrastructural organization of the glomerular capillary wall in the absence of changes 
that would be caused by lower blood pressure or anoxia. They found that the endothelial cells 
are covered with a 300nm thick glycocalyx, and that the fenestrae of the endothelial cells were 
bridged by filaments (25). In a later study, the same authors described the presence of a surface 
coat, presumably made up of proteoglycans on the endothelial cells, which extended into and 
filled up the endothelial fenestrations (213). This led them to hypothesize that these ‘sieve plugs’ 
or ‘fascinae fenestrae’ would be the actual basis for the glomerular permselectivity (213). Oth-
ers have shown that the glomerular endothelial cells produce negatively charged proteoglycans 
(214). Taken together, the glomerular endothelial cells may indeed play a more important role in 
glomerular filtration than has been generally acknowledged (43,202,208,211). 
Integrative views of glomerular filtration
Some explanations bring a more integrative view of the filter. These include the view of the glo-
merular filration barrier as size and charge barriers in series, the ‘Electrokinetic glomerulus theory’ 
by Douglas Somers, and Oliver Smithies’ ‘Permeation diffusion hypothesis’. 
Size and charge barriers in series
In the classic view of the glomerular filtration barrier, the GBM and the podocyte slit diaphragm 
are two size and charge selective barriers that are placed in series. The GBM functions as a coarse 
filter for the larger molecules, while the slit diaphragm is the fine filter (204,215). If this view of 
the glomerular filtration barrier were correct, this would lead to a concentration polarization, ie, 
a clogging of the filter. Thus, this view of glomerular filtration seems to suffer from the combined 
inconsistencies mentioned in the discussion of the individual components of the filter.
Electrokinetic glomerulus theory
In Douglas Somers’ ‘Electrokinetic glomerulus theory’ (Somers D, J Am Soc Nephrol 2005 (16): 
109A), the central tenet is that anion transport over the GBM occurs more easily than cat-
ion transport, because the latter will continuously interact with the fixed negative charges of 
basement membrane components. This transport imbalance will result in the accumulation of 
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negative charge at the urinary space side of the GBM. In steady-state conditions, this will lead 
to a charge gradient with the highest negative charge downstream in the GBM. The increasing 
negative charge provides the restriction to negatively charged molecules such as albumin and, ac-
cording to this model, explains the glomerular filtration characteristics. The observation that the 
concentration of molecular tracers was higher in the subendothelial than the subepithelial part of 
the GBM (193,216) has been explained to support this view of an increasingly restrictive barrier, 
although other explanations are possible for this finding. 
Because ion transport takes place by convection, the formation of the charge gradient is depen-
dent on flow. Flow, as described above, is dependent on the filtration pressure characteristics in 
the glomerulus: the combined pressure and osmotic forces that drive the fluids out of the capil-
laries minus those that would drive fluids in. Halfway the glomerulus the in- and outward forces 
are similar (“raising the question why we have an efferent capillary in the first place”), resulting 
in a filtration pressure equilibrium. Consequently, in the glomerular capillaries downstream of 
the filtration pressure equilibrium, there will be no flow and thus no negative charge will build 
up. This would result in a loss of albumin by simple diffusion through the GBM. To explain the 
fact that this does not seem to occur, Somers suggests that the podocyte, by crossing the space 
between different capillaries, may transport the negative charge built up in afferent capillaries to 
efferent capillaries. This is compatible with the negatively charged surface of the podocyte’s major 
and foot processes that would prevent a loss of charge through an ‘electric shortcut’.
One of the predictions of this model is that proteinuria will occur in situations where GFR is de-
creased, because the subepithelial negative charge will not build up completely. Indeed, Rippe 
et al recently found that the sieving coefficient of Ficoll is increased (meaning that Ficoll is less 
effectively retained by the glomerular barrier) in low GFR conditions (217).
Permeation/diffusion hypothesis
In the Permeation/diffusion hypothesis (212), the size-selective properties of the glomerular filtra-
tion barrier are thought to reside in the GBM. Smithies assumes that the GBM can be viewed as a 
gel, and argues that – as in all gels – only a limited fraction of gel space is available for macromol-
ecules, determined by factors such as concentration of the gel and radius of the macromolecules. 
The small amounts of macromolecules that can permeate into the gel are subsequently trans-
ported across the GBM by either flow or by diffusion. With regard to the GBM-gel, the fraction 
available for albumin is about 0.02. Smithies calculates that the main means of macromolecular 
transport in the glomerulus is diffusion. In contrast, transport of water and small solutes depends 
on flow. Changes in flow have no effect on the diffusion, and will thus have only a minimal ef-
fect on the amount of albumin in Bowman’s space. However, the concentration of albumin is 
greatly influenced by flow. A decrease in glomerular flow (GFR) will lead to an increase in albu-
min concentration, saturating the tubular albumin reabsorption mechanisms and thus leading to 
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albuminuria. In other words, the transport of albumin into Bowman’s space is fairly constant, but 
the absence of the diluent is responsible for proteinuria. In this view, albuminuria is not necessar-
ily the result of a pathologic change in the glomerular filtration barrier, but may be the physiologic 
result of a decrease in GFR. On the other hand, changes in the glomerulus do induce albuminuria 
if they increase the hydrodynamic resistance of the filtration barrier, as for example in podocyte 
foot process effacement (218), or if they change the properties of the GBM (219). The experi-
ments by Rippe et al, showing increased sieving coefficients for Ficoll in low-GFR conditions, are 
in line with this theory of glomerular filtration.
In general, rodents have a relatively higher urinary protein excretion than humans. This could pos-
sibly be explained to be in line with the permeation diffusion theory: if the protein concentration 
is determined by the diffusion of albumin and the filtration of the diluent, the factors that deter-
mine these two variables are, respectively, the surface available for diffusion, and the amount of 
filtrated fluids. Human glomeruli are larger than those of rodents, and thus the diffusion surface 
and fluid content of human glomeruli is also larger than that of rodents. But diffusion surface 
increases with a factor to the power 2, while fluid content increases with a factor to the power 
3. Thus more diluent is available, suggesting that larger glomeruli would elaborate a more dilute 
pre-urine.
The permeation-diffusion theory does not readily explain the proteinuria seen in situations with 
a normal GFR and normal foot process morphology, as has been observed in animal models and 
sporadic human cases (85,103,143,220).
Absence of glomerular permselectivity
The most extreme view of glomerular filtration is that there is no, or at least very limited glomeru-
lar permselectivity, a hypothesis that has been fueled by several studies of Comper and cowork-
ers. Their hypothesis explains the inconsistencies that remain in the other theories concerning 
glomerular selectivity, but brings up another problem: if the glomerulus would filter ‘nephrotic 
levels of albumin’ (221), this would result in an albumin excretion of about 600 g per day (202). 
To explain the fact that only limited amounts of this reach the urine, Comper et al have hypoth-
esized that there is a high capacity albumin retrieval pathway in the proximal tubulus. Over the 
years, Comper et al have brought evidence for the absence of glomerular size and charge selec-
tivity (205), the presence of tubular retrieval pathways for example through tubular transcytosis 
(221), and have raised a hypothesis to explain proteinuria seen in glomerular diseases (222). Al-
though the potential interest of their findings is acknowledged (223), the methods of the experi-
ments have been criticized (14,43,202,223,224) and their results could not be reproduced (190). 
Synthesis
Most reviews on the subject of permselectivity move towards the recognition that the three layers 
of the glomerular filtration barrier are functionally interdependent, making it difficult to attribute 
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a more important role to one of the three (225). Indeed, damage to any of the three layers can 
be associated with the development of proteinuria (see below). Although intuitively true – why 
else would the glomerular capillary wall be endowed with its special properties – this view leaves 
the question as to how exactly the glomerulus elaborates its low-protein ultrafiltrate unanswered. 
From Bowman’s space, the glomerular ultrafiltrate empties into the tubular lumen, where its com-
position is modified on its way to the collecting ducts. The tubular system will be discussed next.
The tubular system
Each glomerulus is connected to a ~5 cm long renal tubule that is built of a proximal, intermedi-
ate, and distal segment. The proximal segment starts as a contortuous tube, containing cells with 
a prominent brushborder, and connects to a straight part. This part of the proximal tubule forms 
the transition to the intermediate segment that loops through the medulla as Henle’s loop. As-
cending from the medulla, Henle’s loop connects to the distal convoluted tubule that on its path 
to the collecting duct makes contact with the glomerular arterioles at the macula densa (226).
The different segments of the tubule contain cells with a different morphology and accordingly 
different functions. The main function of proximal tubular cells is reabsorption of water and the 
dissolved salts and small molecules of the ultrafiltrate. To this end, the cells are equipped with mi-
crovilli that provide a ~40 times increase in apical surface area. At the beginning of Henle’s loop, 
the amount of ultrafiltrate has been reduced to about 70 percent. The cells in Henle’s loop further 
reabsorb water and salts, with a predominance of salts, thereby increasing the medullary salt 
concentration. This forms the basis for the concentration of urine that is eventually performed in 
the collecting ducts. The distal collecting duct further reabsorbs NaCl as well as calcium. Water is 
less efficiently reabsorbed in this segment, resulting in a hypoosmotic fluid that is delivered into 
the collecting duct. 
The reabsorption and excretion mechanisms are extensively regulated throughout the course 
of the tubules by hormonal factors. Of further interest for the regulation is the juxtaglomerular 
apparatus, in which the macula densa of the distal segment takes part. This apparatus is – via 
incompletely elucidated mechanisms – responsible for the so-called tubulo-glomerular feedback 
that regulates the glomerular filtration in relation to the distal tubular output. The exact transport 
and regulation mechanisms at play in the tubular system will not be further dealt with in this 
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introductory chapter. In the interest of a discussion on the effects of filtered proteins on tubular 
epithelial cells, the mechanisms of tubular protein resorption will be discussed in some more 
detail. 
Proteins are mainly reabsorbed in the proximal tubules through receptor-mediated endocytosis. 
The main receptors for albumin in the proximal tubule are cubulin and megalin. Both are multi-
ligand endocytic receptors that are able to bind albumin. Binding of albumin to these receptors 
is followed by endocytosis and transport of the endocytic vesicles to the lysosome. Here albumin 
is degraded into amino acids that are subsequently excreted in the PTCs, while the receptors 
are recycled to the apical membrane (227,228). One research group has found that other ways 
of albumin transport may exist, namely through transcytosis (221). The endocytosed albumin is 
transported through the cell and delivered undegraded into the circulation. This way of albumin 
transport awaits further confirmation.
The tubular epithelial cells manufacture and rest on a basement membrane (TBM) of collagen IV 
(isoforms α1α1α2), laminins (111 and 511), and HSPGs (mainly perlecan).
Interstitium and the extracellular matrix
Between tubuli and glomeruli is the interstitium, which contains the blood vessels, peritubular 
capillaries (PTCs) as well as lymphatics. These vascular structures are embedded in a loose extra-
cellular matrix, produced by the interstitial fibroblasts. Other interstitial cell types include macro-
phages and – more recently described – dendritic cells that form a network surrounding the tubuli 
and glomeruli (229,230). 
The normal interstitial matrix contains collagens type I, III, V, VII, fibronectin, and tenascin. These 
molecules are present only in small amounts, for in the normal kidney cortex the interstitial space 
is limited: tubuli are normally positioned side by side, and the intervening PTCs fill most of the 
remaining space, often fusing their basement membranes with the TBM, at least optically.
Lymphatics accompany the larger arteries of the kidney, but are otherwise not found in the nor-
mal interstitium.
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CAUSES AND CONSEQUENCES 
OF PROTEINURIA
Proteinuria, the presence of abnormally high amounts of plasma proteins in the urine, is a symp-
tom associated with many different kidney diseases. Although the causes of proteinuria are di-
verse, the consequence of proteinuria in different diseases is similar, in that it confers an increased 
risk of loss of kidney function, in association with an increased risk of cardiovascular complica-
tions. This, together with the fact that the development of proteinuria may be modifiable, makes 
it an important risk factor in both native and transplant renal disease. In this paragraph, a brief 
overview of the epidemiology of proteinuria and the kidney diseases in which proteinuria is seen 
is provided. The paragraph focuses on the causes and consequences of proteinuria on the his-
topathological and molecular levels. The paragraph ends with a more general discussion of the 
mechanisms implicated in the progression of renal disease. 
Epidemiology
Several large population screenings have established the epidemiological characteristics of pro-
teinuria. In the district of Okinawa, Japan, more than 100,000 individuals were screened for pro-
teinuria and follow-up was recorded for more than 20 years (231). From these studies it became 
clear that proteinuria is an important independent predictor of the development of end stage 
renal disease. In Groningen, The Netherlands, a large population study, the PREVEND study, was 
performed in which about 40,000 persons were screened for albuminuria (232,233) (www.pre-
vend.org). These studies made clear that in 6.6 percent of the otherwise healthy population mi-
croalbuminuria was present. Furthermore, not only was microalbuminuria found to be associated 
with the progression of renal disease, it also was an important predictor of cardiovascular diseases 
(232,233). Several other epidemiologic studies have found a strong correlation between protein-
uria and the progression of renal disease (234-236). Based on this association, in 2006 the Dutch 
Kidney Foundation started the ‘Niercheck’, a national campaign to detect kidney damage in an 




Proteinuria can either be caused by a failure of tubular reabsorption of the small amounts of fil-
tered proteins, or by a loss of glomerular permselectivity, leading to larger amount of proteins in 
the pre-urine that saturate the tubular retrieval systems. 
Examples of the first include the Fanconi syndrome, in which there is a dysfunctional proximal 
tubular reabsorption mechanism (187). Such ‘tubular proteinuria’ usually results in only mild in-
creases in the protein content of the urine. Instead, glomerular proteinuria can be associated with 
large increases of albumin and other proteins in the urine, and may lead to the development of 
a nephrotic syndrome (see below). 
Glomerular proteinuria can be associated with damage to all different levels of the glomerular 
filtration barrier, the endothelium, the GBM, and the podocyte.
For example, preecclampsia is associated with endothelial cell damage and profound proteinuria. 
In the glomerulus, swelling of endothelial cells (endotheliosis) is seen. Pathogenetically, the de-
velopment of preecclampsia has been linked to the excess production of a soluble VEGF receptor 
(soluble Fms-like tyrosine kinase, sFlt), that binds and inactivates VEGF. In the glomerulus, VEGF-
A produced by podocytes may therefore not reach the endothelial compartment in sufficient 
amounts, leading to a loss of endothelial viability (21,237,238). Enzymatic breakdown of the 
endothelial glycocalyx resulted in an increased permeability for proteins that was mainly due to a 
loss of charge selectivity (239). 
The correct molecular make-up of the GBM is crucial for a normal filtration barrier; impaired as-
sembly of the GBM components leads to proteinuria or an otherwise more permeable GBM. This 
is most clearly underscored by hereditary syndromes that have been associated with mutations 
in genes coding for GBM components. Patients with Alports syndrome carry a mutation in one 
of the collagen chains of the mature GBM. Alports syndrome is characterized by hematuria, pro-
teinuria, and loss of renal function (240). Similarly, in nail-patella syndrome, a malfunction of the 
transcription factor Lmx1b leads to an aberrant collagen IV assemblage, followed by nephrotic 
syndrome (241). Also, incorrect assembly of the GBM matrix components as seen in the ILK 
knockout mice (139), is related to the development of proteinuria. 
A laminin β2 chain knockout mouse was shown to develop severe proteinuria, despite normal 
glomerular development and continued expression of the fetal laminin β1 chain (242). The lam-
inin 521 composition thus appears crucial for the correct function of the GBM. In retrospect, 
the laminin β2 knockout mouse appeared to accurately mimic the characteristics of Pierson’s 
syndrome, a hereditary nephrotic syndrome that was described by Pierson et al in 1963 (243). 
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Recently, it was recognized that the cause of Pierson’s syndrome is a mutation in the gene coding 
for laminin β2 (244,245). 
Strikingly, mice that in a podocyte-specific fashion lack expression of perlecan (200) or large parts 
of agrin (197,199) – the major heparin sulphate proteoglycans of the GBM – show no proteinuria, 
although perlecan null mice seem to be more susceptible to glomerular damage (246). Likewise, 
mice that lack Ext, the protein responsible for heparan sulphate biosynthesis, in podocytes are 
not proteinuric (201). Also, in vivo degradation of heparan sulphates in the GBM does not cause 
proteinuria (198). As discussed before, this indicates that the charge barrier of the GBM may be 
of less importance for the correct function of glomerular permselectivity than previously thought. 
Damage of podocytes is almost always accompanied by proteinuria. There are several ways in 
which podocytes can be damaged, including through genetic, inflammatory, and infectious dis-
eases, through growth factors, cytokines, medication, and mechanical stress. Several of the he-
reditary forms of proteinuria have already been discussed, as they have been closely related to the 
elucidation of the cell biology of the podocyte. The currently known forms of hereditary protein-
uria are listed in table 1. Other forms of podocyte damage will be illustrated in the description of 
proteinuria that occurs in various kidney diseases.
Causes of proteinuria in various kidney diseases
Proteinuria is a symptom of many kidney diseases and is especially seen in diseases characterized 
by a glomerular involvement. These comprise among others minimal change disease, focal seg-
mental glomerulosclerosis, diabetic nephropathy, membranous nephropathy, membranoprolif-
erative nephropathy, and lupus nephritis. In these diseases, proteinuria can occur as a component 
of the nephrotic syndrome, characterized by a loss of more than 3,5 gram of protein per 24 hours 
(nephrotic range proteinuria), edema, and hypoalbuminemia. 
How does the development of proteinuria in these different diseases relate to the different pro-
cesses discussed above? 
Minimal change disease
Minimal changes disease (MCD), also termed minimal lesion or lipoid nephrosis, is the main 
cause of proteinuria in children, and the third most common cause of nephrotic syndrome in 
adults (247). The presentation is that of a nephrotic syndrome, not infrequently following infec-
tions or vaccinations. The condition is generally responsive to treatments with steroids, although 
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patients may show relapses, and some may even be steroid resistant. In such cases FSGS should 
be suspected.
The histopathology of MCD, as the name implies, does not show gross abnormalities on light 
microscopy. On electron microscopic evaluation, extensive effacement of podocyte foot processes 
is seen. The pathogenesis of MCD remains unknown, although several mechanisms have been 
hypothesized (247). A T-cell derived permeability factor has been suggested to induce the devel-
opment of MCD (248), although definitive proof for this is lacking. Several cytokines have been 
shown to be upregulated in MCD, and these could act via cytokine receptors that have been 
found to be expressed by podocytes (249). Van den Berg et al (250) found that through the ac-
tion of IL-4 and IL-13 on podocytes, the activity of the proteases cathepsin L and heparanase in 
the GBM is increased. This may subsequently lead to a degradation of heparan sulphate in the 
GBM, leading to proteinuria. Indeed, alterations of the heparan sulphate moieties in the GBM 
have been repeatedly found in MCD (251). 
The group of Bakker and coworkers has postulated that hemopexin might be the circulating 
factor that is responsible for the development of MCD. Injection of hemopexin in rats resulted 
in a disorganization of the anionic sites at the subendothelial side of the GBM, and transient 
proteinuria (252).
Table 1. Hereditary forms of proteinuria
Gene Disease Protein Glomerular morphology References
NPHS1 Congenital Nephrotic syndrome of the Finnish type Nephrin FSGS (88)
NPHS2 Steroid resistant nephrotic syndrome Podocin FSGS (111)
ACTN4 FSGS1 α-actinin-4 FSGS (56)
TRPC6 FSGS2 TRPC6 FSGS (112,113)
CD2AP FSGS3 CD2-associated protein FSGS (502)
PLCE1 Nephrotic syndrome Phospholipase Cε1 DMS (503)
LMX1B Nail-patella syndrome Lmx1b DMS, FSGS (181,182,241)
WT1 Isolated DMS, Denys Drash syndrome, Frasier syndrome, WAGR Wilms tumor protein 1 DMS/FSGS (504)
LAMB2 Pierson’s syndrome Laminin β2 DMS (245)
FSGS – focal segmental glomerulosclerosis; DMS – diffuse mesangial sclerosis; WAGR – Wilms’ tumor, aniridia, genitourinary 
malformations, mental retardation.
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Others have attributed a more direct role to the podocyte in the development of MCD. Patrakka 
et al found that the slit diaphragm is often lacking in patients with MCD (253). Regele et al (142) 
found that the expression of dystroglycan was decreased in minimal change disease in com-
parison to FSGS. Recognizing the role of podocyte-associated proteins in hereditary proteinuric 
syndromes, several investigators have studied the expression of these proteins in MCD (254-257). 
The results varied, but seem to be most compatible with a secondary change rather than primary 
involvement in the development of proteinuria in MCD (258,259). In a scenario in which the 
podocyte is the key player in the development of MCD, the fact that this disease is responsive to 
steroids could be explained by the steroid responsiveness of podocytes (157).
Focal segmental glomerulosclerosis (FSGS). 
FSGS is also characterized by nephrotic range proteinuria, often in the setting of a nephrotic syn-
drome. In contrast to MCD, the proteinuria is mostly refractive to steroid treatment, and comes 
with a progressive decline in renal function that eventually may necessitate transplantation. The 
histopathology of FSGS is characterized by scarring of some of the glomeruli (focal), in a way 
that involves only limited parts of a glomerulus (segmental). The lesions that are seen in FSGS are 
diverse, and recently a classification has been made to describe the different forms of FSGS (260). 
In this classification, five patterns of FSGS are distinguished on the basis of their morphologic 
features, namely the collapsing, tip lesion, cellular, perihilar, and not otherwise specified variants 
of FSGS. Diagnosis of one of the variants requires exclusion of the previous variants in the order 
listed here. These different variants of FSGS may coexist in a single renal specimen (38), and it 
is unclear whether the classification on morphologic basis relates to different pathophysiologic 
mechanisms. The first studies that evaluate the clinical implications of the classification do show 
differences between the variants; for example, the collapsing variant is associated with a popu-
lation that differs in demographics from that of the other variants, and clearly carries a worse 
prognosis (261). 
FSGS should not be regarded as a disease in itself, but rather as the stereotypic histomorphologi-
cal representation of different specific diseases. These include hereditary diseases, obesity, hyper-
tension, viral infection, medication, and mechanical stress. A substantial percentage of cases of 
FSGS, however, are of unknown origin, the so-called primary or idiopathic forms of FSGS.
In diseases that lead to FSGS, the secondary forms of FSGS and hereditary syndromes, podocyte 
injury has been shown to be a central step in development of FSGS and the associated proteinuria 
(262). In hereditary cases, the mutated genes often code for proteins with a more or less specific 
expression in podocytes, as discussed before. In animal models, direct damage to podocytes, for 
example through the injection of puromycin aminonucleoside, leads to proteinuria and subse-
quently development of FSGS. Medication like cyclosporine and pamidronate may damage the 
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podocyte; the latter gives rise to a collapsing variant of FSGS with high proteinuria (263). Podo-
cytes have been shown to be a target of infection by HIV (264), which may lead to HIV-associated 
nephropathy, a disease characterized by rapid decline in renal function, high proteinuria, and 
FSGS of the collapsing type (265).  FSGS can be seen in hypertensive patients. In these cases, 
the mechanical stress put on podocytes through the increased intraglomerular pressure may lead 
to damage of podocytes. Indeed, cultured podocytes have been found to be stress-responsive 
(266). Protein overload also leads to the development of FSGS (267,268). Consequently, not only 
damage to the podocyte, but also other mechanisms that cause increased passage of proteins 
through the glomerular filtration barrier may, via podocyte injury, lead to FSGS. 
Despite this progress in the elucidation of the secondary FSGS, the etiology of the primary forms 
of FSGS remains elusive. Much research has been done to identify a putative humoral permeabil-
ity factor. Such a factor would explain the high rate of FSGS recurrence in patients that receive 
a renal transplant because of FSGS. Also, a permeability factor would explain the transmission 
of a proteinuric condition from mother to her unborn child (269). Several groups, most notably 
that of Savin and coworkers, identified characteristics of this permeability factor, but the ultimate 
structure and origin remain unknown (262,270). Others have supposed that not the presence 
of a permeability factor, but the absence of crucial plasma factors lead to the development of 
proteinuria and FSGS. The hypotheses about the pathophysiologic mechanisms again incorpo-
rate the podocyte as a crucial target. Coward et al tested the influence of plasma of normal 
and nephrotic patients on the distribution and signaling of slit diaphragm proteins in cultured 
podocytes, and found that the effect of nephrotic plasma could be abrogated by adding normal 
plasma (271). Wei et al found that the plasma concentration of soluble urokinase receptor (uPAR) 
is elevated in serum of patients with recurrent FSGS (Wei et al, J Am Soc Nephrol 2008(19):103A). 
In mouse models, uPAR signaling in podocytes has been shown to cause foot process effacement 
and proteinuria (272), but mechanistical evidence for a pathogenic role of soluble uPAR in human 
FSGS is lacking.
Irrespective of the cause of proteinuria, podocyte injury is a crucial step in the further develop-
ment of FSGS. Using combined observations from different animal models, Kriz (273) has de-
scribed a sequence of events that explains the development of FSGS: podocyte injury leads to 
loss of podocytes, which results in denuded parts of the GBM and hypertrophy of the remaining 
podocytes. This will increase the possibilities for the formation of adhesions of the podocytes or 
the GBM to the parietal epithelial cells. Once such an adhesion has been formed, this leads to an 
encroachment of the parietal cells on the capillaries, and to ‘misdirected filtration’, the delivery of 
glomerular filtrate to the space between Bowman’s capsule and the overlying parietal epithelial 
cells. 
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Despite the initial pivotal role of the podocyte, the further development of the FSGS lesions does 
involve other glomerular cell types. Kihara et al and Nagata et al suggested that in the collapsing 
and cellular variants of FSGS, the proliferating cells are of parietal origin (274,275). In a series of 
studies, Smeets et al and Dijkmans et al have recently brought more evidence for the involvement 
of parietal epithelial cells in the development of collapsing FSGS in animal models (35), human 
idiopathic FSGS (38), as well as HIV and pamidronate associated collapsing FSGS (39). 
Taken together, the pathogenetic mechanisms in secondary FSGS all converge on podocyte dam-
age as a central initiating step of development of proteinuria. In primary causes of FSGS, the initial 
pathogenetic mechanisms of proteinuria remain unclear, although a contribution of the podocyte 
is to be expected, and certainly this cell is at play in the later development of FSGS.
Diabetic nephropathy
Diabetic nephropathy is a complication of both type I and type II diabetes, and is currently the 
main cause of end stage renal diseases. Clinically, diabetic nephropathy is characterized by a 
decline in renal function that is preceded or accompanied by the development of proteinuria. 
Microalbuminuria is an important risk factor for the progression of the disease, and is currently 
used to screen patients at risk for development of diabetic nephropathy (276). 
The histopathologic features of diabetic nephropathy comprise glomerular hypertrophy, thick-
ening of the GBM and mesangial expansion in early stages of the disease. Later phases are 
characterized by the presence of glomerulosclerosis, sometimes showing the pathognomonic 
Kimmelstiel-Wilson nodules, together with interstitial fibrosis. 
Mesangial cells as well as podocytes have been implicated in development of glomerulosclerosis 
in diabetic nephropathy, and especially cytokines and growth factors, such as TGF-β, connec-
tive tissue growth factor (CTGF), and insuline like growth factor have been extensively studied. 
With regard to the proteinuria in diabetic nephropathy, different components of the glomerular 
filtration barrier have received attention, and all seem to be affected by the diabetic condition. 
The thickening of the GBM may relate to a dysregulated assembly of matrix components, which 
translates into dysfunction. The endothelial cells are damaged in the diabetic milieu, through 
both metabolic and hemodynamic factors (277). In recent years, most attention has been given 
to the role of podocyte injury and podocyte loss in diabetic nephropathy. The attention for the 
role of the podocyte has been fueled by the seminal observation by Pagtalunan et al (278), that 
in Pima Indians with type II diabetes glomeruli show a marked decrease in podocyte number, a 
feature now called ‘podocytopenia’. Podocyte damage in diabetic nephropathy can be induced 
by different factors, including high glucose per se (279), oxidative stress, the altered glomerular 
hemodynamic conditions (280), advanced glycation end products (281), growth factors such 
as TGF-β (279), and an increased activity of the local renin-angiotensin system (282,283). The 
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podocytes may subsequently be lost through different mechanisms. For example, increased TGF-β 
signaling has been linked to podocyte apoptosis (124). Also, the adhesion of podocytes to the 
GBM may be diminished as a result of a decreased integrin expression (284). These loosely at-
tached podocytes may shed into the urine, and podocytes, as well as podocyte proteins, can be 
recovered from urine of diabetic patients (285,286). Furthermore, the podocyte may show func-
tional deficits, as is exemplified by a decreased nephrin expression and foot process effacement. 
Many of the deleterious factors in the diabetic milieu affect the podocyte through stimulation of 
local angiotensin II production. Stimulating podocytes with angiotensin II in vitro leads to upregu-
lation of TGF-β, providing a link to podocyte apoptosis (287). The effect of angiotensin II on the 
expression of nephrin and other slit diaphragm-proteins has been studied. A decreased immu-
nostaining for these proteins in the presence of elevated angiotensin II levels has been described 
(283,288,289). These findings also explain the notion that in diabetic nephropathy angiotensin 
converting enzymes and angiotensin II inhibitors have a beneficial effect that cannot be explained 
solely by systemic blood pressure normalization.
Through podocyte loss, mechanisms are set in motion that further aggravate the proteinuria and 
glomerular damage. For example, Baelde et al (126) suggested podocyte loss as the cause of de-
creased glomerular VEGF expression, and hypothesized that this may infringe on the endothelial 
maintenance. 
Membranous nephropathy
Membranous nephropathy is characterized by its histopathologic presentation, namely deposi-
tion of subepithelial immune complexes along the GBM in a granular fashion, without inflamma-
tion. In response to this, the podocyte forms and deposits GBM components between these im-
mune complexes, visible as ‘spikes’ in light microscopy. Proteinuria, usually in the nephrotic range, 
is the most frequent symptom. The clinical course is related to the severity of the proteinuria, 
with frequent progression to end-stage renal disease in high-proteinuric individuals. Although 
several diseases, including malignancies, are associated with the development of membranous 
nephropathy, most cases are idiopathic.
Most of the knowledge about the pathogenetic mechanisms of proteinuria in membranous ne-
phropathy has been derived from studies in an animal model that closely mimics this disease, Hey-
mann nephritis (290). In this model, antibodies directed against the rat podocyte protein megalin 
(see above) give rise to the formation of immune complexes at the podocyte basal membrane 
that are subsequently shed and deposited in the lamina rara externa of the GBM. Here, these im-
mune complexes activate complement, and the C5b-9 complex causes damage to the podocyte. 
Apart from causing direct damage, the C5b-9 complex also activates podocytes, resulting in the 
formation and release of proteases and reactive oxygen species (146,291). These components 
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damage the GBM as well as the podocyte itself through lipid and protein peroxidation. Further-
more, there are several intracellular consequences that result from the damage of podocytes by 
complement, including DNA damage (292) and cytoskeletal reorganization (293). The latter also 
influences the expression and distribution of nephrin and podocin (294,295), and presumably 
alters the function of the slit diaphragm. The activated podocytes also increase their production 
of GBM components, but it has been suggested that the assembly of this extracellular matrix is 
abnormal (171,296). Consequently, the proteinuria that is seen in the Heymann nephritis model 
has been explained by 1) changes in the GBM through abnormal assembly, increased breakdown, 
and damage through reactive oxygen species; and 2) damage to the podocyte, diminishing its 
adhesive properties to the GBM, disrupting the organization of the slit diaphragm, increasing 
podocyte DNA damage and apoptosis.
It is likely that in human membranous nephropathy, similar pathogenetic mechanisms are at 
play. Indeed, the role of reactive oxygen species has been suggested by a small clinical study that 
showed beneficial effects of the antioxidant probucol in patients with membranous nephropathy 
(297). However, in most cases, the antigen responsible for the development of this sequence of 
events is still elusive. The one exception is the antigen that is responsible for a rare congenital 
form of the disease, described by the group of Ronco in 2002 (148). They found that antenatal 
membranous nephropathy is caused by antibodies directed against neutral endopeptidase (NEP), 
an enzyme expressed at the podocyte membrane but also in the placenta. Anti-NEP antibodies 
developed in mothers that were NEP-deficient due to a mutation in the MME gene, but were 
exposed to the protein of fetal origin during pregnancy. In a subsequent pregnancy, the antibod-
ies could cross the placenta and induce the disease (147,148). Recently, a preliminary report 
suggested that the phospholipase A2 receptor could be the target antigen in a subset of patients 
with membranous nephropathy (Beck et al, J Am Soc Nephrol 2008(19):104A).
If the pathogenetic mechanisms that have been revealed in animal models would also apply 
to humans, this could be of particular interest in patients that have developed membranous 
nephropathy secondary to a malignancy. These patients have apparently developed antibodies 
directed against components of the tumor that also react with normal components of the glom-
erulus. In the glomerulus, these antibodies are able to activate complement, thus it could be sus-
pected that the same antibodies could have anti-tumor effects. It would be of interest to evaluate 
the clinical course of patients that have developed membranous nephropathy in comparison to 
those with the same type of cancer, but without membranous nephropathy development.
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Consequences of proteinuria
Effects of proteinuria on the glomerulus
The effects of proteinuria on the glomerulus are often difficult to distinguish from causes of 
proteinuria. Injury to podocytes may, as discussed above, lead to proteinuria, but also one might 
envision harmful effects of increased protein passage on podocytes. Adding to this difficulty is the 
notion that factors that give rise to proteinuria may in addition lead to histopathologic changes, 
but without a causal relation between the two. A disturbed GBM make-up, for example, may 
lead to proteinuria and podocyte changes independently. 
Cause and effect discussions aside, there are some clear histopathologic observations in pro-
teinuria, the most consistent being that proteinuria is almost always accompanied by profound 
changes in podocyte morphology. The highly organized cellular podocyte architecture is lost, 
transforming the podocyte into a flattened, simplified epithelial cell. Effacement of foot processes 
takes place through widening and shortening, and at the base of the flattened foot processes, 
a dense band of actin filaments is seen (298). Podocyte hypertrophy is often observed, together 
with microvillous transformation and pseudocyst formation. Also, protein reabsorption droplets 
that contain plasma proteins are seen in the podocyte cytoplasm. There is often an increased 
or renewed expression of mesenchymal – and thus for podocytes embryonic – markers, and 
according to Kerjaschki it may be concluded that in proteinuria ‘podocytes recapitulate their 
development in reverse’ (50). There is some discussion as to whether the extent of foot process 
effacement is related to the amount of proteinuria, with some studies indicating a positive rela-
tion (259,298), while others did not find such a correlation (299). Foot process effacement influ-
ences the ultrafiltration coefficient, and there is a correlation between the amount of foot process 
effacement and the GFR (218). Consequently, according to Smithies, the decrease in GFR may 
result in proteinuria (212). In most cases, however, podocyte foot process effacement seems to 
accompany the development of proteinuria, sometimes lagging behind.
Abbate et al studied the changes in podocytes in a rat model of renal mass reduction, and 
described that the changes in the podocytes related to the amount of protein accumulation in 
podocytes in vivo, and that anti-proteinuric therapies proved to be helpful. In vitro, stimulation of 
podocytes with albumin led to an increases production of TGF-β (267). In a follow-up study, the 
same group found that protein overload led to the upregulation of the noxious molecule endo-
thelin-1 via dysregulation of the podocyte cytoskeleton (53). In this way, proteinuria per se may 
be the podocyte-damaging factor that leads to loss of podocytes, and to a sequence of changes 
as described before under focal and segmental glomerulosclerosis (300).
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Effect of proteinuria on the tubulointerstitial compartment
The pathophysiology of the consequences of proteinuria for the tubulointerstitial compartment 
has been more clearly delineated. Again, it has been difficult to indicate to what extent the 
amount of proteinuria is a marker of the damage, instead of the actual cause of it (301). This 
question has been addressed using the amphibian axolotl as a model system. Some nephrons in 
the kidneys of these amphibians are connected to the peritoneal cavity, while others are closed. 
Gross et al found that upon injection of fetal bovine serum in the peritoneal cavity of these ani-
mals, only the tubular epithelial cells of the nephrons with a connection to the peritoneal cavity 
were activated and showed interstitial fibrosis (302). This suggests a causal role for increased 
protein passage in tubulointerstitium injury, and supports hypotheses based on more correlative 
evidence. 
Several mechanisms may be responsible for the toxic effect of proteinuria on tubules. For ex-
ample, protein cast formation may lead to obstruction of tubuli (301), filtered proteins such as 
complement factors may be toxic to the tubular epithelial cells, and cytokines may directly acti-
vate the tubular epithelium (303). Most attention has been given to uptake of proteins by tubular 
epithelial cells. During proteinuria, multiple macromolecular components reach the apical side 
of the tubules. Which one of these is harmful is a matter of discussion. Below is a description of 
the factors that are held responsible for the toxic effects of proteinuria on the tubulointerstitial 
compartment, and the molecular pathways through which such an effect is mediated.
The toxicity of albumin has received a lot of attention. In vitro, incubation of tubular epithelial 
cells with albumin has a profound effect: the endocytosed albumin, either directly or via the 
protein kinase C-dependent formation of reactive oxygen species (304), activates several signal-
ing proteins, including mitogen-activated protein kinases (305), nuclear factor κB (306,307), and 
signal transducer and activator of transcription proteins (308). This activation of tubular epithelial 
cells results in the modulation of cytokine production and ECM regulation: albumin upregulates 
the tubular expression of interleukin-8 (307), macrophage chemoattractant protein-1 (306), RAN-
TES (309), and endothelin-1 (310); it increases the expression of different collagens (311), pro-
fibrotic cytokines such as TGF-β (312), and tissue inhibitors of metalloproteinases (TIMPs) (313). 
Also tubular production of angiotensin II is increased (314). These changes lead to an interstitial 
inflammatory response, and promote the development of interstitial fibrosis. Furthermore, pro-
tein overload has been shown to directly lead to increased tubular apoptosis (315). 
However, there are reports that failed to show a direct effect of albumin on tubular epithelial 
cells (316). For example, Burton et al found that although plasma had a clear effect on cytokine 
production and ECM regulation, purified albumin failed to induce this effect (317,318). This sug-
gested that the substances bound to albumin, but not albumin itself, promotes the aforemen-
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tioned cellular changes. Indeed, several experiments have shown an effect of albumin-bound free 
fatty acids (319,320).
Proteinuric Nagase analbuminaemic rats do develop tubulointerstitial fibrosis in the absence of 
albumin (321). This, together with other observations, has suggested that other proteins may 
also be responsible for the toxic effect of proteinuria on the tubular epithelial cells. These include 
transferrin, immunoglobulins, cytokines, growth factors, and complement (301). For example 
in membranous nephropathy, the C5b-9 complex may bind to the tubular apical surface and 
damage these cells (293). Also, filtered complement components may be activated locally via 
the alternative pathway, and tubular epithelial cells also synthesize complement in response to 
protein overload (322). 
Most of the insight into the consequences of exposure of tubular epithelial cells to increased 
amounts of plasma proteins has been derived from in vitro studies. These studies have been criti-
cized because they use protein concentrations that are outside the physiologic range. However, 
as stressed by Remuzzi (323), the protein concentration in vivo may be low in Bowman’s space, 
but increases as the pre-urine passes along the nephron and water is absorbed. Also the duration 
of the in vivo exposure is usually longer than in cultured cells. 
Taken together, several components that are present in excessive amounts during proteinuria 
seem to act on the tubular epithelial cells, thereby creating a pro-inflammatory and pro-fibrotic 
milieu. Together with tubular atrophy and apoptosis, interstitial inflammation and fibrosis form 
the histopathological representation of progressive renal diseases, for which mechanisms are 
discussed in a later paragraph.
Cardiovascular risk
The nephrotic syndrome comes with changes in the blood lipid profile (hyperlipidemia and hy-
percholesterolemia). Such changes are related to the development of atherosclerosis. However, 
also low levels of albuminuria, even in the high normal range, increase the risk for cardiovascular 
disease. How can the effect of microalbuminuria on the cardiovascular system, most notably 
atherosclerosis, be explained at a pathophysiological level? This is a question that remains largely 
unanswered. In a review on the different possibilities to explain the clear epidemiologic link be-
tween the two, Stehouwer and Smulders (324) propose that atherosclerosis and microalbumin-
uria may be the result of a common pathophysiologic process, such as endothelial dysfunction. 
This hypothesis, modified from the Steno hypothesis that places more emphasis on systemic 
changes in basement membrane composition (325), is of interest in the context of an increas-
ing appreciation of the importance of the endothelium in the permselectivity of the glomerulus. 
Another pathophysiological explanation is that mutations in genes that cause proteinuria also 
affect the heart, as may be the case with NPHS2 (326). However, it is unlikely that this explains 
chapter 1 > causes and consequences of proteinuria48
the cardiovascular risk in the majority of patients that do not have similar mutations. Furthermore, 
a systemic proinflammatory state associated with nephrotic syndrome may provide a link to car-
diovascular changes (327).
Progression of renal disease
The kidney has a stereotypic reaction to injury
Regardless of the initial cause of renal disease, the histopathologic lesions that parallel the decline 
in renal function include glomerulosclerosis, tubular atrophy, interstitial fibrosis, and interstitial in-
flammation. This has given rise to the widely accepted notion that the progression of renal dam-
age involves a common mechanism. Ideas about the nature of this mechanism and, accordingly, 
the temporal relationship of the histopathological lesions (e.g., does the inflammation precede or 
follow the development of fibrosis) vary, as discussed below in more detail.
Next to common histopathological features, the different renal diseases, both in native and trans-
plant nephropathies, share risk factors for progression. These include proteinuria and hyperten-
sion. Proteinuria as a risk factor for native kidney diseases has already been discussed. Proteinuria 
has a comparable detrimental effect in the transplantation setting. Several groups found that 
even low grade proteinuria in renal transplant patients is an independent predictor of graft loss, 
and anti-proteinuric therapies have a beneficial effect on graft survival (328-330). Zayas et al 
measured dextran sieving coefficients in allografts and found that even in well-functioning grafts, 
there is some loss of glomerular permselectivity (331), and suggested a link between this glo-
merular leakiness and progression of transplant pathology.
Hypertension represents another risk factor for progression of both native and transplant renal 
disease (332). Haroun et al found a relationship between the severity of hypertension and the 
risk to develop end stage renal disease (333). This is also true in the transplantation setting (334). 
Proteinuria and hypertension seem to amplify each others effect (330,332). The pathophysiologic 
explanation for this interaction will be outlined below.
Of all the histopathological characteristics of progressive kidney disease, the lesions that correlate 
most closely with renal function loss are those found in the interstitium (335,336). Interestingly, 
a substantial portion of renal disease primarily affects glomeruli. The link between the damage 
in these two tissue compartments and the role of the mentioned risk factors therein will be de-
scribed in the following paragraphs. 
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How does glomerular injury lead to tubular damage
There are several theories about the mechanisms that connect glomerular damage to tubular 
injury and interstitial fibrosis (303,336,337).
1) In a previous paragraph, the hypothesis that proteinuria has a central role in the connection 
between glomerular and tubular injury has been discussed. This so-called Remuzzi theory attri-
butes a toxic effect of the increased amount of proteins filtered by the glomerulus on the tubular 
epithelial cells, resulting in a cellular reaction that promotes influx of inflammatory cells and 
fibrogenesis (234,235,322). 
2) In a series of studies, Kriz has lined out another sequence of events that connects glomerular 
damage to tubular injury and nephron loss (303,338-340). The starting point is damage to or loss 
of podocytes that predisposes for the formation of an adhesion of the naked GBM to Bowman’s 
capsule. Capillaries in these adhesions may still be patent, at least for some time, leading to filtra-
tion of plasma products into the space between the parietal epithelial cell and their basement 
membrane – so-called misdirected filtration. This leads to the formation of a proteinaceous cres-
cent that, if misdirected filtration persists, spreads over a large part of the glomerular circumfer-
ence and continuously into the tubular compartment, separating the tubular epithelial cells from 
their basement membrane (338). This leads to atrophy of the proximal part of the tubule or even 
complete obstruction of the tubular lumen, resulting in collapse of the tubule and further atrophy 
downstream. Tubular atrophy is followed by apoptosis of tubular epithelial cells, removal by the 
infiltrating mononuclear cells, and scar formation, ie, interstitial fibrosis. 
Damage remains confined to the individual nephron involved in the process of misdirected filtra-
tion – proximal tubular atrophy and obstruction – tubular decomposition and scar formation. This 
is in seeming contradiction with the notion that loss of renal function is related to tubulointersti-
tial changes, and not to glomerular injury. Kriz and co-workers explain this by pointing out that 
the nephron disappears completely, leaving a fibrotic nephron recognized as a tubulointerstitial 
scar, but including a sclerotic glomerulus (338).
3) The glomerular cytokine theory (341) is yet another explanation of the link between tubular 
injury and glomerular damage. The theory applies most directly to inflammatory glomerular dis-
eases. Three phases are distinghuished: i. delivery of cytokines and growth factors expressed in 
the glomerulus via diverse routes to the tubulointerstitial compartment, stimulating local inter-
stitial and tubular cells; ii. stimulated cells express further chemotactic factors that attract mono-
nuclear cells; iii. these cells release growth factors that mediate further injury to the tubules, and 
promote interstitial fibrosis.
4) Another concept of the etiology of chronic kidney disease focuses on the role of vascular 
changes and ischemia (342). Indeed, areas of tubular atrophy and interstitial fibrosis show a 
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decreased density (rarefaction) of peritubular capillaries. In these areas, there seems to be an 
impaired angiogenic balance, with a predominance of antiangiogenic factors such as thrombo-
spondin-1 and a decrease of angiogenic factors such as nitric oxide and VEGF (342,343). The 
resulting ischemia drives the development of interstitial fibrosis, which in turn results in an even 
more impaired delivery of nutrients to the tubular epithelial cells, thus perpetuating the process. 
Conversily, injection of pro-angiogenic compounds such as VEGF slow the development of inter-
stitial fibrosis (344). Also, hypoxia promotes inflammation, resulting in further tissue damage and 
fibrosis.
While these observations clearly point at the importance of the microvasculature in chronic renal 
diseases, the way in which glomerular damage leads to ischemia and tubulointerstitial micro-
vascular changes is less clear (303). One might envision an impaired blood flow as a result of 
glomerular capillary damage (345). Furthermore, glomerular production of angiotensin II may 
cause vasoconstriction in the efferent arterioles, resulting in a diminished blood flow into the peri-
tubular capillaries. Also, pro- and anti-angiogenic factors expressed in the glomerulus may reach 
the tubular compartment via the normal blood flow; a disturbance in the glomerular expression 
pattern of pro- and anti-angiogenic factors may thus translate to a shift in the tubulointerstitial 
angiogenic balance. In this regard, it is of interest that Baelde et al (126) found a negative cor-
relation between glomerular VEGF production and interstitial fibrosis. However, the exact nature 
of the mechanisms that link glomerular changes to interstitial vasculature deserves further study.
5) Related to the previous mechanism of interstitial fibrosis is the hypothesis that, as nephrons are 
lost during disease progression, the remaining nephrons start to hyperfunction, thereby increas-
ing their metabolic demands (336). This will impact on their oxygen consumption and even in the 
presence of a normal microvasculature this may lead to hypoxia (345). Another consequence of 
the increased workload of tubular epithelial cells may be the increased formation of ammonia, 
which in turn can activate complement via the alternative pathway, favoring an inflammatory 
response (346,347).
These pathways are not mutually exclusive, and several pathways may be at play simultane-
ously and in an additive fashion. For example, interstitial fibrosis as a result of tubular activation 
will aggravate tubular epithelial hypoxia; tubulotoxic effects of proteinuria induce expression of 
vasoconstrictive molecules and evoke inflammatory responses that suppress angiogenic factors, 
leading to further ischemia. 
Kriz’ misdirected filtration theory is the most dissimilar of other pathways, although misdirected 
filtration does not rule out a concomitant role for excess protein trafficking. The misdirected 
filtration theory is especially applicable in diseases that have a glomerular cause, while the other 
pathways listed also apply to situations in which the tubulointerstitium is primarily targeted, for 
example in the case of transplant rejection. The most crucial difference between the misdirected 
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filtration theory and the other theories listed relates to the role that interstitial fibrosis is assumed 
to have. From a teleological point of view, Kriz et al (303) argue that the inflammation clears the 
remnants of an already irreversibly damaged nephron, which is subsequently replaced by fibrotic 
material. This limits the damage to a single nephron and at the same time retains the architecture 
of the remaining tissue. A common theme in the other pathways is the attraction of inflamma-
tory cells to functional, albeit damaged, nephrons that orchestrate the development of interstitial 
fibrosis. In this scenario interstitial fibrosis is assumed to be a harmful event leading to further 
interstitial damage and loss of functional tissue. The molecular mechanisms that underlie devel-
opment of such inflammation and fibrosis will be discussed next.
Mechanisms of interstitial fibrosis
Inflammation
As a result of the injuring mechanisms lined out above, tubular epithelial cells become activated 
and express pro-inflammatory molecules. MHC class II expression on tubular epithelial cells is 
upregulated, adhesion molecules including osteopontin and VCAM are expressed, and cytokines 
and chemokines including MCP1, RANTES, fractalkine, endothelin 1, and IL-6 and IL-8 are re-
leased (348,349). This is generally seen as the starting point of further damage: The pro-inflam-
matory milieu attracts leukocytes, primarily monocytes/macrophages and T-lymphocytes. These in 
turn secrete factors such as IL-1, interferon γ, and TNF-α which further activate tubular epithelial 
cells, thus initiating a self-perpetuating process of injury and inflammation. 
Cells that contribute to fibrosis; EMT
Injury, inflammation, and ischemia are at the basis of fibrosis: this milieu promotes fibrogenesis 
by different cells. Tubular epithelial cells may increase their production of ECM, and also macro-
phages are thought to contribute to the interstitial fibrosis, although they additionally regulate 
matrix degradation. The cells that are mainly responsible for the deposition of the ECM are fibro-
blasts. There is some controversy as to what the main source of these fibroblasts is. Increase in the 
number of fibroblasts in the tissue results from the proliferation of local fibroblasts. A small per-
centage probably originates from the circulation. Furthermore, fibroblasts may derive from the tu-
bular epithelial cells through a process of epithelial-mesenchymal transformation (EMT), a process 
that has received much attention in recent years. During EMT, epithelial cells lose typical epithelial 
characteristics (intracellular adhesions, cellular polarity, differentiation markers), gain features of 
mesenchymal cells (cell motility, expression of fibroblast markers such as FSP1/S100A4), and mi-
grate to the interstitium. In mouse models of progressive fibrosis, EMT was an important source 
of interstitial fibroblasts, responsible for at least 36 percent of these cells (350). Although such a 
cellular plasticity may seem striking at first, it should be remembered that tubular epithelial cells 
derive from mesenchymal cells, making EMT a known pathway traveled in the opposite direction 
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(351). Others have disputed the importance of EMT, pointing at the fact that tubular epithelial 
cells in transit have up until now never been observed (352). Irrespective of the source of fibro-
blasts, the inflammatory milieu in the interstitium promotes their proliferation, activation, and 
ECM production. Activated fibroblasts are characterized by the expression of α-smooth muscle 
actin, although not all fibroblasts that contribute to fibrosis express this marker (353). 
The signaling pathways that promote fibrogenesis have been investigated, but will not be exten-
sively covered here. One of the best studied proteins in this respect is TGF-β, a multifunctional 
cytokine that has a central role in interstitial fibrosis. Indeed, TGF-β increases the production of 
ECM components by tubular epithelial cells and fibroblasts. Also, TGF-β, together with other 
cytokines such as basic fibroblast growth factor 2 (FGF-2), is an important inducer of EMT (2). 
ECM composition and regulation
As described in paragraph, under normal conditions collagen IV is present in the tubular base-
ment membrane. During interstitial fibrosis tubular epithelial cells also express other types of ECM 
molecules such as fibronectin, and collagens I and III. Fibroblasts express these ECM molecules, 
and also laminin and tenascin.
Accumulation of ECM is the result of an imbalance between synthesis and repair. The factors that 
determine this balance have been mapped in some detail. Matrix metalloproteinases degrade 
ECM components, and may thus contribute to the resolution of fibrosis. The activity of MMPs is 
regulated by, among other factors, tissue inhibitors of metalloproteinases (TIMPs), indicating that 
the synthesis and degradation-balance is regulated at multiple levels. Adding further complexity 
to the system is the fact that the role these molecules play is in part dependent on their spatial 
expression pattern. For example, MMP2 may have a beneficial effect in degradation of interstitial 
fibrotic material, but at the other hand may promote the process of EMT by disruption of the 
tubular basement membrane (2,353). 
Damage is progressive
After loss of a critical amount of nephrons loss of kidney function is progressive. The widely tested 
and accepted mechanism for this progression is explained by the hyperfiltration hypothesis, as put 
forward by Brenner and Hostetter and co-workers in the 1980s (354,355). This hypothesis states 
that as nephrons are lost, an adaptive process is initiated that leads to increased intraglomerular 
pressure and flow across the glomerular capillary wall. These two factors increase the single 
nephron glomerular filtration rate. While these adaptations limit the total loss of renal function 
(as determined by the GFR), they are eventually detrimental. In rat models a severe reduction in 
renal mass brought about hemodynamic and histopathologic changes within one week (355). 
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The mechanisms that regulate the initial adaptive hemodynamic changes are incompletely under-
stood. Also, several factors may be held responsible for the further damage of the glomerulus, 
including mechanical stress due to increased intraglomerular pressure that disrupts vascular integ-
rity or leads to podocyte damage. Increased protein trafficking has also been suggested to directly 
damage podocytes. These uncertainties at the molecular level aside, it is clear that at the tissue 
level the adaptive response to a loss of nephrons has an adverse effect that potentially results in 
glomerular damage, leading to further nephron loss along pathways lined out before, thus result-
ing in a self-perpetuating loss of renal function. 
As a result of this progressive course of kidney diseases, patients suffering from these diseases will 
eventually need renal replacement therapy. One of these therapies, kidney transplantation, will be 
discussed in the next paragraphs.
chapter 1 > long-term dysfunction of kidney transplants54
LONG-TERM DYSFUNCTION OF 
KIDNEY TRANSPLANTS
In the last 40 years, transplantation has become the treatment of choice for end-stage kidney 
failure. In 1954, the first successful kidney transplantation was performed by dr. Joseph Murray, 
who was later awarded the Nobel Prize for this achievement. In the absence of rejection – the 
transplanted kidney was donated by the twin brother of the recipient – this operation showed 
the technical feasibility of transplantation. Developments in immunosuppression, starting with 
prednisone and azathioprine, made non-HLA identical transplantation possible, although rejec-
tion severely limited graft survival. In these early days of kidney transplantation the first year graft 
survival rate was around 50 percent (356). The application of the newly discovered immunosup-
pressive drug Cyclosporine A in 1978 (357) proved to be a breakthrough in transplantation. This 
immunosuppressive drug, together with improvements in donor matching and storage condition 
of the graft, provided the basis for the current successful use of kidney transplantation as a treat-
ment of end-stage renal disease. Nowadays, the factors that limit the success of transplantation 
have shifted from the acute to the chronic phase after transplantation. Long-term failure of kid-
ney transplants, chronic allograft dysfunction, is the main reason of allograft loss. 
This paragraph describes the clinical and histopathological characteristics, pathophysiologic 
mechanisms, and diagnostic molecular markers of chronic allograft dysfunction. 
General description and definitions
Limited improvement in long-term survival
The introduction of current immunosuppression including calcineurin inhibitors and mycopheno-
late mophetil fostered an increase in short-term graft survival. Currently, the first year renal trans-
plant survival rate is about 90 to 95 percent. In contrast, long-term graft survival has not made 
similar progress. The long-term attrition rate has even remained fairly constant over the past 25 
years, with a half-life of cadaveric transplants of about 8 years in the United States (358-360). 
Thus, for patients with a kidney transplant the most threatening problems are those that arise 
on the long-term, with chronic allograft dysfunction and death with a functioning graft being 
the two leading causes of graft loss (359,361,362). Intriguingly, diverse and seemingly opposed 
processes may contribute to this long-term attrition of allografts, including ongoing immunologi-
PART 3
55chronic allograft dysfunction > clinical manifestations
cal activity or ‘chronic rejection’, as well as toxicity of immunosuppressive medication, meant to 
prevent chronic rejection.
Definitions of long-term graft failure
Over the years ideas about the pathophysiological mechanisms leading to long-term allograft 
failure have changed, and description of the clinical and histopathological presentation has var-
ied. This has led to some unclarity in definition of the subject, with terms as chronic allograft/
transplant dysfunction, chronic allograft nephropathy, and chronic rejection used interchangeably 
to describe the same problem. In this paragraph, the following definitions are used: 
Chronic allograft dysfunction describes the clinical aspects of long-term renal allograft failure. 
The clinical features are not specific for one diagnosis, and chronic allograft dysfunction should 
thus be regarded as a clinical syndrome that can be brought about by different and mixed patho-
physiological processes (363). Its pleomorphic etiology is in part reflected by the elaborate list of 
risk factors. 
Chronic allograft nephropathy (CAN) is the term used to describe the histopathological changes 
seen in biopsies from patients with chronic allograft dysfunction. Again, these histopathological 
changes are not specific for one diagnosis, and in this definition CAN is the histopathological 
representation of the spectrum of causes that lead to chronic allograft dysfunction. In biopsies 
with features compatible with only one diagnosis the term CAN should be avoided (364). Chronic 
rejection, for example, is a distinct diagnosis. It denotes a central role for immunological pro-
cesses as the cause of chronic allograft dysfunction, and can be differentiated from other causes 
of allograft functions by certain discriminatory features in the renal biopsy (365). 
This paragraph will describe chronic allograft dysfunction and its risk factors, chronic allograft ne-
phropathy, and the pathophysiological processes involved in these two syndromes, with a special 
focus on chronic rejection and chronic calcineurin inhibitor toxicity. 
Chronic allograft dysfunction
Clinical manifestations
Chronic allograft dysfunction is characterized by a slow but progressive decline in renal function 
starting after the first three months post transplantion. This is often combined with aggravation 
or de novo development of hypertension and proteinuria (366,367). The time to eventual com-
plete loss of renal function depends on the initial graft function (intercept) and rate of progression 
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(361). The decline in GFR in patients that have survived the first year post transplantation varies 
between 1.2 and 2.5 ml/min per year (368).
Scope of the problem
Once chronic allograft dysfunction has started to develop, the process will invariably progress to 
end stage allograft failure. Chronic allograft dysfunction is the main cause of returning to dialysis 
after transplantation (369). Currently, patients waiting for a repeat transplant make up about 15 
to 20 percent of the total number of patients on the waiting list for renal transplantation (www.
transplantatiestichting.nl, www.optn.org). Retransplantation carries an additional risk to develop 
chronic allograft dysfunction (370).
Risk factors
The development of chronic allograft dysfunction is influenced by a plethora of factors, both 
immunological and non-immunological, and related to donor and recipient. The intuitive bottom-
line, as stated by Paul in a review on the subject, is that chronic allograft dysfunction ‘seems to 
develop in kidneys from older donors or kidneys that have acquired damage later on’ (371). The 
most important risk factors are listed below, grouped as immunological and non-immunological 
factors. It should be noted that grouping risk factors is artificial, as it is their combined and often 
synergistic effects that modulate graft survival. Indeed, different forms of primarily non-immu-
nological damage directly affect graft function, and in addition modulate the immunogenicity of 
the tissue (372). 
Immunological risk factors
Histoincompatibility
Evaluation of large series of renal transplants in the US (373), Europe (374), and the UK (375) has 
made clear that human leukocyte antigen (HLA) mismatches have a detrimental effect on long-
term allograft survival. In a US series, the 10 year graft survival was 52 percent in HLA-matched 
and 37 percent in HLA-mismatched transplants (373). Mismatches in the different HLA loci (HLA-
A, B, DR) seem to have a comparable impact on graft function, at least on the long-term (376). 
The importance of HLA matching for long-term allograft survival may be declining (377,378). 
Indeed, in comparison to risk factors such as donor age, the effect of HLA mismatches is nowa-
days relatively small (368).
Sensitization and Panel Reactive Antibodies
Blood transfusions, pregnancies, and previous transplantations may give rise to the formation 
of anti-HLA antibodies. The presence of such antibodies is tested by evaluating the reactivity of 
the serum of a potential transplant patient with a ‘panel’ of lymphocytes obtained from selected 
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blood donors. The number of donor samples in the panel with which the patients’ serum reacts is 
an indication of the patients’ extent of presensitization. The amount of ‘panel reactive antibodies’ 
(PRA) present before transplantation and the formation of such antibodies after transplantation 
is related to the development of chronic allograft dysfunction (363,379-381).
Immunosuppression and non-compliance
Improvements in immunosuppression have been instrumental in reducing the number of acute 
rejections but not the long-term complications. Non-compliance to immunosuppressive drugs 
may be one of the factors explaining this discrepancy (361,382). In a meta-analysis the odds ratio 
of graft loss in non-compliant versus compliant patients was 7.1 (382).
Acute rejection
HLA-mismatches, presensitization, and non-compliance all relate to what is the most important 
immunological risk factor of chronic allograft dysfunction: acute rejection (363,383). Progress in 
graft survival has been less pronounced in patients that have experienced acute rejection episodes 
(362). The effect on long-term allograft function varies with the number, severity, timing, type, 
and response to treatment of acute rejection (369,384,385). When adequately treated, early 
acute rejection (within 3 months after transplantation) does not (386,387), or to a lesser extent 
(388,389), affect long-term outcome when compared to late acute rejections. The effect of vas-
cular rejection is worse than that of interstitial rejection (390).
At the same time, improvements in treatment of acute rejection have not translated into better 
survival on the long-term (360). This may indicate that only the less harmful acute rejections are 
treated sufficiently, and also points towards the influence of other risk factors that may coexist 
or interfere (386). For example, it has been suggested that while cyclosporine accurately prevents 
acute rejection, it also inhibits development of tolerance (391,392). Additionally, nephrotoxic 
adverse effects of immunosuppressive medication such as cyclosporine may explain the lack of 
enhanced long-term graft survival over the years.
Non-immunological risk factors
Elegant studies by Gourishankar et al showed that the function of a renal allograft could be 
predicted by the function of its ‘mate graft’ – the other graft from the same donor (393). Even 
though rejection was not influenced by this so-called ‘mate effect’, long-term outcome was 
paired even up to 8 years after transplantation (368). This suggests that donor-related factors 
have an important role in transplantation. 
Donor age and renal mass
Donor age is an important risk factor for long-term graft loss (383,394-396), and explains 30 
percent of the variation in transplant outcome after five years (366,397). The influence of do-
nor age on graft survival can in part be explained by immunological mechanisms. Donor age 
modulates the occurrence of rejection and subsequent tissue repair: older kidneys seem to be 
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more immunogenic and have impaired repair mechanisms (398). However, it is unlikely that this 
increased immunogenicity completely explains the effect of donor age, as donor age also influ-
ences survival of zero HLA-mismatch transplantations (394). 
A risk factor related to donor age is renal mass: small kidney size in relation to the recipient is 
related to adverse outcome (399), although this may not be true in a pediatric setting (400). Like-
wise, male donor gender seems to convey a benefit in long-term graft survival, which is probably 
also related to renal mass (368).
Recipient age and sex also have a clear influence on allograft survival, explaining 10-25 percent of 
the variation of the long-term outcome (397), with female sex and younger age having a better 
prognosis (401). In the long-term, the effects of donor and recipient age are synergistic (402). 
Peritransplant injuries
The donation and transplantation procedures have influence on the long-term function of renal 
allografts. Risk factors include brain death, preservation of the allograft, and ischemia/reperfusion 
injury. Terasaki et al (403) studied the three-year survival rates of cadaveric donors, living related 
donor, and unrelated donor grafts (e.g. spouses). They found that survival rates were similar be-
tween living related and living unrelated donors, despite a higher number of HLA mismatches in 
the latter. Both living donor groups showed a higher survival than cadaveric donors (403). This 
shows the importance of brain death, preservation, and ischemia/reperfusion injury in determin-
ing survival on the long-term. Through which mechanisms these factors influence graft function 
is not completely known. Again, an interaction between non-immunological and immunologi-
cal mechanisms is to be expected. Koo et al demonstrated an increased expression of tubular 
antigens and inflammatory molecules in biopsies from cadaveric donor kidneys in comparison to 
living donor kidneys. This was associated with the occurrence of acute rejection episodes (404). 
Delayed graft function
Delayed graft function is a form of acute renal failure, mostly defined as the requirement of 
dialysis early after transplantation. According to some studies delayed graft function is an inde-
pendent predictor of late allograft function (405-407). Others attribute the effects of delayed 
graft function to the influences on the occurrence of acute rejections, for example through an 
increased immunogenicity of the graft (367). Indeed, acute rejection in the setting of delayed 
graft function has an additive adverse effect on graft function (405,408). In itself, delayed graft 
function is the result of a number of risk factors, including some of those mentioned above 
(368,406,409).
Post transplant injuries
After transplantation, complications may arise that have a detrimental influence on long-term 
graft survival:
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Proteinuria conveys an increased risk of renal allograft loss (328,329,383,386,398,410-413). 
Twenty to 28 percent of the patients with chronic allograft dysfunction have proteinuria, com-
pared to six to eight percent of patients without this condition (386,414). In a study by Hohage et 
al, early development of proteinuria that lasted longer than 6 months was noted in a quarter of 
patients. The proteinuric patients had a 5 year survival rate of 59 percent, compared to 86 percent 
in the non-proteinuric patients (329).
Hypertension is also associated with increased chances of late graft failure (334,415), although 
the effect is less pronounced than that of proteinuria (412). Development of proteinuria seems 
to be linked to development of hypertension (330), and the presence of both conditions has an 
additional risk for allograft loss (410). 
Immunosuppressive treatments contribute importantly to the development of chronic allograft 
dysfunction. The nephrotoxic effects of calcineurin inhibitors such as cyclosporine A and tacro-
limus are well-recognized, but also corticosteroids have been found to contribute to chronic al-
lograft dysfunction (366). The extent of their contribution is more difficult to estimate (369). The 
histopathologic changes that are related to calcineurin toxicity will be discussed in more detail in 
the following sections.
The pathology of chronic allograft dysfunction
Changing definitions
As pointed out before, concepts about pathophysiological mechanisms that lead to chronic renal 
allograft dysfunction have changed over the years. In the Banff 91 classification (see below), the 
term chronic allograft nephropathy was introduced to describe the histological changes seen in 
biopsies from patients with chronic allograft dysfunction that could not be related to one specific 
cause. These changes had previously been described as chronic rejection, but as this term implied 
a predominantly immunological mechanism of damage, the more neutral terms chronic allograft 
nephropathy (CAN) was chosen (364-366). Since then, definitions of CAN in the literature have 
been different, ranging from strict histopathological entities to loose descriptions of clinicopatho-
logical syndromes. It was increasingly noticed that the indiscriminate use of the term CAN would 
limit the possibilities of establishing an etiologic diagnosis, and would result in a term with ‘little 
value other than to hide our ignorance’ (364). Indeed, treatments for the different causes of 
CAN, once they could be distinguished, are likely to be fundamentally different (416). In order to 
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prevent further indiscriminate use of CAN, the latest iteration of the Banff classification has now 
moved towards elimation of the term CAN, replacing it by the category ‘Interstitial fibrosis and 
tubular atrophy, no evidence of any specific etiology’. 
Because most of the studies described herein have used the term CAN to denote the changes 
seen in biopsies, we will also use it in the following paragraph. Here, CAN is defined as the histo-
pathological changes seen in biopsies from patients with chronic allograft dysfunction without a 
recognizable single cause or diagnosis. In this definition, CAN is the histopathological representa-
tion of the spectrum of causes that lead to chronic allograft dysfunction. From a clinical point of 
view the most important differential diagnoses of CAN are chronic rejection, chronic calcineurin 
inhibitor toxicity (414), obstruction, and infection (365). In this paragraph, the histopathology of 
CAN, chronic rejection, and chronic calcineurin inhibitor toxicity will be described.
Causes and course of CAN
The factors that contribute to the development of CAN in allograft kidneys include ischemia, hy-
perfiltration, proteinuria, hypertension, de novo or recurrent glomerular disease, infection, drug 
toxicity, and (chronic) allo-immune injury (417). These different factors damage all compartments 
of the kidney (vasculature, tubules, interstitium, and glomeruli), though not always simultane-
ously or to the same extent. This often limits the possibilities to distinguish the contribution of 
different causes to the development of the lesions seen in CAN.
At 1 year post transplantation CAN is already widely present in renal allografts. In protocol biop-
sies the number of patients affected by CAN ranges from 50 to 94 percent (418-420). The largest 
of these per-protocol series, a study of 120 simultaneous kidney-pancreas transplants with over 
950 biopsies, found that the development that CAN could be divided in two phases. The initial 
phase was characterized by interstitial damage and rapid development of tubular atrophy and 
interstitial fibrosis. CAN developed earlier in allografts that showed signs of peritransplant injury 
(acute tubular necrosis) and acute rejection (420). Also, subclinical rejection was related to earlier 
development of CAN, but this was not found in later studies specifically addressing this relation 
(421). The later phase of CAN was characterized by a more severe involvement of the vasculature 
and glomerulosclerosis (420).
Histopathologic features
The three main features of CAN are fibrous intimal thickening, interstitial fibrosis, and tubular 
atrophy.
Fibrous intimal thickening indicates the changes seen in renal arteries of allografts, and affects 
mostly the larger (arcuate) arteries. The normal intima consists of a single layer of endothelial 
cells, based on the internal lamina elastica. In CAN, the renal arteries show a concentric expansion 
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of the intima, narrowing the arterial lumen. Al-
though this is comparable to the changes found 
in normal atherosclerosis (369), the concentric 
nature of the lesion is somewhat specific for 
CAN. The presence of inflammatory cells in the 
neo-intima, as well as disruption of the internal 
elastica seems to be more specifically related to 
chronic rejection (see below). Smaller vessels and 
arterioles may also be affected in CAN, show-
ing for example arteriolar hyalinosis. This lesion 
is often indicative of calcineurin inhibitor toxic-
ity, and will be discussed below. Multilayering of 
the basement membrane of peritubular capillar-
ies is another vascular feature of CAN. Severe 
multilayering is associated with chronic rejection 
(366).
Interstitial fibrosis and tubular atrophy often occur simultaneously. Atrophic tubules show a thick 
tubular basement membrane and small tubular epithelial cells. An aspecific inflammatory reac-
tion is often found in conjunction with the atrophic tubules and interstitial fibrosis. The molecular 
composition of the interstitial fibrotic lesions will be further discussed below and in chapter 6 of 
this thesis. 
Glomerular changes may also be seen in CAN, and include focal segmental as well as global glo-
merulosclerosis, and mesangial matrix expansion. Other lesions affecting the glomeruli include 
mesangiolysis and duplication of the GBM. This may again point to a specific etiology discussed 
below.
Since 1991, the Banff Working Classification of Renal Allograft Pathology (‘Banff classification’) 
has been used for standardization and grading of renal allograft biopsy interpretation. The Banff 
classification provides a grading for the individual CAN lesions (tubular atrophy, interstitial fibro-
sis, fibrous intimal thickening, mesangial changes, glomerulopathy). Because tubular atrophy and 
interstitial fibrosis are in general most accurately sampled, the extent of these changes is used 
for grading the severity of CAN (in grades I to III, corresponding to mild/moderate/severe) (422). 
The most recent iteration of the Banff classification has maintained this grading system, but now 
with respect to the category ‘Interstitial fibrosis and tubular atrophy, no evidence of any specific 
etiology’ (365).
Figure 4. Transplant glomerulopathy. Transplant glomeru-
lopathy is seen in chronic rejection. This glomerular lesion is 
characterized by a duplication of the glomerular basement 
membrane (inset).
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Lesions related to specific etiology
As mentioned before, the mixture of pathophys-
iologic processes operating simultaneously leads 
to a histopathological picture that does not al-
low diagnosis of a single factor as the cause of 
the allograft dysfunction. In some cases, howev-
er, a single cause may be of predominant impor-
tance, and can be recognized by certain clinical 
and histological features. Two of these disease 
entities are described below: chronic rejection 
and chronic calcineurin inhibitor toxicity.
Chronic rejection
Chronic rejection is defined as injury caused by alloreactivity directed against the graft. Signs of 
both cellular and humoral forms of chronic rejection can be present in the renal allograft biopsy. 
The Banff classification denotes transplant vasculopathy, ie, disruption of the internal elastica, 
and infiltration of inflammatory cells in the thickened intima of the renal vasculature, as a sign 
of chronic rejection (422). At the level of the peritubular capillaries, extensive duplication of the 
peritubular basement membrane, as seen with electron microscopy, is associated with chronic 
rejection (423). Furthermore, characteristic lesions in the glomerulus (transplant glomerulopathy), 
characterized by duplication of the GBM (figure 4) also points to the involvement of chronic 
rejection. In recent years, the role of chronic humoral rejection (or chronic antibody mediated 
rejection) as a cause of chronic allograft dysfunction has received renewed attention. During 
anti-donor HLA antibody mediated rejection, a component of the complement system is found 
to remain covalently bound to the surface of endothelial cells. This component, C4d, can be 
visualized by immunohistochemistry, and indicates an ongoing or previous antibody mediated 
rejection (424,425) (figure 5). In 88 percent of patients that showed widespread C4d positivity 
in peritubular capillaries circulating anti-donor HLA antibodies were found, compared to none of 
the C4d negative patients (416), indicating an ongoing humoral rejection. 
Calcineurin inhibitor toxicity
Calcineurin inhibitors (CNIs), such as cyclosporine A and tacrolimus are very potent immunosup-
pressive drugs that are widely used in transplantation. By inhibiting the enzyme calcineurin these 
compounds suppress IL-2 production and thus prevent maturation of T-cells. Already in the first 
report on cyclosporine A a nephrotoxic side effect was mentioned (357). In subsequent years, the 
histopathology of the chronic form of CNI toxicity – although structurally unrelated, cyclospo-
rine A and tacrolimus cause identical histopathologic lesions (426) – has been described, mostly 
Figure 5. C4d deposition. In chronic humoral rejection, the 
complement split product C4d remains covalently bound to 
endothelial cells. This picture shows widespread deposition of 
C4d in peritubular capillaries.
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through studies by Mihatsch and coworkers (427-429). Studies in non-kidney transplantation in 
which cyclosporine A was used have been instrumental, since the renal effects of cyclosporine 
can be studied in the absence of other types of damage to the kidney (430). 
Chronic CNI toxicity develops after months to years of CNI use, and in large series it is related to 
the dose. Since the bioavailability is highly variable in individual patients, dosage of CNIs is not a 
good correlate of CNI exposure. Sophisticated drug-monitoring and dosing may help overcome 
this problem. 
The scope of the problem seems to be considerable. In the Leiden University Medical Center, 20 
percent of a cohort of patients that switched from once daily Sandimmune to twice-daily Neoral 
(two different formulations of cyclosporine A) developed chronic cyclosporine A toxicity, even 
though they received their medication according to nationwide guidelines (431). In this study, 
cyclosporine toxicity was defined by functional and histological criteria, ie, a decline in renal func-
tion temporally related to the switch in cyclosporine A formulation that could not be explained 
by other features in the renal biopsy. The number of patients that show histological signs of CNI 
toxicity after long-term treatment with CNIs may be even higher. In the aforementioned study 
by Nankivell et al CNI toxicity became ‘virtually universal’ by 10 years after transplantation (420).
Similar to the chronic lesions seen in CAN, the histopathology of chronic CNI toxicity is character-
ized by tubular atrophy and interstitial fibrosis, representing a nonspecific response to damage. 
The fibrosis has been reported to affect rays of cortex and medulla, leading to so-called ‘striped 
fibrosis’. This band-pattern of fibrosis is thought to be caused by a watershed infarction, ischemia 
in the debit of a larger artery affected by cyclosporine. The lesion is typical but not specific for CNI 
toxicity (432), and its value is debated.
Glomerular lesions are also common in chronic 
CNI toxicity and include glomerular hypertrophy, 
mesangial matrix expansion, and focal segmen-
tal glomerular sclerosis. Again, these changes 
are of limited specificity (433). The most spe-
cific lesion of chronic CNI toxicity is arteriolar 
hyalinosis, in which nodular depositions of hya-
line material are seen in the media of arterioles 
(figure 6). Pathogenetically, CNIs are thought to 
damage arteriolar smooth muscle cells that are 
subsequently replaced by hyaline material from 
the circulation (427,433). In advanced cases, the 
hyalinosis may be circumferential (434), and se-
verely narrow the vascular lumen.
Figure 6. Arteriolar hyalinosis. Nodular depositions of hyaline 
material are seen in the media of arterioles, indicating the 
presence of chronic CNI toxicity.
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Nevertheless, use of arteriolar hyalinosis as a marker of chronic CNI toxicity has certain draw-
backs. For example, lesions that are characteristic for CNI toxicity appear focally in the tissue and 
thus carry the risk of sampling error (435). Also, the interobserver consistency of scoring renal 
biopsies has been low (436,437). Attempts have been made to increase the reproducibility of 
arteriolar hyalinosis scoring by introducing a different classification (434). This new classification 
system seemed to outperform the previous one, but it is questionable whether this is due to a 
real improvement or just to a reduction of categories in the new scoring system (438). Another 
complicating factor in the use of arteriolar hyalinosis as a marker of CNI toxicity is that this lesion 
is also seen in association with other diseases such as diabetic nephropathy, hypertension, and 
hemolytic uremic syndrome / thrombotic microangiopathy (439). 
Although chronic rejection and chronic CNI toxicity are both individual causes of chronic allograft 
dysfunction, they can coexist and contribute to the histopathological picture of CAN. 
Pathophysiologic processes in chronic allograft 
dysfunction
There are several non-mutually exclusive pathophysiologic processes that damage the kidney 
and lead to development of chronic allograft dysfunction and CAN, often in a way that is similar 
to the progression of renal disease in native kidneys. Indeed, the kidney responds to injury in a 
relatively stereotypic manner, eventually culminating in replacement of functional nephrons by 
sclerosed glomeruli, atrophic tubuli, and interstitial fibrosis. The shared features and final com-
mon pathway of renal disease progression is highlighted in a previous paragraph. Those of special 
interest in the setting of transplantation will be discussed here and include alloimmunity, immu-
nosuppressive drug toxicity, and accelerated senescence.
Alloimmunity
Shishido et al found a relation between subclinical acute rejection and extent of CAN (387). 
This implies that cellular infiltrates continue to inflict damage on the allograft on the long term. 
This continuing inflammation will lead to a destruction of the tissue, and may in addition lead 
to an enhanced allorecognition due to an increase in MHC expression (369), resulting in a self-
perpetuating cycle of injury and inflammation. At the same time, not all cellular infiltrates are 
associated with the development of CAN (421), suggesting that cellular infiltrates differ in their 
destructive properties.
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An interesting process contributing to the immunological cause of chronic allograft nephropathy 
was recently described in a series of studies by Kerjaschki. Using relatively novel markers for lym-
phatic endothelial cells, including the glycoprotein podoplanin, they found that the number of 
lymphatic vessels was increased over 50-fold in allografts that showed nodular infiltrates (150). 
In a follow-up paper they showed that these newly formed lymphatics are in part derived from 
recipient lymphatic progenitor cells, possibly macrophages (440,441). The lymphatics were co-
localized with a nodular infiltrate that contained active and dividing T and B lymphocytes, mac-
rophages and dendritic cells, resembling an intragraft lymphoid organ. Moreover, the lymphatic 
endothelial cells were shown to produce cytokines that would enable them to recruit lympocytes 
and thus initiate or sustain an anti-allograft immune response. Not only could this response be of 
a cellular nature, this study and several other studies also found evidence for the involvement of 
B-cells in rejection (442).
Indeed, humoral allograft rejection has received renewed attention in the last decade since the 
discovery of C4d as a marker of chronic rejection coinciding with the presence of circulating 
antidonor antibodies (see above). The pathogenic processes will only be described briefly, and 
have been reviewed in detail by several authors (367,424). Antidonor antibodies are generally 
directed against donor HLA. Dendritic cells of the donor (the direct pathway) or the recipient 
(the indirect pathway) present donor HLA antigens to recipient T-cells. This activates the T-cells 
that, through production of a series of cytokines and co-stimulatory molecules such as CD28 and 
CD40, activate the B-cell (turning them into plasma cells) and thus initiate formation of antidonor 
antibodies. These antibodies bind to donor tissue, predominantly endothelial cells, and cause 
complement fixation, leading to formation of the membrane attack complex, attraction of other 
inflammatory cells, and activation of endothelial cells. This either leads to apoptosis of endothelial 
cells, or, if the cells survive, production of inflammation promoting factors such as intracellular 
adhesion molecule 1 (ICAM), vascular cell adhesion molecule 1 (VCAM) and E-selectin, and other 
chemotactic cytokines, providing a link to cellular immunity. Also, the cytokines produced by 
activated endothelial cells may be harmful to the kidney. 
Circulating antibodies may also be directed against non-HLA antigens. Joosten et al described the 
presence of antibodies directed against the GBM proteoglycan agrin in patients with transplant 
glomerulopathy (443). 
Immunosuppressive drug toxicity
Immunosuppressive drugs, in particular CNIs, may promote allograft damage through a variety 
of processes, including vasoconstriction, direct cellular toxicity, and modulation of fibrosis-related 
gene transcription. CNIs are known to increase vascular resistance and promote vasoconstriction. 
This may result from an inhibition of nitric oxide production or an increased release of renin from 
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the juxtaglomerular apparatus, activating the renin-angiotensin system (RAS) (414,444). Also, ne-
crosis of arteriolar smooth muscle cells and replacement by hyaline material may contribute to the 
obliteration of the vascular lumen (432). The resulting impaired blood flow may lead to ischemia, 
and result in glomerular and tubulointerstitial fibrosis. Also, CNIs may have a direct cytotoxic ef-
fect on renal cells, including podocytes (158), but results have been controversial with regard to 
tubular epithelial cells (444). 
Furthermore, CNIs increase the expression of profibrotic and proinflammatory cytokines, as well 
as interstitial matrix molecules, either directly or via stimulation of the RAS (445). Among the 
cytokines influenced by CNIs are TGF-β (446-448), osteopontin (448), ET-1, MCP-1, and RANTES 
(449). Cyclosporine A was shown to stimulate the promoter of the collagen III gene in monkey 
fibroblast cells (450), and increased the expression of collagen I in human and experimental renal 
cortical tissue (448,451). Recently, it was described that cyclosporine A may induce epithelial-to-
mesenchymal transition (EMT) of tubular epithelial cells, and thus contribute to interstitial fibrosis 
(452). The mechanism of EMT is discussed in more detail in a previous paragraph. 
Another aspect of immunosuppressive medication is that it increases the chance of viral infec-
tions of the allograft. For example, cytomegalo virus infection and BK virus nephropathy (BK virus 
is named after the patient in whom the infection was first described (453)) have been related 
to the development of chronic allograft dysfunction. This may take place through stimulation of 
immunological pathways leading to chronic inflammation (365,454) as well as direct damage of 
renal epithelial cells (455).
Accelerated senescence
As mentioned previously, donor age is an important risk factor for the development of chronic al-
lograft dysfunction. One pathophysiologic concept that has been raised to explain this association 
is the so-called accelerated senescence of renal allografts (369). In vitro, after a limited number 
of cell cycles, cells become quiescent and usually die. This ‘cellular senescence’ is characterized by 
a number of factors. The length of the telomeres of chromosomes, for example, decreases with 
each replication, and in senescent cells, cell cycle inhibitory molecules such as p16 and p21 are 
upregulated. Halloran and co-workers noted that the histopathological characteristics of ageing 
overlap with that of CAN. They studied the expression of p16, and found that this protein was 
expressed in increased amounts in allografts with inferior function and with signs of CAN (456). 
Similarly, Ferlicot et al found that the severity of CAN was correlated with the extent of telomere 
shortening (457). These data support the hypothesis, as put forward by Halloran (369), that the 
multiple stresses that the allograft encounters would put replicative stress on the allograft kidney 
cells, thereby accelerating cellular senescence. Indeed, in an animal model of chronic rejection 
studied by Joosten et al, stressors such as warm ischemia time correlated with the expression of 
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p16 and p21 as well as with telomere shortening in the tubular epithelial cells, although this was 
not exclusively associated with chronic rejection (458). Together, these data suggest that replica-
tive senescence may be a pathophysiologic pathway of progression in both native and allograft 
kidney diseases: once the continuously stressed cells have reached their replicative limit, they are 
unable to effectively keep up their normal response to damage, leading to atrophy and fibrosis 
rather than reepithelialization and ECM remodeling. 
Molecular diagnostics in chronic allograft 
dysfunction
The clinical course of long-term graft dysfunction is aspecific, and often does not provide a firm 
basis for therapeutic decision making. As pointed out in the previous paragraphs, histopathologi-
cal evaluation of renal biopsies may help in defining the cause of renal function loss, but also has 
limitations. 
This has urged researchers to search for markers that might complement or even replace rou-
tine histopathologic evaluation. Such studies have been performed using hypothesis-driven ap-
proaches, in which parts of the pathogenesis of renal transplant pathology were studied. Others 
have utilized broader approaches, for example through application of microarray and proteomics. 
A summary of these studies is given in the following paragraphs, with a focus on studies on 
chronic allograft dysfunction in humans. For a broader scope on the subject, see more thorough 
reviews of the use of molecular markers in native kidney diseases (459-462), and acute rejection 
(463,464).
Diagnostic markers at the tissue level
The extent of interstitial fibrosis is the most important histological predictor of progression of 
renal disease in both native and allograft kidneys. However, semi-quantitative scales as provided 
by the Banff classification impair the reliable measurement of the extent of interstitial fibrosis 
in renal allografts (436,437). To circumvent this problem, several researchers have used a semi-
automated approach using digital image analysis. Nicholson et al studied the predictive properties 
of quantitative immunohistochemistry in protocol transplant biopsies. They found that the col-
lagen type III positive area at 6 months was correlated with renal function at 12 and 24 months 
after transplantation (465). Others have used Sirius Red, a red dye that intercalates with the 
interstitial collagens I and III, to stain the interstitial compartment (466). These studies showed 
that computerized measurement of the Sirius Red positive material in biopsies taken early after 
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transplantation is correlated with the long term decline in renal function and may outperform the 
semi-quantitative scoring method (467,468). Quantification of interstitial fibrosis using Sirius Red 
has also proven to be useful as a surrogate marker of CAN, for example to compare fibrogenic 
effects of different types of CNIs (418) and long term effects of subclinical acute rejection (421).
One of the reasons to use interstitial fibrosis and tubular atrophy for grading of chronic allograft 
nephropathy in the Banff criteria is that these changes are fairly common in renal allograft biop-
sies and therefore less subject to sampling error (422). Studies in animal models of glomeruloscle-
rosis made clear that the composition of glomerular extracellular matrix harbors disease specific 
features (469). Similarly, it is conceivable that the composition of the interstitial fibrotic lesions 
varies with the cause of the disease (470). Thus, studying composition of the interstitial fibrosis 
may provide valuable markers and overcome the sampling error limitations of the abovemen-
tioned histopathological markers. 
Following this approach, Abrass et al (471) studied the composition of the extracellular matrix of 
renal allograft biopsies by staining for different interstitial collagens (I, III, and IV), laminins, fibro-
nectin, and thrombospondin. In addition, they studied particular collagen IV and laminin chains. 
In a pilot study, they identified three different patterns of ECM composition in renal allograft 
biopsies. Pattern 1 showed no change in comparison to normal interstitium, pattern 2 showed 
an generalized accumulation of collagens I and III, while pattern 3 showed a de novo expression 
of collagen α3(IV) and laminin β2 in the proximal tubular basement membrane. Subsequently, 
they studied the presence of these patterns in biopsies from patients with either chronic rejection 
or chronic cyclosporine A toxicity. Chronic rejection was exclusively associated with the third pat-
tern, indicating that indeed ECM patterns could help distinguish the two causes of late allograft 
dysfunction (471).
Other molecular markers at the tissue level have proven to be useful in the diagnosis of specific 
causes of chronic allograft dysfunction. For example, as discussed above, the complement split 
product C4d has become integrated in routine diagnostics as a marker of humoral rejection.
In conclusion, studying changes at the tissue level – using conventional histologic as well as im-
munohistochemical approaches – can help predict the clinical course and may help distinguish 
different causes of allograft dysfunction. The downside of these techniques is that the damage 
has to be present, at least to some extent, to make the diagnosis. This probably limits the suc-
cess of subsequent treatments (472). In this context, analysis of mRNA expression levels could be 
promising. This will be lined out in the following section.
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Genomics
Single gene measurements
In the early 1990s, studies in experimental renal disease showed that the mRNA expression levels 
of ECM components such as collagen I and IV correlated with the severity of glomerulosclerosis 
(473,474). Moreover, the changes in mRNA levels preceded the morphological changes (475). 
These studies raised the concept, as reviewed by Striker (476), that studying mRNA expression 
levels could be of predictive value with regard to both occurrence and severity of renal disease. 
This concept has been elaborately tested in the setting of transplantation. Measurements of 
mRNA expression levels of immune activation genes in renal allografts proved to be a tool to 
diagnose the presence of acute rejection (477-479). Furthermore, such measurements can be 
performed non-invasively using urinary cells. The group of Suthanthiran showed that urinary 
mRNA expression levels of transcripts related to rejection (granzyme B and perforin) and regula-
tory T-cells (FOXP3) predict the presence of acute rejection (480) and reversal of acute rejection 
(481), respectively. Although these results remain to be confirmed in larger patient groups (482), 
and although studying the urine may neglect valuable information that can exclusively be found 
in the renal biopsy (483), it clearly shows the strength of molecular analysis. 
Acute rejection episodes are associated with profound and quick alterations in the cellular compo-
sition of the graft, and it is in this regard not surprising that this is reflected in differences in mRNA 
expression. Can molecular biological techniques be applied to the more indolent development 
of chronic allograft dysfunction? Because CAN is characterized by interstitial fibrosis, researches 
have initially focused on ECM components and profibrogenic cytokines. Sharma et al were the 
first to describe a relation between elevated mRNA expression levels of the profibrogenic cytokine 
TGF-β and the presence of CAN (484), a finding later also reported in protocol biopsies (419). Ex-
pression levels of TGF-β mRNA in the urinary cells of patient with CAN also proved to be increased 
(485). Suthanthiran also found that TGF-β mRNA levels were related to ‘chronic rejection’ and in-
terstitial fibrosis, but found no relation to acute rejection (479). This may be explained by the fact 
that besides its profibrogenic properties, TGF-β has a strong immunosuppressive effect. Eikmans 
et al (486) found that an upregulation of TGF-β mRNA in biopsies from patients with early acute 
rejection was associated with the absence of the development of chronic allograft dysfunction, 
underscoring the dual action of this cytokine. Scherer et al found similar results using a microar-
ray approach (487). Plasminogen activator inhibitor 1 (PAI-1) is another profibrotic cytokine that 
has been implicated in the development of interstitial fibrosis. Delarue et al found that increased 
levels of PAI-1 mRNA correlated with a decline in renal function over 5 years of follow-up (488). 
Increased PAI-1 expression has also been observed at the protein level in CAN (489). 
chapter 1 > long-term dysfunction of kidney transplants70
Not only fibrogenesis, but also an impaired ECM turnover may result in interstitial fibrosis. Indeed 
increased transcripts of tissue inhibitors of metalloproteinases – proteins that inhibit matrix de-
grading enzymes – are related to the extent of interstitial fibrosis (490). 
In keeping with the multifactorial etiology of chronic allograft dysfunction, others found that the 
expression of immunologic transcripts was related to chronic allograft nephropathy (491-493), 
although this has not been a consistent finding (484). 
The problem of prediction
Most of the studies listed so far describe associations between mRNA transcripts and develop-
ment of chronic allograft dysfunction. Demonstration of various mRNA transcripts in chronically 
deteriorating kidneys may help unravel the pathogenesis of CAN. Also, comparable to the use of 
quantitative measurements of interstitial fibrosis as a surrogate marker for CAN, mRNA expres-
sion analysis has been instrumental in determining the fibrotic response to different immunosup-
pressive treatment modalities (494). Still, the ultimate goal of mRNA expression analysis would be 
to find markers that predict development of CAN. Few studies have actually tested the predictive 
value of investigated markers (495). In a protocol biopsy study, Baboolal et al found that, al-
though TGF-β, thrombospondin and fibronectin were upregulated in biopsies that showed CAN, 
none of these markers alone could reliably indicate renal injury, and acute rejection and interstitial 
fibrosis continued to have the most profound impact on prognosis (419). 
Microarray studies
The problem, that many genes are associated with CAN but few predict its development, has 
become more apparent after a landmark study by Sarwal et al (442). This microarray study on 52 
pediatric renal transplant patients, the largest microarray study performed in transplantation so 
far, has raised a number of intriguing concepts. Clustering of the samples showed considerable 
heterogeneity in biopsies with acute rejection. One of the acute rejection clusters contained a 
large number of B-cell markers, again suggesting an important role for humoral rejection (see 
above) and opening new directions for therapy. However, such a heterogeneity was not found in 
the samples that were on histological criteria diagnosed as CAN (442). In a review on the use of 
microarray in transplantation, Sarwal et al state that the late sampling of CAN biopsies impairs 
the identification of specific causes of CAN. The differential regulation of genes compared to 
stable allografts at the late stage only reflects the ongoing damage mechanisms (495). This is 
exemplified by a study by Hotchkiss and co-workers, who studied 16 transplant biopsies with 
CAN with and without arteriolar hyalinosis in comparison to 6 normal transplant biopsies using 
microarray (496). They found that the CAN biopsies were clearly different from the controls, 
but – similar to Sarwals report – did not find differences between CAN subgroups. They did find 
genes known to be involved in CAN pathogenesis, but concluded that for more insight in CAN 
development, earlier biopsies should be studied. Donauer et al compared 13 transplants with 
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chronic transplant failure with normal controls and end stage renal disease (497). They found 
that the end-stage renal disease kidneys, either transplants or native kidneys, clustered together, 
suggesting a shared pathway to chronic renal failure. Moreover, the chronically rejected kidneys 
showed two distinct subsets at the transcriptional level, but these could not be traced back to 
clinical or histological differences. 
In conclusion, microarray studies in the field of chronic allograft dysfunction have shown that it is 
difficult to obtain information on different pathogenetic pathways or markers of disease progres-
sion once CAN has started to develop. Instead, strategies should aim at defining such markers 
early in the course after transplantation. 
A number of microarray studies have used this approach to more specifically address the predic-
tive value of gene expression measurements. Scherer et al (487) defined two groups that showed 
a divergent course of allograft function between 6 and 12 months after transplantation. Using 
microarray, they selected and validated a set of 10 genes (eight up- and two downregulated) that 
could differentiate between the two groups. Eikmans et al defined two groups of patients that 
both experienced acute rejection but diverged in their long-term follow up. Biopsies of the two 
groups, designated progressors and non-progressors, were studied using microarray, and a num-
ber of differentially regulated genes were further analyzed with respect to their predictive proper-
ties in a separate group of patients (498). Surfactant protein C showed the best predictive value 
of long-term outcome (498), while the combination of several array-selected markers in addition 
to conventional histological and clinical parameters had an even superior predictive performance 
(M. Eikmans, personal communication).
Proteomics, metabolomics, urinomics
It is imaginable that the large scale-analysis of proteins would provide extra tools for monitoring 
renal transplant function and identification of complications. The validity of this concept has been 
scarcely tested in transplantation, but there are some examples of recognition of acute rejection 
using a proteomic approach with sensitivity and specificity comparable to that of mRNA analysis 
(499,500). Whether this also holds true for chronic allograft dysfunction remains to be estab-
lished, but it should be kept in mind that the proteomics approach may meet the same caveats as 
discussed in relation to genomics. Metabolomics is even more in its infancy (with reviews on the 
subject outnumbering original research publications) but may hold promise for the development 
of novel and – if measured in urine – non-invasive biomarkers for transplant monitoring (501).
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Outline of the thesis
Two relatively distinct topics are covered in this thesis: the molecular mechanisms related to the 
development of proteinuria, and those related to kidney transplant failure. Our interest in the 
development of proteinuria was triggered by the discovery of several genes mutated in hereditary 
nephrotic syndromes. Following these findings, it was suggested that the genes and respective 
proteins might likewise be involved in the development of acquired proteinuric diseases. This was 
the subject of the study described in chapter 2, in which we compared the regulation of several 
podocyte-associated genes and proteins in relation to podocyte morphology in patients with and 
without proteinuria. Studying human material often restricts the evaluation of changes in time, 
which was the reason to use a rat model for follow-up studies on the same subject: the regula-
tion of podocyte molecules during the development of proteinuria. In chapter 3, the results of a 
time-course study of the spontaneously proteinuric Dahl salt-sensitive rat in comparison to the 
non-proteinuric spontaneously hypertensive rat are described. This is a largely descriptive study 
that focuses on the glomerular changes in the early phase of proteinuria development. In an at-
tempt to get more insight in the cause of proteinuria in this rat model, we performed a microarray 
study using the same rat model, of which the findings are described in chapter 4.
Proteinuria is an important risk factor for the progression of renal disease, both in setting native 
and transplant diseases. Upon initial injury, kidneys succumb to a progressive course of renal 
function loss that is histologically characterized by the replacement of functional tissue by scar 
tissue, a process referred to as interstitial fibrosis. This process seems to be uncoupled from the 
initial cause of injury, although this injury may still persist in the progressively fibrotic kidney. This 
makes it difficult to install treatments directed at the etiology of the disease. This is especially true 
in the transplantation setting, in which different kinds of injury give rise to similar histopathologi-
cal presentations. We were mainly interested in two distinct causes of kidney transplant injury 
that both operate in the late phase after transplantation: the toxic effects of the immunosup-
pressant cyclosporine A, versus the injurious effects of chronic immunologic activity. Although 
the clinical and histopathological presentation of these two causes is relatively similar, the modes 
of treatment obviously differ. We tried to dissect the role of the different causes by focusing on 
the differences in mRNA expression in two well-defined groups of patients suffering from either 
disease; the results of this study are described in chapter 5. In a similar patient group, we studied 
the protein composition of the interstitial fibrosis, which is the subject of chapter 6.
In chapter 7 these studies are summarized and placed in a more general perspective.
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Abstract
Proteinuria is a poorly understood feature of many acquired renal diseases. Recent studies con-
cerning congenital nephrotic syndromes and findings in genetically modified mice have demon-
strated that podocyte molecules make a pivotal contribution to the maintenance of the selective 
filtration barrier of the normal glomerulus. However, it is unclear what role podocyte molecules 
play in proteinuria of acquired renal diseases. This study investigated the mRNA and protein ex-
pression of several podocyte-associated molecules in acquired renal diseases. Forty-eight patients 
with various renal diseases were studied, including minimal change nephropathy, focal segmental 
glomerulosclerosis, IgA nephropathy, lupus nephritis, and diabetic nephropathy, together with 
13 kidneys with normal glomerular function. Protein levels of nephrin, podocin, CD2-associat-
ed protein, and podocalyxin were investigated using quantitative immunohistochemical assays. 
Real-time PCR was used to determine the mRNA levels of nephrin, podocin, and podoplanin 
in microdissected glomeruli. The obtained molecular data were related to electron microscopic 
ultrastructural changes, in particular foot process width, and to clinical parameters. In most ac-
quired renal diseases, except in IgA nephropathy, a marked reduction was observed at the protein 
levels of nephrin, podocin, and podocalyxin, whereas an increase of the glomerular mRNA levels 
of nephrin, podocin, and podoplanin was found, compared with controls. The mean width of the 
podocyte foot processes was inversely correlated with the protein levels of nephrin (r = -0.443, P 
< 0.05), whereas it was positively correlated with podoplanin mRNA levels (r = 0.468, P < 0.05) 
and proteinuria (r = 0.585, P = 0.001). In the diseases studied, the decrease of slit diaphragm 
proteins was related to the effacement of foot processes and coincided with a rise of the levels 
of the corresponding mRNA transcripts. This suggests that the alterations in the expression of 
podocyte-associated molecules represent a compensatory reaction of the podocyte that results 
from damage associated with proteinuria.
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Introduction
Proteinuria is an important risk factor for the progression of renal disease, but the pathophysi-
ologic mechanisms underlying its development are unclear (1). Ultrafiltration in the glomerulus 
is accomplished by a fenestrated endothelial layer, the glomerular basement membrane (GBM), 
and the overlying podocytes, highly specialized cells with primary and secondary interdigitating 
branches (foot processes) that cover the external surface of the GBM (2). On the basis of its 
structural arrangement and isoporous substructure, the slit diaphragm, bridging the space be-
tween adjacent foot processes, was assumed to make an important contribution to the molecular 
sieve for glomerular filtration (3,4). However, this assumption remained a matter of debate (5). 
Only recently, increased insight in the molecular makeup of the podocyte foot processes and 
slit diaphragm led to the support for the pivotal role of these structures in the maintenance of 
permselectivity (6-8).
In kidney diseases accompanied by a nephrotic syndrome, the spatial organization of the podo-
cyte is simplified, characterized by effacement of the foot processes and sporadic detachment 
of the podocyte from the GBM (9). In the development of the congenital nephrotic syndrome, 
several molecules have been pointed out to play an important role, including those that assemble 
and stabilize the slit diaphragm and those that anchor the foot process to the GBM. Mutations 
in NPHS1 and NPHS2, the genes encoding the slit diaphragm–associated proteins nephrin and 
podocin, respectively, lead to the development of a nephrotic syndrome (10,11). Similarly, injec-
tion of monoclonal antibody 5-1-6, directed against the extracellular part of nephrin (12), causes 
heavy proteinuria in rats (13). Absence of CD2-associated protein (CD2AP), normally linking 
nephrin and podocin to the actin cytoskeleton (14,15), also evokes proteinuria (16). Podoplanin 
is one of the molecules that possibly serve in the connection between foot process and GBM, and 
injection of antipodoplanin antibodies in rats gives rise to proteinuria and foot process efface-
ment (17). The sialoprotein podocalyxin is normally located at the apical part of the foot process. 
Absence of this protein or changes in its spatial organization also has a detrimental effect on the 
glomerular filtration function (18,19). Thus, disruption of the normal gene regulation and protein 
distribution in the podocyte is related to effacement of foot processes and proteinuria. The study 
of molecules associated with defective glomerular ultrafiltration in acquired renal diseases might 
lead to a better understanding of its pathogenesis. 
In the current study, we sought to examine whether glomerular expression levels of several 
podocyte-associated molecules differ between groups of patients who have various acquired 
renal diseases. We also investigated whether the expression levels were related to clinical pa-
rameters and ultrastructural changes. For this, we simultaneously quantified the expression of 
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several podocyte-associated molecules at the protein and the mRNA levels and combined this 
with clinical parameters and morphometric analysis of ultrastructural changes of the podocyte. 
Materials and Methods
Patients and Controls
Forty-eight patients who had acquired renal diseases were included. From each patient, two 
core biopsies were taken on clinical indication. A small piece of cortex was removed from fresh 
biopsies, and glomeruli were microdissected for RNA extraction. One of the biopsies was snap-
frozen and stored at -80°C, and the other was formalin fixed and embedded in paraffin. From 
29 patients, an additional piece of cortex was available for electron microscopic analysis. Diag-
nostic groups were made on the basis of routine pathologic examinations. We defined the fol-
lowing groups: minimal change disease (MCD); focal segmental glomerulosclerosis (FSGS); IgA 
nephropathy; lupus nephritis; diabetic nephropathy; light-chain excretion nephropathy (LCEN); 
nephrotic syndrome as a result of other causes (membranoproliferative glomerulonephritis [n = 
2] and membranous glomerulopathy [n = 1]); and nephritic syndrome as a result of other causes 
(pauci-immune glomerulonephritis [n = 3] and postinfectious glomerulonephritis [n = 1]). For 
controls, renal tissue was derived from cadaver donor kidneys unsuitable for transplantation for 
technical reasons (n = 5), autopsy kidneys (n = 1), tumor nephrectomy samples (n = 2), and bi-
opsies without glomerular lesions (n = 5). In the last group, two showed interstitial nephritis; the 
biopsies of three other patients were indecisive concerning the diagnosis. However, in all biopsies, 
Table 1. Patient characteristics
Diagnostic group N EM (b)
age 
(years ± SD)
gender (female) proteinuria (g/24 h ± SD)
serum creatinine 
(μmol/l ± SD)
Controls (a) 13 3 51 ± 19 7 (53%) 0.4 ± 0.3 150 ± 104 
MCD 10 8 31 ± 24 4 (40%) 4.4 ± 3.8 76 ± 28
FSGS 5 3 36 ± 8 1 (20%) 5.1 ± 2.1 113 ± 67
IgA nephropathy 10 6 37 ± 23 1 (10%) 2.4 ± 2.8 166 ± 150
Lupus nephritis 7 3 30 ± 12 7 (100%) 2.7 ± 2.0 147 ± 94
Diabetic nephropathy 6 1 50 ± 21 3 (50%) 1.1 ± 0.9 141 ± 85
LCEN 3 1 64 ± 6 1 (33%) 1.8 ± 1.3 354 ± 254
Nephrotic Syndrome – other causes 3 1 44 ± 8 2 (67%) 6.7 ± 3.9 92 ± 33
Nephritic syndrome – other causes 4 3 54 ± 22 2 (50%) 2.0 ± 1.4 214 ± 99
Total 61 29 44 ± 21 28 (46%) 2.7 ± 2.8 146 ± 118
a) The control group consisted of one autopsy kidney, five cadaveric donor kidneys, two tumor nephrectomy samples (taken 
from a location remote from the tumor), and five biopsy samples without glomerular lesions. b) Number of samples studied with 
electron microscopy.
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the glomeruli were unaffected, (ie, they were normocellular, had a normally developed capillary 
network, and had a normal GBM and mesangium). The control samples were processed in the 
same way as the patient biopsies. Clinical characteristics, including age, gender, serum creatinine 
levels, and proteinuria, of the patients and controls were collected. The patient groups and their 
clinical characteristics are listed in Table 1.
Antibodies
The polyclonal antibody against human nephrin was generated in rabbits immunized with 1 mg 
of human nephrin peptide (ERDTQSSTVSTTEAEPYYRSLC, located in the cytoplasmic region) con-
jugated with KLH three times with an interval of 2 wk. Human podocalyxin-like protein was pre-
pared with a WGA column according to the same method for the purification of rat podocalyxin 
described by Kerjaschki et al (20). Briefly, isolated glomeruli from normal human kidneys were 
extracted with 0.2% Triton X-100 in PBS containing protease inhibitors. The extract was then 
incubated with WGA-Sepharose 4B at 4°C overnight, and unbound material was removed by 
washing with PBS. The sialic-acid–rich material 
that bound to the WGA column was released 
with 120 mM N-acetyl-b-glucopyranoside in 
PBS. Rabbits were immunized with the sialic-
acid–rich material three times with an interval of 
2 wk. The rabbits were killed and bled 2 wk after 
the last immunization. Rabbit anti-human podo-
cin antibody p35 raised against the C-terminal 
part of human podocin (21) was supplied by 
Dr. C. Antignac (Hôpital Necker, Paris, France). 
Rabbit anti-CD2AP was obtained from Santa 
Cruz Biotechnology (SC9137; Santa Cruz, CA). 
Horseradish peroxidase–conjugated anti-rabbit 
Envision was obtained from DAKO (Glostrup, 
Denmark). FITC-conjugated goat anti-rabbit IgG 
antibody was obtained from Sigma (St. Louis, 
MO). 
Western Blot Analysis
Western blot analysis of the anti-human nephrin antibody was performed with glomeruli isolated 
from normal human kidney by a standard sieving method with PBS containing protease inhibitors 
(PBS-PI; 1 mM each antipain, benzamidine, di-isopropylfluorophosphate, leupeptin, pepstatin A, 
and PMSF). The glomeruli were solubilized with RIPA buffer (consisting of 0.1% SDS, 1% Triton 
X-100, 150 mM NaCl, and 10 mM EDTA in 25 mM Tris-HCl [pH 7.2]) with protease inhibitors 
Figure 1. Characterization of the anti-nephrin and anti-
podocalyxin antibodies. Western blot for anti-human neph-
rin antibody (lanes 1, 2 and 3) and anti-human podocalyxin 
antibody (lanes 4 and 5). A glomerular extract was incubated 
with preimmune rabbit serum (lanes 1 and 5), the anti-human 
nephrin antibody produced in rabbits immunized with a pep-
tide of 21 amino acids of human nephrin sequence (lane 2), 
with the anti-human nephrin antibody preabsorbed with the 
peptide used for immunization (lane 3), or the anti-human 
podocalyxin antibody produced in rabbits immunized with a 
WGA-column purified glomerular lysate (lane 4). A clear band 
of approximately 180 kD was seen in lanes 2 and 4. No bands 
were observed in lanes 1, 3 or 5.
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described above. For Western blot analysis of the anti-human podocalyxin antibody, human glo-
merular lysate solubilized with 0.2% Triton X-100 in PBS-Pis was used. Insoluble material was 
removed by centrifugation at 15,000 x g for 10 min. Solubilized material was subjected to SDS-
PAGE with 7.5% acrylamide gel according to the method of Laemmli (22) and transferred to a 
nitrocellulose membrane (Bio-Rad, Hercules, CA) by electrophoretic transblotting for 30 min us-
ing Trans-Blot SD (Bio-Rad). After blocking with BSA, strips of membranes were exposed to preim-
mune rabbit serum, anti-human nephrin, or anti-human nephrin preabsorbed with the peptide 
used for immunization, and anti-human podocalyxin or preimmune rabbit serum. The strips were 
then washed and incubated with alkaline phosphatase-conjugated anti-rabbit IgG (Bio Source 
International, Tago Immunologicals, Camarillo, CA). The reaction was developed with an alkaline 
phosphatase chromogen kit (Biomedica, Foster City, CA). 
Immunohistochemistry and Immunofluorescence
Three-micrometer cryostat sections were cut, transferred to Starfrost slides, air dried, and stored 
at -20°C until use. For immunohistochemistry, the slides were washed in PBS and incubated for 
1 h at room temperature with the primary antibody diluted in 1% BSA in PBS (rabbit anti-neph-
rin 1:1000; rabbit anti-podocalyxin 1:2000; rabbit anti-podocin 1:2000). The slides were then 
washed in PBS and incubated for 30 min with horseradish peroxidase–conjugated anti-rabbit 
Envision (1:1). The slides were again washed in PBS, and the staining was developed with diami-
nobenzidine. The color was enhanced by rinsing the slides in 0.5% CuSO4 solution for 5 min. 
After counterstaining with hematoxylin, the slides were dehydrated and mounted. 
For immunofluorescence, the slides were thawed in PBS, fixed in a mixture of 50% alcohol and 
50% acetone for 5 min and subsequently in 100% alcohol for 10 min, and washed in PBS. The 
slides were then incubated overnight with the primary antibody at room temperature (rabbit anti-
CD2AP 1:500) and thereafter washed in PBS. The slides were incubated with the FITC-conjugated 
anti-rabbit IgG antibody (1:200) for 30 min, washed in PBS, and covered with Vecta shield (Vector 
Laboratories, Burlingame, CA). For each antibody, all samples were stained in one session. 
Digital Image Analysis
Of the immunohistochemically stained samples, images of all of the glomeruli in the section were 
taken at a x400 magnification using a Zeiss Axioplan microscope equipped with a Sony DXC-
950P 3CCD color camera (Sony Corporation, Tokyo, Japan) and further analyzed using KS-400 
image analysis software (Windows version 3.0; Carl Zeiss Vision, Oberkochen, Germany). The 
glomerular area stained was calculated by drawing a region of interest around the glomerulus in 
which the amount of staining within a color spectrum specific for the diaminobenzidine staining 
and above a fixed intensity threshold was determined, as described before (23,24).
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Slides stained by immunofluorescent methods were evaluated with a Zeiss Axioplan 2 micro-
scope, equipped with an AxioCam CCD color camera, connected to a computer equipped with 
AxioVision 3.0 software (Carl Zeiss Vision). In each section, five images of individual glomeruli 
were recorded at x400 magnification. The intensity of the staining was determined by drawing a 
region of interest around the glomerulus and measuring the mean luminosity value of the region 
with the histogram function of ImageJ 1.26t software (National Institutes of Health, rsb.info.nih.
gov/ij), as described in detail elsewhere (25). Recording and analysis of the digital images were 
performed with fixed settings.
mRNA Isolation, cDNA Synthesis and Real-Time PCR
Total RNA was extracted from microdissected glomeruli using the Trizol-method and used for 
cDNA synthesis with the aid of the sensiscript-RT kit (Qiagen, Westburg BV, Leusden, The Neth-
erlands), as described previously (26). For nephrin, podocin, podoplanin, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), β2 microglobulin (B2M), TATA box binding protein (TBP), 
hydroxymethyl-bilane synthase (HMBS), and hypoxanthine phosphoribosyltransferase 1 (HPRT1), 
forward and reverse primers (Isogen Bioscience BV, Maarsen, The Netherlands) and probes (Eu-
rogentec Nederland BV, Maastricht, The Netherlands) were designed using Primer Express 1.5 
software (PE Applied Biosystems, Foster City, CA). The sequences of the primers and probes are 
shown in Table 2. Real-time PCR was performed using the ABI PRISM 7700 sequence detector 
and software (PE Applied Biosystems). All measurements were performed in duplicate. Amplifica-
tion cycles were 95°C for 10 min, followed by 50 cycles at 95°C for 30 s and at 60°C for 60 s. 
To correct for the amount of tissue used for RNA extraction and the efficiency of cDNA synthesis, 
we used the ratio between the mRNA levels of nephrin, podocin, and podocalyxin and the mRNA 
level of GAPDH, a constitutively expressed gene. The suitability of GAPDH as a housekeeping 
Table 2. Primer and probe sequences
Molecule Forward primer Reverse primer Probe
Nephrin AGGACCGAGTCAGGAACGAAT CTGTGAAACCTCGGGAATAAGACA TCAGAGCTCCACGGTCAGCACAACAG
Podocin GGCTGTGGAGGCTGAAGC CTCAGAAGCAGCCTTTTCCG CAGCAATCATCCGCACTTTGGCTTG
Podoplanin CCAGGAACCAGCGAAGACC GCGTGGACTGTGCTTTCTGA TTGACACTTGTTGCCACCAGAGTTGTCAA
GAPDH TGGTCACCAGGGCTGCTT AGCTTCCCGTTCTCAGCCTT TCAACTACATGGTTTACATGTTCCAATAT-GATTCCACCAA
B2M TGCCGTGTGAACCATGTGA CCAAATGCGGCATCTTCAA TGATGCTGCTTACATGTCTCGATCCCACT
TBP CACGAACCACGGCACTGATT TTTTCTTGCTGCCAGTCTGGAC TGTGCACAGGAGCCAAGAGTGAAGA
HMBS CTGGTAACGGCAATGCGGCT GCAGATGGCTCCGATGGTGA CGAATCACTCTCATCTTTGGGCT
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT CTTGACCATCTTTGGATTATACTGCCT-GACCA
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; B2M, β2 microglobulin; TBP, TATA box binding protein; HMBS, hydroxy-
methyl-bilane synthase; HPRT1, hypoxanthine phosphoribosyl-transferase 1. Primers and probes are located within 1500 bp 
from the 3’ end of the mRNA. All 5’ ends of the probes were 6-carboxy-4,7,2’,7’-tetrachloro-fluorescein (TET)-labeled, except 
those for GAPDH and TBP, which were 6-carboxy fluorescein (FAM)-labeled. The quencher dye at the 3’ ends of the probes was 
6-carboxy-tetramethyl-rhodamine (TAMRA).
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gene for standardization of mRNA levels was confirmed by testing correlations between GAPDH 
mRNA for all samples (n = 61) and each of the other four housekeeping genes (B2M, TBP, HMBS, 
and HPRT1) measured.
Transmission Electron Microscopy and Morphometry
Small pieces of cortex were fixed in 1.5% glutaraldehyde and 1% paraformaldehyde, dehydrat-
ed, and embedded in Spurr. In semithin sections stained with toluidine blue, nonsclerosed glom-
eruli were localized. Ultrathin sections were made of one or two glomeruli per tissue specimen 
and stained with lead citrate for transmission electron microscopy. Four to ten photographs, cov-
ering one or two glomerular cross-sections, were made with a Philips CM10 transmission electron 
microscope (Philips, Eindhoven, the Netherlands). A calibration grid with 2160 lines/mm was 
photographed to determine the exact magnification. Negatives were digitized, and images with 
a final magnification of approximately x17,500 were obtained. With the use of ImageJ 1.26t 
software (National Institutes of Health, rsb.info.nih.gov/ij), the length of the peripheral GBM was 
measured and the number of slit pores overlying this GBM length was counted. The arithmetic 









∑slits  where slits is 
the total number of slits counted, GBM length is the total GBM length measured in one glomeru-
lus, and the correction factor π⁄4 serves to correct for the random orientation in which the foot 
processes are sectioned (27,28). A mean GBM length of 276 µm was evaluated in each glomeru-
lus.
Statistical Analyses
Data are presented as means ± SD. One-way ANOVA combined with a least significant difference 
post hoc correction was used to test differences between groups. Correlations were calculated 
using Pearson correlation test. P < 0.05 was considered statistically significant. 
Figure 2. Staining pattern of nephrin, podocin, podocalyxin, and CD2-associated protein (CD2AP) in normal and diseased 
human kidney sections. Nephrin (A), podocin (B), and podocalyxin (C) show a podocyte-like staining pattern in normal glomeruli 
as visualized by an immunohistochemical diaminobenzidine staining. The staining pattern of nephrin is more dispersed than that 
of podocin and podocalyxin, which show a fine glomerular basement membrane (GBM)-like line along the capillary loops of 
the glomerulus. CD2AP, visualized with immunofluorescence, shows a GBM-like staining pattern (D). In diseased situations, the 
staining for nephrin (E; minimal change disease), podocin (F; focal segmental glomerulosclerosis [FSGS]), and podocalyxin (G; 
FSGS) is less intense, and nephrin and podocin stainings show a more granular staining pattern. CD2AP staining shows no clear 
differences between control (D) and diseased tissue (H; diabetic nephropathy). Magnification x 400.




The results of the Western blot assays of nephrin and podocalyxin are shown in Figure 1. For both 
antibodies, the Western blot assay showed a clear band of approximately 180 kD in the lane in-
cubated with the anti-human nephrin or anti-human podocalyxin antibodies, whereas no bands 
were seen in the lanes incubated with preimmune rabbit serum or with antibody preabsorbed 
with the peptide used for immunization. This confirmed the specificity of the anti-nephrin and 
anti-podocalyxin antibodies. 
Immunohistochemistry and Immunofluorescence
In normal glomeruli, nephrin, podocin, and podocalyxin showed an intense epithelial staining 
along the peripheral capillary loops of the glomeruli. Nephrin showed a more dispersed pat-
tern than podocin and podocalyxin. The GBM-like pattern for CD2AP was very subtle, and the 
staining, therefore, was analyzed using immunofluorescence. In glomeruli of diseased kidneys, 
Figure 3. Glomerular expression of podocyte-associated proteins. Nephrin, podocin, and podocalyxin stainings were per-
formed immunohistochemically. Images of the glomeruli in the sections were recorded and analyzed using digital image analysis 
as described in the Materials and Methods section. Nephrin, podocin, and podocalyxin show a downregulation in many disease 
categories compared with controls. CD2AP protein levels, as determined by measuring the mean luminosity in glomeruli stained 
with anti-CD2AP antibody, showed no significant differences between patient groups and controls. NoSy, other, nephrotic syn-
drome as a result of other causes; NiSy, other, nephritic syndromes as a result of other causes. *P < 0.05; ‡P < 0.001.
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the staining of nephrin, podocin, and podo-
calyxin was weaker, and sometimes the staining 
showed a more granular appearance. Figure 2 
gives a graphical overview of the staining pat-
terns for the different molecules in control and 
diseased kidneys. Quantification of the stain-
ing using digital image analysis showed that 
the stained glomerular surface for nephrin and 
podocin was significantly diminished in several 
disease categories, including FSGS, lupus nephri-
tis, and the group of nephritic syndrome as a re-
sult of other causes. Podocalyxin also showed a 
decrease in stained glomerular surface, although 
in MCD and diabetic nephropathy, this was less 
prominent. Protein levels of all molecules were 
not significantly altered in IgA nephropathy 
compared with controls (Figure 3). The glomeru-
lar fluorescence intensity of the CD2AP staining 
did not differ significantly between controls and 
disease groups (Figure 3). 
There was a strong correlation between protein 
levels of nephrin and podocin (r = 0.576, P < 
0.001), nephrin and podocalyxin (r = 0.477, P = 
0.001), and podocin and podocalyxin (r = 0.693, 
P < 0.001). There was no correlation between 
serum creatinine levels and protein levels of 
nephrin, podocin, or podocalyxin. 
mRNA Quantification
mRNA levels for nephrin, podocin, and podo-
planin were measured and corrected for the 
mRNA level of GAPDH. In all of the 61 samples used in this study, significant correlations (P < 
0.001) were found between GAPDH mRNA and mRNA for each of the four other housekeeping 
genes, namely B2M (r = 0.81), TBP (r = 0.78), HMBS (r = 0.82), and HPRT1 (r = 0.80). This con-
firmed the suitability of GAPDH as a housekeeper gene in this case.
The corrected mRNA levels for the various molecules are depicted in Figure 4. In general, mRNA 
levels of nephrin, podocin, and podoplanin in isolated glomeruli were elevated in most disease 
Figure 4. Glomerular mRNA levels of nephrin, podocin, 
and podoplanin. mRNA levels of nephrin, podocin, and 
podoplanin were measured in microdissected glomeruli us-
ing real-time PCR. Podocin and podoplanin mRNA levels are 
most prominently altered in diseased states. *P < 0.05; ‡P 
< 0.001.
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categories compared with controls. The mRNA levels of nephrin showed an upregulation in most 
disease categories, reaching a significant difference in lupus nephritis. The nephrin mRNA levels 
of patients who had diabetic nephropathy were slightly lower than in controls, although not 
significantly. The mRNA levels of podoplanin and podocin were most prominently upregulated, 
reaching significant difference in MCD, FSGS, and lupus nephritis for both podocin and podo-
planin. 
Electron Microscopy and Morphometry
Assessment of the mean FPW revealed various degrees of foot process effacement between pa-
tients, being most outspoken in patients who had MCD and FSGS (ie, up to 1900 nm compared 
with 640 nm in controls). The mean FPW correlated with proteinuria (r = 0.585, P = 0.001), pro-
tein levels of nephrin (r = -0.443, P < 0.05), and podoplanin mRNA levels (r = 0.468, P < 0.05). 
Correlation plots are shown in Figure 5. 
Discussion
Resulting from the identification of the important role that podocyte-associated molecules play in 
maintaining the glomerular filtration barrier, the hypothesis emerged that these molecules might 
also be involved in acquired nephrotic syndromes (6,12). We investigated whether glomerular 
expression of podocyte-associated molecules is different between various groups of patients with 
acquired renal diseases and whether these expression levels are related to clinical parameters and 
ultrastructural changes. 
The basolateral region of the podocyte foot process is the insertion place of the slit diaphragm (8). 
Nephrin and podocin are two crucial proteins in the complex of molecules that assemble and rein-
force the slit diaphragm. These molecules are bound to the actin cytoskeleton via CD2AP, a gen-
eral adapter molecule (14,15). The basal aspect of the podocyte foot processes is firmly attached 
to the GBM by several linkage proteins, including α3β1-integrin and α- and β-dystroglycan (2,29). 
Podoplanin, a 43-kD molecule expressed in the glomerulus and in lymphatic tissue, is thought to 
have a similar function (8) and controls the shape of the podocyte foot processes (30). Proteins 
located at the apical part of the podocyte foot process play an important role in ultrafiltration, 
mainly by maintenance of the negative charge of the membrane domain. The sialoprotein podo-
calyxin is the most important of these molecules (20) and plays a crucial role in the maintenance 
of the normal morphology of the podocyte foot processes (19). 
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At the protein level, we observed in most patient groups a decrease of the examined podocyte-
associated molecules compared with controls, except for CD2AP. We found that the glomerular 
amount of nephrin was significantly decreased in most proteinuric kidney diseases. Several studies 
concerning nephrin expression in human acquired renal diseases have recently been performed, 
but the various observations do not firmly support each other. Patrakka et al (31) did not find sig-
nificant changes in the expression of nephrin at 
the protein level, whereas Doublier et al (32) and 
Wang et al (33) both reported a downregulation 
of nephrin protein expression in MCD, FSGS, 
and membranous glomerulonephritis. Our ob-
servations are in line with the latter findings. In a 
variety of experimental models, nephrin protein 
levels have been shown to decrease, suggesting 
a crucial role for nephrin in the development of 
proteinuria (25,34-36). 
Expression of podocin in human acquired pro-
teinuric diseases has until now not been de-
scribed. In our study, we found that the podocin 
protein levels were significantly decreased in 
most disease categories compared with con-
trols. The expression patterns of podocin protein 
resemble those described for puromycin amino-
nucleoside (PAN) nephrosis in the rat, a model 
for MCD, which is characterized by heavy pro-
teinuria (37). 
In contrast to nephrin and podocin, the protein 
expression of CD2AP did not show major differ-
ences between patient groups and controls in 
our study. The same pattern has been described 
for the passive Heyman nephritis model in the 
rat, in which an overt decrease of nephrin pro-
tein expression was observed, whereas CD2AP 
protein expression remained unaltered (25). 
Still, it is remarkable that in proteinuric states, 
podocin and nephrin protein levels are severely 
decreased, whereas in the same cluster of mol-
ecules, CD2AP remains unimpaired. This might 
Figure 5. Correlation plots. (A) The amount of proteinuria 
was related to the mean foot process width (FPW; r = 0.585, 
P = 0.001). (B) The mean FPW of all patients was significantly 
correlated with the glomerular area percentage of nephrin (r 
= 0.443, P = 0.034). (C) Podoplanin mRNA levels were also 
correlated to the mean FPW (r = 0.430, P = 0.036). 
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suggest that upon damage to the podocyte, the binding of CD2AP with nephrin and podocin is 
disconnected, whereas CD2AP itself remains attached to the actin cytoskeleton (25). As observed 
in experimental models, the uncoupled proteins might be shed from the podocyte membrane 
and excreted in the urine (38,39), whereas CD2AP condenses in the scaffold of microfilaments in 
the effaced foot processes (25,40). 
The glomerular podocalyxin protein expression in most proteinuric diseases was reduced com-
pared with controls. This might suggest uncoupling of podocalyxin from the actin cytoskeleton 
as a result of rearrangements of the cytoskeleton. This phenomenon has been described in rat 
models of proteinuria, in which the complex linking podocalyxin to the actin cytoskeleton is dis-
rupted (19). 
In remarkable contrast to decreased protein levels in most patient groups, the mRNA levels in 
proteinuric states were generally increased compared with controls. Nephrin mRNA levels were 
significantly elevated in lupus nephritis, whereas only in diabetic nephropathy was there a slight 
decrease in nephrin mRNA levels. The latter finding is in line with other studies measuring nephrin 
mRNA expression in diabetic nephropathy by in situ hybridization (41). Our results are in sharp 
contrast with the study by Furness et al (42), which described a downregulation of nephrin mRNA 
in four patients with nephrotic syndrome. Patrakka et al (31) did not find significant changes in 
nephrin mRNA levels, as studied in proteinuric patients using in situ hybridization. In experimental 
studies, both up- and downregulation of nephrin mRNA in proteinuric states has been described 
(34,35,38,43). Following the same pattern as nephrin mRNA, the podocin mRNA levels showed 
an increase in most patient groups. Likewise, podoplanin mRNA levels were increased in most pa-
tient groups compared with controls. In PAN nephrosis of the rat, mRNA levels of molecules that 
bind the podocyte to the GBM are increased, suggesting an effort of the podocytes to remain 
attached to the GBM (37). Similarly, in human and experimental proteinuric states, the mRNA ex-
pression of α-actinin-4 is increased, probably reflecting a compensatory reaction of the podocyte 
(44,45). The rise in mRNA levels of nephrin, podocin, and podoplanin might likewise result from 
a compensatory reaction to the damage inflicted on the podocyte. 
The pathogenic effects exerted on the glomerulus in the various renal disease entities studied dif-
fer in nature and severity. For example, putative circulating permeability factors might cause the 
loss of the glomerular permselectivity in MCD (46). In lupus nephritis and membranous nephropa-
thy, subepithelial Ig deposits are formed, thereby inflicting damage on the podocyte, whereas in 
IgA nephropathy, more preferentially mesangial areas are affected (47). Diabetic nephropathy is 
thought to impair the charge selectivity of the glomerular filtration barrier and might thereby in-
directly damage the podocyte (48). Damage to the podocyte leads, irrespective of its origin, to ef-
facement of foot processes (40). Therefore, as a measure of podocyte damage, we examined the 
extent of foot process effacement by assessment of the mean FPW. The mean FPW was positively 
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correlated with proteinuria and podoplanin mRNA levels, whereas it was inversely correlated with 
nephrin protein levels. This suggests that the changes seen in protein expression are related to the 
severity of the damage inflicted on the podocyte. For instance, that IgA nephropathy is character-
ized primarily by damage to the mesangial areas and, to a lesser extent, to the podocytes might 
be reflected by the absence of significant changes in the podocyte-associated molecules at the 
protein level, as has been observed before (32). The observation that downregulation of nephrin 
protein is paralleled by foot process effacement is in line with results from a study by Huh et al 
(49) and Wernerson et al (50), which suggests that not the quantity of nephrin between adjacent 
foot processes is different but that merely the total glomerular amount of nephrin is decreased 
as a result of foot process effacement. The decreased protein staining of nephrin, podocin, and 
podocalyxin might also be explained by a reduction of podocytes, as has been observed in several 
diseases (51,52). Furthermore, the accessibility of the antigen might be diminished. 
The development of a nephrotic syndrome and effacement of podocyte foot processes is nowa-
days known to occur upon mutations in a wide range of podocyte-associated molecules, includ-
ing those investigated in this study. The molecular scaffold in the podocyte foot process therefore 
seems to be fragile, disassembling when one of its components is removed. Generally, in the 
current study, the protein expression of most podocyte-associated molecules was diminished 
in acquired proteinuric diseases, coinciding with an increase in mRNA levels. A divergence be-
tween mRNA and protein levels has been described for synaptopodin and α-actinin 4 in patients 
with nephrotic syndromes (24,44) and in podocyte-associated molecules in the PAN nephrosis rat 
model (37,45). There was no direct correlation between the level of proteinuria and the protein 
and mRNA expression of the molecules studied. However, nephrin protein levels and podoplanin 
mRNA levels were correlated with the effacement of podocyte foot processes, which might point 
in the direction of an association between the expression of podocyte-associated molecules and 
proteinuria. It is still unclear whether changes in expression of these podocyte-associated mol-
ecules are the underlying cause of the development of proteinuria. Taken together, there is a 
cluster of molecules, at both the protein and the mRNA levels, that seem to show a stereotypic 
reaction in proteinuric diseases. Besides taking into account the correlation between foot process 
effacement and protein and mRNA levels, the observed changes in expression levels merely seem 
to be the consequence of podocyte foot process effacement as a result of other causes and the 
subsequent reaction of the podocyte to this phenomenon.
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Selective Loss of Podoplanin 
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Proteinuria and Precedes 
Alterations in Podocyte 




To evaluate changes during the development of proteinuria, podocyte morphology and protein 
expression were evaluated in spontaneously proteinuric, Dahl salt-sensitive (Dahl SS) rats. Dahl SS 
rats on a low-salt diet were compared with spontaneously hypertensive rats (SHR) at age 2, 4, 6, 
8, and 10 weeks. Blood pressure, urinary protein excretion, urinary albumin excretion, and podo-
cyte morphology were evaluated. In addition, the expression of 11 podocyte-related proteins was 
determined by analyzing protein and mRNA levels. In Dahl SS rats, proteinuria became evident 
around week 5, increasing thereafter. SHR rats remained non-proteinuric. Dahl SS rats showed 
widespread foot process effacement at 10 weeks. At 8 weeks, expression and distribution of the 
podocyte proteins was similar between the two strains, except for the protein podoplanin. At 4 
weeks, podoplanin began decreasing in the glomeruli of Dahl SS rats in a focal and segmental 
fashion. Podoplanin loss increased progressively and correlated with albuminuria (r = 0.8, P < 
0.001). Double labeling experiments revealed increased expression of the podocyte stress marker 
desmin in glomerular areas where podoplanin was lost. Dahl SS rats did not show podoplanin 
gene mutations or decreased mRNA expression. Thus, podocyte morphology and the expression 
and distribution of most podocyte-specific proteins were normal in young Dahl SS rats, despite 
marked proteinuria. Our study suggests that decreased expression of podoplanin plays a role in 
the decrease of glomerular permselectivity. 
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Introduction
The permselectivity of the glomerular filtration barrier restricts passage of proteins into Bowman’s 
space. Loss of permselectivity leads to proteinuria, which is common in renal diseases of diverse 
origin. Proteinuria is related to the progression of renal and cardiovascular disease (1-3) Although 
the details of glomerular filtration remain unknown, it is clear that the glomerular visceral epithe-
lial cell or podocyte is an important component of the glomerular filtration barrier. Damage to 
podocytes is frequently involved in the pathogenesis of glomerular diseases (4). 
Podocyte damage can be the result of changes in individual podocyte-associated proteins. Ex-
amples include mutations in the genes that encode nephrin, podocin, CD2AP, and α-actinin-4 
(5-8). Such mutations can result in both congenital and hereditary forms of glomerular dysfunc-
tion. Podocyte damage also appears to be of pathogenic importance in acquired diseases. For ex-
ample, in diabetic nephropathy and IgA nephropathy, podocyte loss is related to disease severity 
(9-11). Similarly, animal models have shown that loss of podocytes is related to the development 
of proteinuria and glomerulosclerosis (12-15).
A change in podocyte morphology often accompanies proteinuria. In the normal glomerulus, the 
podocyte has an arborized phenotype, and its terminal branches or foot processes cover the outer 
wall of the glomerular capillaries. In proteinuric states, this morphology is typically lost as the 
podocyte converts to a flatter epithelial cell, a process referred to as “foot process effacement”. 
In foot process effacement, the cytoskeleton that normally supports the delicate architecture of 
the foot processes is condensed at the basal side of the flattened podocytes (16).
We previously studied the mRNA and protein expression of several podocyte-associated proteins 
in acquired proteinuric diseases (17). Based on the results of that study, we hypothesized that the 
changes in expression of podocyte proteins represented a compensatory reaction of the podo-
cyte to the occurrence of proteinuria. Accordingly, we wanted to investigate how the expression 
of podocyte-associated proteins is regulated during the development of proteinuria, and how 
changes in expression are related to podocyte morphology. We studied proteins that have been 
shown to be involved in congenital and hereditary nephrotic syndromes, as well as podocyte 
proteins that have been studied in animal models. Among these is the glycoprotein podoplanin, 
of which the expression was previously found to change in the puromycin aminonucleoside ne-
phrosis model of the rat (18). Studying human kidney biopsy samples does not allow the rigor-
ous evaluation of changes over time. In this study, we therefore used the Dahl salt-sensitive rat 
(Dahl SS) proteinuric model (19) to evaluate changes in podocyte morphology and expression of 
podocyte-associated proteins during the development of proteinuria. 
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Materials and Methods
Animals and study design
We compared the spontaneously proteinuric Dahl SS rat strain with non-proteinuric spontane-
ous hypertensive (SHR) rats. Male Dahl SS and SHR rats were obtained from colonies at the Freie 
Universität Berlin as previously reported (19). All animals were fed a low-salt diet containing 0.2 
percent NaCl by weight; on this diet, Dahl SS rats develop mild spontaneous hypertension com-
parable to SHR rats. To study changes in expression of podocyte-associated proteins during the 
development of proteinuria, groups of rats (n = 5 to 8 rats per group) were studied at 2, 4, 6, 8, 
and 10 weeks of age. Experiments were performed in accordance with institutional guidelines. 
Urinalysis and blood pressure measurements
Urinalysis was performed in each rat. Rats that were 4 weeks of age or older were placed in 
metabolic cages for a 24-hour period. In the 2-week-old rats, a urine sample was obtained by 
bladder punction before the perfusion procedure described below. Urinary albumin excretion was 
subsequently determined by enzyme-linked immunosorbent assay (20). Urinary protein excretion 
rates were determined using the Bradford method. In rats of 6 weeks of age or older, systolic 
blood pressure was determined using the tail-cuff method, as described previously (20). Three 
blood pressure measurements were performed each day on two consecutive days. 
Perfusion, tissue preservation and isolation of glomeruli
Rats were anesthetized using intraperitoneal injection of ketamine/xylazine. After the abdomen 
was opened, the aorta was ligated below the diaphragm and both kidneys were perfused with 
PBS. After clamping the vascular pole, the right kidney was removed. For electron microscopy, 
small pieces of the cortex of the right kidney were immersion-fixed for 24 hours in 0.1M glutaral-
dehyde containing cacodylate and were processed according to standard procedures. For histol-
ogy and immunohistochemistry, part of the remaining right kidney was embedded in paraffin, 
and the other part was snap frozen and stored at –80°C. 
The left kidney was used for isolation of glomeruli. Because the standard differential sieving 
method is not suitable for isolation of glomeruli in very young animals, we used the magnetic 
retraction method to isolate glomeruli from all animals (21). Briefly, the left kidney was perfused 
with sonicated 1.25% suspension of Fe3O4 (Sigma-Aldrich Chemicals, Zwijndrecht, The Neth-
erlands) in PBS, removed, and placed in ice-cold PBS. The kidney was then cut into pieces and 
pressed through a 106 µm (weeks 2 and 4) or 150 µm (weeks 6 to 10) mesh filter. The glomeruli 
were isolated by holding the suspension to a magnet. The fluid was discarded, and the glomeruli 
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were resuspended in fresh PBS. After repeating this procedure two times, glomeruli were pelleted 
and stored at –80°C until RNA extraction. 
RNA isolation, cDNA synthesis and real-
Time PCR
RNA was isolated from the glomeruli using 
the TRIzol (Invitrogen) method. Total RNA 
(0.5 µg) was reverse transcribed into cDNA 
using Avian Myeloblastosis Virus reverse 
transcriptase (Roche Diagnostics). 
Primers (Isogen Bioscience) for 14 podo-
cyte-expressed genes were designed using 
BeaconDesigner 4.0 software (PREMIER 
Biosoft International). To prevent genomic 
contamination, all primers, except those for 
the synaptopodin gene that contains only 
one exon, were chosen to span at least one 
splice-site. Primers sequences are listed in 
Table 1 . Real-time PCR was performed us-
ing an iCycler real-time PCR machine with 
iCyclerIQ 3.1 software (Bio-Rad laborato-
ries). Sybrgreen was used as the fluorescent 
dye. The mean expression levels of three 
housekeeping genes (Hmbs, Tbp, and Hprt) 
were used to correct for variations in the 




Three-micron paraffin sections were depa-
raffinized, rehydrated, and used for immu-
nostaining after appropriate antigen retriev-
al procedures. Three-micron cryosections 
were used untreated or after fixation with 
acetone/ethanol for 5 minutes and 100% 





































































































































































































































































































































































































































































































































































































































































































































































































































































Endogenous peroxidase activity was blocked for 15 minutes in 0.1% H2O2 in water. After washing 
with PBS, sections were incubated with primary antibodies diluted in 1% bovine serum albumen 
in PBS for 2 hours. Details regarding antibodies, fixation, and antigen retrieval are listed in Table 
2. After 1 hour incubation with the secondary antibody, the slides were developed with diamino-
benzidine. Slides were counterstained with hematoxylin, dehydrated, and mounted. To minimize 
variations in intensity, staining for each antibody 
was performed on all sections during one session. 
Podoplanin staining was evaluated on a semiquan-
titative scale: 0, normal intensity and pseudo-linear 
staining pattern; 1, loss of staining <25 percent of 
the glomerular surface or a granular staining pat-
tern; 2, loss of staining involving 25 to 75 percent 
of the glomerular surface; and 3, loss of staining in 
>75 percent of the glomerular surface. 
Podoplanin and desmin were costained on paraf-
fin sections and cryosections using the appropriate 
Alexa 466- and 536-conjugated secondary antibod-
ies. Staining was evaluated with a Zeiss LSM 510 
confocal microscope. 
For morphometric analysis of the size of the glom-
eruli and the number of podocytes, we used slides 
stained for WT-1, a podocyte-specific transcription 
factor that is used to identify and count podo-
cytes in tissue sections (22). Slides stained for WT-1 
were evaluated with a Zeiss Axioplan microscope 
equipped with a Sony DXC-950P 3CCD color cam-
era (Sony Corporation, Tokyo, Japan). Ten randomly 
chosen regions of the outer glomerular cortex were 
photographed at x200 magnification. The surface 
area of all glomeruli in the photographs was deter-
mined using ImageJ 1.34 software (National Insti-
tutes of Health, http://rsb.info.nih.gov/ij). The num-
ber of WT-1 positive nuclei in each glomerular cross 
section was counted using the same software. The 
number of podocytes per glomerulus and the glo-
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these measurements (22). Periodic acid-Schiff staining was performed to determine changes in 
morphology. 
Sequencing
To check for genetic differences between the 
Dahl SS and SHR rats, we sequenced the full-
length podoplanin cDNA in a representative rat 
from each strain. The sequences of the primers 
used are available on request. 
Laser capture microscopy
We used laser capture microscopy to determine 
whether there were differences in podoplanin 
mRNA expression in glomeruli that showed a 
difference in podoplanin protein expression. 
Four-micron cryosections were obtained from 
four 8-week-old Dahl SS rats. One section was 
used for immunohistochemical staining for 
podoplanin to identify glomeruli that had either 
completely lost or retained podoplanin expres-
sion. The cross-section of the same glomerulus 
was identified in the sequential unstained sec-
tion and isolated by laser capture microdissec-
tion using a PALM Laser-MicroBeam system 
(Wolfratshausen, Germany). RNA was isolated 
from the isolated glomeruli, and quantitative 
measurements of the expression of podoplanin 
and RhoA mRNA were performed as described 
above. 
Electron microscopy and immunoelectron 
microscopy
Small pieces of the cortex were fixed in 1.5% 
glutaraldehyde and 1% paraformaldehyde for 
Figure 1. Urinary protein excretion (A), urinary albumin excretion (B) and blood pressure (C) in Dahl SS and SHR rats. As 
expected, SHR rats remained non-proteinuric throughout the time course of the study. Dahl SS rats developed proteinuria and 
albuminuria between 4 and 6 weeks of age (A and B). In Dahl SS rats, measurements were taken at an additional time point, 
5 weeks of age, to obtain a more detailed view of the early phase of proteinuria development in these rats. Both rat strains 
developed hypertension starting at week 8. At 10 weeks of age, the blood pressure of SHR rats was significantly higher than that 
of Dahl SS rats (C). An asterisk indicates P < 0.05.
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24 hours and then stored in 0.1 M cacodylate 
buffer with 6% sucrose. After postfixation in 
1% reduced osmium in 0.1 M cacodylate buffer, 
the samples were dehydrated and embedded in 
EPON. Ultrathin sections were cut using a Leica 
Ultracut microtome and mounted on uncoated 
copper grids. Sections were contrasted with 
uranyl acetate and lead citrate before evalua-
tion with a JEOL JEM-1011 electron microscope 
equipped with a digital camera. 
Random pictures of 2 to 3 glomeruli were taken 
in two rats per group using x15,000 magnifica-
tion. Using image analysis, we determined the 
extent of foot process effacement by measuring 
the average foot process width, as described 
previously (17).
For immunoelectron microscopy, small pieces of 
the cortex from 8-week-old Dahl SS rats were 
fixed in 4% paraformaldehyde in 0.1 M PBS and 
stored in 0.1% paraformaldehyde in 0.1 M PBS. 
Immunogold labeling was performed on ultra-
thin frozen sections as described previously (18).
Statistical analysis
Data are reported as the mean ± SD. Analysis 
of variance with a Least Significant Difference 
posthoc correction was used to test for differ-
ences between groups. Correlations were tested 
using Pearson’s or Spearman’s tests, where ap-
propriate. P < 0.05 was considered significant.
Figure 2. Number of podocytes per glomerulus (A) and 
glomerular volume per podocyte (B) in Dahl SS and SHR 
rats. The total number of podocytes per glomerulus increased 
over time in both Dahl SS and SHR rats, and remained stable 
from 6 to 8 weeks onwards at 350 to 400 podocytes per 
glomerulus. Although there was no difference in absolute 
number of podocytes per glomerulus, the glomerular volume 
per podocyte was higher in Dahl SS compared with SHR rats. 
The glomerular volume per podocyte is an index used to in-
dicate the glomerular volume that one podocyte ‘serves’ and 
is calculated as the mean glomerular volume divided by the 
mean number of podocytes per glomerulus. This difference 
was statistically significant from week 4 onward. An asterisk 
indicates P < 0.05.
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Results
Proteinuria and blood pressure
Starting at 4 weeks, proteinuria was increasingly evident in Dahl SS rats. As expected, SHR rats 
remained non-proteinuric throughout the time course of the study (Figure 1, A and B). Both rats 
developed hypertension starting at the age of 8 weeks (Figure 1C). The blood pressure of the 10-
week old SHR rats was significantly higher than that of Dahl SS rats of the same age (P < 0.05). 
Glomerular volume, podocyte number, and light microscopy
The number of podocytes per glomerulus, as determined using WT-1 staining, was not different 
between the two rat strains (Figure 2A). The glomerular volume was higher in Dahl SS rats than 
in SHR rats. The glomerular volume per podocyte (22) was also higher in Dahl SS rats (Figure 2B); 
this difference was statistically significant from 4 weeks of age onwards. Fibrotic changes in glom-
eruli or in the interstitium were not observed at 
any time point. 
Electron microscopy
Throughout the first 8 weeks of life, both the 
Dahl SS and the SHR rats generally showed nor-
mal ultrastructural glomerular morphology. In 
6- and 8-week-old Dahl SS rats, subtle coarsen-
ing of the foot processes was occasionally seen, 
together with protein droplets in the podocyte 
cell bodies and major processes (Figure 3A). 
Figure 3. Electron microscopy of podocytes in Dahl SS and 
SHR rats (A) and evaluation of the mean foot process width 
(B). In 4-week-old Dahl SS rats (A, top panel), the podocyte 
ultrastructure was normal, showing regularly spaced foot pro-
cesses. Occasionally, protein droplets were observed in podocyte 
major processes and cell bodies (arrowheads). At 8 weeks, sub-
tle coarsening of the foot processes was observed sporadically in 
Dahl SS rats (A, second panel). At 10 weeks of age, widespread 
foot process effacement was observed in segmental areas of the 
glomerulus, with condensation of the actin cytoskeleton at the 
basal site of the effaced processes (arrow). Microvillous transfor-
mation of podocytes was observed frequently at this time point. 
In contrast, the podocytes of SHR rats had normal ultrastructure 
throughout the time course studied (A, bottom panel). Original 
magnification: x 15,000. Quantification of the mean foot pro-
cess width showed significant effacement only in the 10-week-
old Dahl SS rats (B). An asterisk indicates P < 0.05.
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Ten-week-old Dahl SS rats showed more widespread foot process effacement. Quantification of 
the mean foot process width underscored the normal ultrastructure of the podocyte in the first 
8 weeks of life (Figure 3B). Detachment of podocytes from the glomerular basement membrane 
was not seen at any time point, and alterations in the glomerular basement membrane morphol-
ogy were not observed. 
Protein expression
Immunohistochemistry showed that expression of α3-integrin, α-actinin-4, α-dystroglycan, ezrin, 
podocalyxin, podocin, and synaptopodin, was similar at all time points in both rat strains (Figure 
4). Expression of the nephrin protein showed a normal pseudo-linear staining pattern throughout 
the first 8 weeks of life; however, by 10 weeks of age, expression became more granular in a 
Figure 4. Immunohistochemistry of podocyte proteins. Despite marked proteinuria, 10-week-old Dahl SS rats showed normal 
expression of α-actinin-4, α3 integrin, α-dystroglycan, ezrin, nephrin, podocin, podocalyxin, synaptopodin, and WT1. Original 
magnification: x 400.










































































































































































































































































































































































































































































































































































































focal and segmental fashion in Dahl SS rats (Figure 5C). In contrast to all other proteins studied, 
and only in Dahl SS rats, expression of the podoplanin protein decreased in a focal and segmental 
fashion. The decrease in podoplanin expression started as early as week 4 and increased with age 
(Figure 5A and Figure 6A). There was a strong correlation between development of albuminuria 
and loss of podoplanin protein expression (r = 0.8, P < 0.001, Figure 6B). The loss of podoplanin 
protein expression was not related to changes in glomerular morphology, and did not coincide 
with changes in expression of other podocyte-associated proteins (Figure 5B). Podoplanin expres-
sion in endothelial cells in intrarenal lymphatic vessels was not diminished.
Expression of the intermediate filament desmin can be used as a marker of podocyte stress or 
damage in rat podocytes. Indeed, we found an increase in desmin protein expression during the 
time course (Figure 5A). When desmin and podoplanin were costained, we found that desmin 
expression was absent in glomeruli that retained podoplanin expression. In contrast, segmental 
loss of podoplanin was mirrored by an increase in desmin expression in that particular segment 
(Figure 7). Desmin expression seemed to lag behind podoplanin loss. 
Figure 6. Loss of podoplanin protein expression was determined using a semiquantitative method. The loss of podoplanin 
protein staining in Dahl SS samples was statistically significant from week 4 onward (A). The extent of loss of podoplanin expres-
sion was positively correlated with urinary albumin excretion rates (r = 0.8, P < 0.001) B: In contrast, there was a slight but 
significant increase in podoplanin mRNA expression levels in Dahl SS rats compared with SHR rats at weeks 4 to 10 (C). Nephrin 
mRNA expression was increased only in 10-week-old Dahl SS rats (D). An asterisk indicates P < 0.05.
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mRNA expression
We also investigated the expression of 14 podocyte-expressed genes at the mRNA level (Table 1), 
revealing varied expression patterns. In both strains, the expression of podocyte-specific genes 
was lowest at the early time points. At 4 weeks of age, the podoplanin and ezrin genes were 
more highly expressed in Dahl SS than in SHR rats. From 4 to 10 weeks, the podoplanin mRNA 
expression levels were significantly increased in Dahl SS rats compared with SHR rats (Figure 6C), 
mirroring the decreased podoplanin protein expression in Dahl SS at these time points (Figure 
5A). Other genes (NEPH-1, podocin, synaptopodin, α-actinin-4) showed late up-regulation (at 8 
to 10 weeks) of mRNA expression in Dahl SS rats as compared with SHR rats. 
Only at 10 weeks were nephrin mRNA expression levels significantly elevated in Dahl SS rats 
compared with SHR rats (P < 0.05, Figure 6D), again mirroring the nephrin protein staining results 
in Dahl SS rats at this time point (Figure 5C). Despite marked proteinuria, the pivotal podocyte 
protein transcription factor WT-1 was not differentially regulated (data not shown). 
Sequencing and laser capture microdissection
Sequencing the full-length podoplanin cDNA in a representative Dahl SS and SHR rat did not 
reveal mutations in the Dahl SS podoplanin gene. There was no difference in podoplanin mRNA 
expression in glomeruli that had completely lost podoplanin protein expression versus those that 
had retained normal podoplanin expression (Figure 8). Podoplanin has been linked to the activ-
ity of the small GTPase RhoA (23) so we evaluated whether such a link existed in glomeruli. We 
found that RhoA mRNA levels were increased in sections of glomeruli that lacked podoplanin 
expression (Figure 8), although this did not reach statistical significance. 
Immunoelectron microscopy
Immunogold labeling of podoplanin in 8-week-old Dahl SS rats revealed that podoplanin was 
extensively expressed in areas that showed no foot process effacement. Conversely, foot process 
effacement was accompanied by a loss of podoplanin expression (Figure 9). 
Discussion
In this study, spontaneous development of proteinuria in Dahl SS rats preceded changes in podo-
cyte morphology and changes in expression of most of the observed podocyte-specific proteins. 
In contrast, focal and segmental loss of the podoplanin protein accompanied proteinuria. The 
early loss of podoplanin expression did not coincide with changes in the expression of other 
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podocyte proteins and could not be explained 
by mutations in the podoplanin gene or by de-
creased transcription. 
Proteinuria is an important risk factor for the 
progression of renal disease (1,2), and under-
standing its pathogenesis may help reduce the 
burden of chronic renal disease. Elucidation of 
the molecular basis of congenital and hereditary 
proteinuric diseases has contributed significantly 
to our understanding of glomerular function in 
health and disease. We previously studied the 
expression of podocyte-associated proteins in 
human acquired proteinuric diseases, and found 
that the mRNA expression of these was up-
regulated, whereas the protein expression was 
down-regulated. These changes correlated with 
the extent of foot process effacement. Based on 
these results, we hypothesized that the changes 
in expression represented a compensatory reac-
tion of the podocyte to damage (17). In the cur-
rent study, we used a rat model to determine 
how the observed changes may have developed 
over time. 
Proteinuria is often, but not always, accompa-
nied by podocyte foot process effacement. A 
remarkable finding in the current study was that 
foot process effacement early after the devel-
opment of proteinuria was subtle, and the dif-
ference in mean foot process width between 
SHR and Dahl SS rats only became statistically 
significant at 10 weeks of age. There are several 
reports in the literature that support this tempo-
ral uncoupling of proteinuria and foot process 
effacement: similar observations were made in 
young proteinuric Dahl SS rats (19), and in other 
spontaneous proteinuric rat strains (24) as well 
as in experimental models (25,26). Some reports 
Figure 8. Podoplanin mRNA expression in podoplanin 
positive and negative glomeruli. In 8-week-old Dahl SS rats, 
podoplanin mRNA expression was not different in glomeruli 
that showed extensive loss of podoplanin protein (ppl) ex-
pression compared with glomeruli that had retained podo-
planin expression. RhoA mRNA expression was higher in 
glomeruli that no longer expressed the podoplanin protein, 
although this difference did not reach statistical significance.
Figure 9. Immunogold electron microscopic analysis of 
podoplanin labeling in 8-week-old Dahl SS rats. Podo-
planin labeling was most prominent in glomerular areas that 
showed no foot process effacement (A). Podoplanin labeling 
was weak or absent in areas in which foot process effacement 
was observed (B).
Figure 7. Podoplanin (red) and desmin (green) were 
costained in kidney sections from 8-week-old Dahl SS rats. 
Normal glomeruli show desmin expression in renal blood ves-
sels and glomerular mesangium and podoplanin expression 
in podocytes. Desmin and podoplanin did not colocalize (A). 
In glomeruli that showed segmental loss of podoplanin ex-
pression, increased desmin expression was observed in the 
podoplanin-negative areas (B). Original magnification: x 630.
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have indicated that in humans, the extent of foot process effacement is not related to the severity 
of proteinuria (27,28). Others have reported patients and families with nephrotic syndromes that 
did not show foot process effacement (29-31). 
Our observations in the spontaneously proteinuric rat model studied here are in agreement with 
the pattern we found in humans in which the mRNA expression levels of several podocyte pro-
teins were up-regulated during the development of proteinuria. For example, only at time points 
at which proteinuria was present in combination with more widespread foot process effacement 
(ie, at week 10) changes in nephrin protein expression were seen, paralleled by increased nephrin 
mRNA expression levels (Figures 5C and 6D). Although the etiology of proteinuria in the Dahl 
SS rat is probably different from that in human disease, these findings support the hypothesis 
that changes in nephrin expression are secondary to proteinuria development and foot process 
effacement. 
In remarkable contrast to the general pattern of most of the podocyte-associated proteins stud-
ied, the glycoprotein podoplanin showed changes in expression with a clear temporal relation-
ship to the development of proteinuria. Increasing loss of glomerular podoplanin expression was 
highly correlated with urinary albumin excretion (r = 0.8, P < 0.001, Figure 6B). Observation of 
rats up to 6 weeks of age showed that the onset of decreased glomerular podoplanin expression 
preceded detectable morphological alterations in the podocytes. At later time points (from 8 
weeks onwards), when proteinuria had already progressed appreciably, immunoelectron micros-
copy showed that foot process effacement coincided with the loss of podoplanin; in contrast, 
areas in which podoplanin expression was retained showed normal ultrastructural morphology 
(Figure 9). The semiquantitative nature of the immunoelectron microscopy experiments did not 
allow us to draw conclusions with regard to more subtle changes in podoplanin expression in 
areas without foot process effacement. The expression of the slit diaphragm-associated proteins 
nephrin and podocin appeared unchanged up until weeks 8 (nephrin) and 10 (podocin) of age 
and was not related to the expression of podoplanin (Figure 5), suggesting that loss of podo-
planin expression was not related to changes in the slit diaphragm. 
Expression of podoplanin in the glomerulus was first reported by Breiteneder-Geleff et al, who 
described a 43-kDa glycoprotein that was specifically down-regulated in puromycin aminonucle-
oside nephrosis in the rat (18). Since down-regulation of this protein was related to foot process 
effacement, it was named podoplanin. The relationship between foot process effacement and 
podoplanin expression was further substantiated by the observation that injection of antibodies 
directed against a specific podoplanin epitope caused reversible proteinuria and foot process 
effacement, but only if divalent IgG antibodies were used (32). Homologs of podoplanin (T1-, 
P2.26, and E-11) are expressed in other cell types, including type I alveolar cells in the lung, ke-
chapter 3124
ratinocytes, and osteoblasts (33-35). In recent years, podoplanin has received more interest as a 
marker of lymphatic endothelial cells (36) and various tumors (37).
The mechanism underlying the involvement of podoplanin in glomerular pathology has remained 
unclear. In the current study, we found that focal and segmental loss of podoplanin protein co-
incided with the occurrence of proteinuria. The down-regulation of podoplanin at the protein 
level in Dahl SS rats could not be explained by decreased mRNA expression, which was actually 
increased during the development of proteinuria compared with non-proteinuric SHR rats. In 
addition, sequencing of the full-length Dahl SS podoplanin cDNA did not reveal any differences 
between Dahl SS and SHR rats that could explain the down-regulation of podoplanin protein in 
Dahl SS rats. 
Although the exact extra- and intracellular interactions of podoplanin are currently unknown, 
several studies have indicated that podoplanin is involved in cell motility and actin cytoskeleton 
modeling. Ectopic expression of podoplanin in cultured cells increases the formation of cell ex-
tensions as well as increasing cell adhesiveness and migration (38,39). Furthermore, podoplanin 
expression in MCF7 cells induces filopodia formation, loss of stress fibers, and relocalization of 
actin to the newly formed filopodia; relocalization is mediated by inhibition of RhoA (23). Stud-
ies indicate that podoplanin and ezrin colocalize in subcellular compartments (23,39), and one 
study found that podoplanin and ezrin could be coimmunoprecipitated (39). Although the details 
of the interaction remain to be elucidated, these studies suggest a role for podoplanin in actin 
cytoskeleton modeling. In our study, ezrin did not show an altered expression pattern. However, 
immunohistochemical staining may not detect protein modifications such as phosphorylation.
How could down-regulation of this protein with actin-modeling properties relate to the devel-
opment of proteinuria? The temporal relationship between podoplanin down-regulation and 
development of proteinuria does not necessarily imply a causal involvement of podoplanin dys-
regulation in the pathogenesis of proteinuria. However, in the current model, because no marked 
regulation of the expression of other podocyte proteins has been observed, it is most likely that 
podoplanin expression is specifically regulated. In puromycin aminonucleoside nephrosis in the 
rat, podoplanin is also down-regulated (18). This suggests that either down-regulation of podo-
planin causes proteinuria, or that the expression of podoplanin is actively down-regulated by the 
podocyte in response to proteinuria. Until now, it has not been possible to study the effect of the 
absence of podoplanin in glomeruli, since podoplanin knockout mice have an embryonic lethal 
phenotype (38). However, injection of divalent anti-podoplanin IgG antibodies in rats induces 
rapid foot process effacement and proteinuria (32), indicating that changes in podoplanin can 
indeed be the initial step in the development of proteinuria. We recently found that podoplanin 
protein expression is also selectively lost in proteinuric Munich Wistar Frömter rats (40). This may 
indicate that loss of podoplanin is a more general phenomenon in proteinuria in rats. 
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It has been suggested that foot process effacement and formation of stress fibers are reactions 
of the podocyte to prevent dilation of capillaries and further leakage of proteins (41). Recently, 
Morigi et al showed that following protein load, podocytes reorganize their cytoskeleton in a 
RhoA-dependent manner (42). Similarly, Zhang et al reported that complement-mediated injury 
of cultured podocytes increases RhoA activity, resulting in a change in cellular morphology that 
mimics foot process effacement (43). Thus, the events that take place during foot process ef-
facement (ie, stress fiber formation and foot process effacement in a RhoA-dependent fashion) 
seem to be the reverse of those brought about by the actin remodeling properties of podoplanin 
(prevention of stress fiber formation, filopodia formation, and RhoA inhibition). The loss of podo-
planin we observed thus suggests a scenario in which the podocyte actively remodels its shape 
and down-regulates proteins, including podoplanin, which normally would promote foot process 
formation. Indeed, we found that RhoA mRNA levels were up-regulated in microdissected glom-
eruli that showed a loss of podoplanin protein expression compared with those that had retained 
podoplanin (Figure 8). 
The extracellular domain of podoplanin is presumably negatively charged (32). Given the pre-
dominant localization on the apical membrane of the foot processes, it has been suggested that 
podoplanin may have a function comparable to that of podocalyxin, another negatively charged 
protein that is thought to serve as a spacer molecule between adjacent foot processes (32,44). 
Loss of podocalyxin is associated with foot process effacement (45), and it could be hypothesized 
that loss of podoplanin has similar consequences.
As the name implies, the Dahl SS rat is known for developing severe hypertension when raised 
on a high-salt diet. The development of hypertension is delayed and diminished when the rats 
are fed a low-salt diet, as in the current study. Although development of hypertension aggra-
vates the rate of disease progression, several lines of evidence suggest that the development of 
proteinuria is uncoupled from the development of hypertension. First, proteinuria in Dahl SS rats 
develops before the onset of hypertension (46), starting from about 4 weeks of age. Furthermore, 
micropuncture experiments indicate that proteinuria is not explained by increased intraglomerular 
pressure (46). From a genetic point of view, development of proteinuria is independent of the 
development of hypertension (19,47). Recently, Nagase et al reported that in Dahl SS rats, podo-
cytes are injured only on salt loading, as judged by de novo expression of desmin and B7–1 and 
down-regulation of nephrin protein expression (48). The authors suggested that podocyte injury 
might underlie the development of proteinuria in these rats. We, too, observed desmin expres-
sion in the podocytes of Dahl SS rats in the absence of salt loading, most notably in glomerular 
segments that showed a loss of podoplanin protein expression. However, this does not necessarily 
implicate podocyte damage as the cause of proteinuria in the Dahl SS rat. Desmin protein expres-
sion may also reflect other injury, such as increased mechanical strain as a result of the increased 
glomerular volume covered per podocyte (14). Furthermore, increased protein trafficking through 
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the glomerular filtration barrier may itself be harmful for podocytes and may promote expression 
of podocyte stress markers (42,49,50).
In conclusion, we found that in the spontaneously proteinuric Dahl SS rat, significant proteinuria 
was detected several weeks before widespread changes in podocyte morphology were observed. 
Moreover, segmental loss of podoplanin protein expression accompanied proteinuria and pre-
ceded widespread podocyte alterations. 
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To get more insight in cause and consequences of proteinuria, we studied glomerular gene ex-
pression patterns before and after the onset of increased urinary albumin excretion (UAE) in a 
proteinuric rat strain.
Spontaneously proteinuric Dahl salt-sensitive rats (Dahl SS) were compared to non-proteinuric, 
spontaneously hypertensive rats (SHR). In Dahl SS, UAE significantly increased starting from week 
5 of age. Glomerular RNA profiles of 4- and 6-week-old rats were studied using Affymetrix micro-
array chips. Gene expression was further studied by quantitative PCR and immunohistochemistry.
398 genes were upregulated and 210 genes were downregulated in Dahl SS compared to SHR. 
The data were analyzed using three main approaches, and the following results were found: 1) 
115 genes, located on quantitative trait loci previously associated with proteinuria, were differen-
tially expressed between the rat strains. These included hedgehog-interacting protein and outer 
dense fiber 3; 2) Several pathways related to changes in the cytoskeleton were represented in 
the list of differentially expressed genes. Expression of the actin-regulating protein dynamin was 
increased in proteinuric rats and in patients with proteinuric disease; 3) The expression pattern 
of a group of 13 genes, of which the expression was previously found to be regulated in tubular 
epithelial cells upon protein loading, was differentially regulated in glomerular samples of Dahl 
SS versus SHR rats (P < 0.03). Expression of the podocyte stress marker desmin co-localized with 
albumin resorption droplets in podocytes.
The list of genes differentially expressed between proteinuric and non-proteinuric rat strains is 
predominated by those encoding for cytoskeletal proteins. Secondly, expression differences be-




The initial step in the production of urine is glomerular filtration, in which water and small sol-
utes are filtered but macromolecules and cells are retained within the glomerular capillaries. Loss 
of the glomerular filtration barrier permselectivity results in the loss of proteins into the urine, 
proteinuria. Proteinuria is an important symptom of various kidney diseases, and its presence is 
related to the progression of renal and cardiovascular diseases (1,2). Knowledge about the mo-
lecular determinants of glomerular filtration has advanced considerably through the discovery 
of mutations in genes that underlie hereditary proteinuric kidney diseases (3). Nevertheless, the 
understanding of the development of proteinuria in the majority of patients that do not have 
such genetic mutations remains limited. 
The Dahl salt-sensitive (Dahl SS) rat strain has been used as a model for the development of salt-
sensitive hypertension. Sterzel et al (4) showed that prior to development of hypertension and 
independent of salt loading, Dahl SS rats also show an increased urinary albumin and protein 
excretion. Several groups have attempted to dissect the genetic basis of the increased urinary 
albumin excretion (UAE) in Dahl SS rats. Using the spontaneously hypertensive rat (SHR) as a ref-
erence strain, genetic linkage analysis yielded several quantitative trait loci (QTLs) of interest for 
the increased UAE (5-8). In several analyses by Kreutz’ group a QTL for UAE was located on rat 
chromosome 19 (5,6), in both high and low salt conditions. Consomic strains in which the SHR 
chromosome 19 was introgressed into the Dahl SS background, showed a considerable ameliora-
tion of the albuminuric phenotype (9). The identification of genomic regions is helpful in eluci-
dating the polygenetic nature of the UAE, and can demonstrate the linkage of other genetically 
determined phenotypes such as hypertension to the development of proteinuria. However, the 
relatively low resolution of the linkage analysis impairs the identification of the genes that play a 
role in the development of proteinuria.
It is hypothesized that proteinuria, once it has developed, exerts a toxic effect on proximal tubu-
lar epithelial cells. Although the exact nature of the compounds that cause this effect (albumin, 
albumin-bound factors, or other macromolecules) is subject of discussion, several studies have 
indicated that upon proteinuria proximal tubular epithelial cells acquire a pro-inflammatory and 
pro-fibrogenic state (10,11). Some studies have indicated that an increased passage of proteins 
through the glomerular filtration barrier may have a similar toxic effect on podocytes (12). Indeed, 
proteinuria is almost always accompanied by changes in podocyte cell structure, and reorganiza-
tion of the podocyte cytoskeleton (13,14).
We used a microarray approach to get insight in the gene expression differences that occur in 
the glomerulus during the development of proteinuria. The results of the microarray experiments 
were used in several ways. Combination of the microarray data and previously identified genomic 
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regions was used to identify genes that could be of interest for the development of the increased 
UAE. Next to studying single genes, we used pathway analysis to identify groups of genes that 
differentiate between the proteinuric and non-proteinuric rat strains. These approaches yielded 
further genes of interest and pathophysiological concepts that were studied in more detail. 
Materials and Methods
Animal studies
We compared the spontaneously proteinuric Dahl SS rat strain with non-proteinuric spontane-
ously hypertensive rats (SHR). Male Dahl SS and SHR rats were obtained from colonies at the Freie 
Universität Berlin as reported (5). The animals were fed a low-salt diet of 0.2% NaCl by weight 
content to prevent early development of hypertension. For the microarray studies, we used 4- and 
6-week-old rats. In follow-up experiments, groups of rats that were 2, 4, 6, 8, and 10 weeks of 
age were studied (n = 5 to 8 per group). Systolic blood pressure, proteinuria, and albuminuria 
were recorded. Following described methods (15), tissues were collected under ketamin/xylazine 
anesthesia, and glomeruli were isolated using perfusion with iron oxide followed by magnetic 
retraction. Experiments were performed in accordance with institutional guidelines.
Microarrays
For the microarray experiments Affymetrix GeneChip Rat Genome 230 2.0 arrays were used (Af-
fymetrix, www.affymetrix.com). These high-density gene chips contain 31,042 probesets, repre-
senting approximately 28,000 different genes and ESTs, on a single chip. 
We compared 4- and 6-week-old Dahl SS and SHR rats, studying two rats from each strain at 
each time point. Total RNA from isolated glomeruli was purified with Qiagen RNeasy mini col-
umns (Qiagen, www.qiagen.com). Quality and purity of the RNA was controlled by gel electro-
phoresis and measurement of the 260/280 ratio, which was between 1.8 and 2.1 in all samples. 
Biotin-labeled cRNA was produced using the Ambion MessageAmp II-Biotin Enhanced kit (Am-
bion, www.ambion.com), according to the manufacturer’s instructions. Briefly, 1µg of total RNA 
was reverse transcribed in the presence of T7 oligo(dT) primer, followed by second-strand cDNA 
synthesis. After purification, in vitro transcription of the double stranded cDNA was performed 
in the presence of T7 RNA polymerase and biotin-11-UTP. Following another round of purifica-
tion, 20 µg of cRNA was fragmented and used for hybridization to the chips. Hybridization and 
scanning of the chips was performed at the Leiden Genome Technology Center (www.lgtc.nl). 
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The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus 
(16) and are accessible through GEO Series accession number GSE13810 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc= GSE13810)
Preprocessing and differential expression analysis
Preprocessing, differential expression analysis, and parts of the pathway analysis were performed 
in the R-software environment (www.r-project.org). All R-packages used are available at the bio-
conductor website (www.bioconductor.org).
Preprocessing of the data was performed with the GC Robust Multiarray Average (GCRMA) 
package. GCRMA – a modification of RMA (17) – calculates expression values using background 
adjustment, quantile normalization, and summarization of the probe intensities, and uses the 
probe sequence information (e.g., GC-content) to estimate the non-specific binding related to 
the background noise (18). Quality control was performed using functions in the affyPLM pack-
age in R, and included evaluation of RNA degradation plots, relative log expression, and normal-
ized unscaled standard errors. All chips were of good quality with regard to these parameters.
To identify statistically significant differences in gene expression levels we used the Linear Models 
for Microarray Data (Limma) package (19,20). Limma first fits a model to each gene in the differ-
ent arrays, as in a standard ANOVA approach. With a contrast matrix, the differently expressed 
genes can subsequently be extracted. We used Benjamin and Hochberg’s method to correct 
for multiple testing. Comparisons of strain differences and time differences within strains were 
made. A differential gene expression of more than 1.5 fold, with an adjusted P-value < 0.01 in 
strain comparisons, and an adjusted P-value < 0.05 in time comparisons, was considered signifi-
cant. In the text and tables, fold changes are given as base 2 logarithmic values.
Comparison to genomic studies
Previous genetic analysis of the strains that we studied has yielded several QTLs of importance 
for the development of urinary albumin excretion. To integrate these genetic analyses with the 
microarray data, we obtained the QTLs found by Poyan Mehr et al (5), Siegel et al (6), and Garrett 
et al (7,8) from the rat genome database (RGD, http://rgd.mcw.edu). Of the genes that showed 
a differential expression in the array experiments, we evaluated those that were located within a 
chromosomal location identified in the previous genetic linkage analyses, using information in the 
RGD and Ensemble (www.ensembl.org) databases.
Pathway analysis
For pathway analysis, we used several complimentary approaches. For the evaluation of known 
pathways, we used the online pathway analysis program Gene Ontology Tree Machine (GOTM, 
bioinfo.vanderbilt.edu/gotm)(21) and the global test. GOTM uses a hypergeometric test to evalu-
ate whether the genes of a certain Gene Ontology (GO) category are overrepresented in the 
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group of differentially ex-
pressed genes as defined using 
Limma (21). In a complemen-
tary approach, the global test 
was used to evaluate whether 
genes within a certain gene 
set (ie, a GO category or KEGG 
pathway, www.genome.jp/
kegg) were differentially ex-
pressed (22). The global test 
assigns a p-value to this asso-
ciation. In addition, a so-called 
comparative p-value can be 
calculated. In this calculation, 
the association of the group of 
genes of interest is compared 
to that of a large number of 
randomly selected groups of 
genes of the same size. The 
benefit of the global test ap-
proach is that it also allows 
identification of pathways in 
which many genes are only 
moderately regulated.
The effect of proteinuria on 
gene regulation in proximal 
tubular epithelial cells has 
been extensively studied. From 
such studies, we extracted a 
group of well-substantiated 
genes that were shown to be 
regulated in response to pro-
teinuria in mouse, rat, and 
human proximal tubular epi-
thelial cells. We identified the 
rat homologue of these genes, 





































































































































































































































































































































































































135materials and methods > biopsies from patients with acquired proteinuric kidney diseases
evaluate whether this group of genes was also differentially expressed in the glomeruli of Dahl 
SS and SHR rats.
RNA isolation and QPCR
RNA was isolated from the glomeruli using the TRIzol (Invitrogen) method. Total RNA (0.5µg) was 
reverse transcribed into cDNA using AMV reverse transcriptase (Roche Diagnostics).
Primers (Isogen Bioscience) were designed using BeaconDesigner 6.0 software (PREMIER Biosoft 
International). To prevent genomic contamination, all primers were chosen to span at least one 
splice-site. Sequences of the primers are listed in Table 1. Real-time PCR using Sybrgreen as the 
fluorescent dye was performed using a iCycler real-time PCR machine with iCyclerIQ 3.1 software 
(Bio-Rad laboratories).
Immunohistochemistry
A rabbit polyclonal anti-rat albumin antibody (Nordic Immunological Laboratories, www.nor-
diclabs.nl) was used for immunofluorescent localization of albumin in formalin-fixed paraffin-
embedded tissue after antigen retrieval by boiling the slides in Tris/EDTA buffer for 10 minutes. 
A mouse monoclonal anti-desmin antibody (clone 33, diluted 1:750) was used in albumin and 
desmin double-labeling studies. As secondary antibodies, Alexa-conjugated anti mouse and anti-
rabbit antibodies were used as appropriate. The immunofluorescent staining was evaluated using 
a Zeiss LSM 510 confocal microscope (Carl Zeiss, Germany).
For immunohistochemical localization of dynamin in rat and human tissues, we used the mouse 
anti-dynamin antibody Hudy 1 (Upstate biotechnology, catalog # 05-319, www.upstate.com, 
diluted 1:80). As secondary antibody, we used anti-mouse Envision (Dako cytomotion, Glostrup, 
Denmark). Staining was performed using standard procedures as described previously (23). Speci-
ficity of the staining was tested through replacing the antibody by serum of the same species, in 
the same dilution as the secondary antibodies. For quantification of the staining of renal biopsies, 
we used both a digital image analysis and a semi-quantitative approach (scoring on a scale of 1 
to 4). The results of both approaches were comparable and correlated highly with each other. 
Biopsies from patients with acquired proteinuric kidney diseases
Biopsies from patients with various proteinuric kidney diseases were studied in comparison to 
controls. Disease categories included minimal change disease (n = 8), focal segmental glomeru-
losclerosis (n = 3), IgA nephropathy (n = 3), lupus nephritis (n = 6), diabetic nephropathy (n = 6), 
other diseases (including post-streptococcal glomerulonephritis, membranous nephropathy, light 
chain excretion nephropathy, n = 6). For controls, biopsies from patients with interstitial nephritis 
or with no glomerular pathology, tissue from kidneys unsuitable for transplantation for technical 




The animals used for the microarray experiments 
had normal systolic blood pressure (125 mmHg 
for 6-week-old SHR and DS rats). The UAE was 
2.9 ± 0.0 and 32 ± 4.5 mg/24h for the 4- and 
6-week-old Dahl SS rats, respectively, and < 0.1 
mg/24h for the SHR rats at both time points. 
These values reflect those of the total group (n = 
5-8) (15). Over the studied 10-week time course, 
the Dahl SS rats showed increasing UAE rates, 
while the SHR rats remained non-albuminuric. 
Differential regulation of genes
We first compared the differential regulation of 
genes between the two rat strains, irrespective 
of the time points. Using a false discovery rate 
of < 0.01 and a 1.5 fold change as cut-off, 366 
genes were found to be significantly upregulat-
ed, and 151 downregulated. The top-20 of up- 
and downregulated of these are listed in Table 2. 
Comparing the differential regulation in time, 
first looking at the strains individually, we found that the gene expression levels of the Dahl rats 
were relatively similar at 4 and 6 weeks: only 16 and 7 genes were up- and downregulated, re-
spectively, between 4 and 6 weeks. In contrast, the non-proteinuric SHR rat showed substantial 
regulation of genes between 4 and 6 weeks, with an upregulation of 397 genes and a down-
regulation of 210 genes at 6 weeks. 
We subsequently evaluated which genes showed a different pattern of regulation in time be-
tween the two rat strains. For example, this would identify genes that over time are downregu-
lated in the Dahl rat, while they are upregulated in the SHR. In total, 63 genes were significantly 
upregulated in the Dahl rat in comparison to the SHR, while 85 were downregulated. 
We validated the results of the microarray using QPCR in individual rats. Measurements of 16 
different genes showed that the direction of changes (up- or downregulation) was always consis-
tent. The extent of changes showed some variability between the microarray and QPCR, but there 
was no consistent under- or overestimation of the regulation in the array results. 
Figure 1. mRNA expression of hedgehog-interacting pro-
tein (Hhip, A) and polyamine modulated factor binding pro-
tein 1 (Pmfbp1, B) in glomeruli of Dahl SS and SHR rats of 
various age. Hhip was upregulated in Dahl SS rats at all time 
points, and also before the development of overt proteinuria 
(week 2). Pmfbp1 was downregulated in Dahl SS rats com-
pared to SHR.
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Table 2. Top 20 up- and downregulated genes
DahlSS vs SHR: Upregulated
Gene name Symbol RNO Fold change
similar to hedgehog-interacting protein RGD1564108 19q11 5.2
osteoglycin Ogn 17p14 4.8
EST   11q11 2.3
SUMO/sentrin specific protease 5 Senp5 11q22 4.2
EST     4.0
osteoglycin Ogn 17p14 4.4
similar to vacuolar protein sorting 13C protein RGD1560364 8q24 3.4
Similar to teratocyte-specific carboxylesterase RGD1564156 8q24 4.7
EST     2.1
RT1 class II, locus Bb RT1-Bb 20p12 7.6
zinc finger homeobox 1b Zfhx1b 3q12 3.9
RT1 class Ib, locus Aw2 RT1-Aw2 20p12 6.4
histone 2a H2a 17q11 1.4
tetraspanin 18 Tspan18 3q24 2.7
EST   9q13 1.9
Cut-like 1 (Drosophila) Cutl1 12q12 1.3
EST RGD1310127 1q36 1.2
Similar to Leucine rich repeat and sterile alpha motif containing 1 RGD1564403 3p11 1.5
GRAM domain containing 3 Gramd3 18q12.1 0.6
Mindbomb homolog 1 (Drosophila) Mib1 18p13 1.4
DahlSS vs SHR: Downregulated
Gene name Symbol RNO Fold change
aldo-keto reductase family 1, member B8 Akr1b8 4q22 -4.5
EST -4.3
similar to interferon regulatory factor 10 RGD1562711 3q41 -3.9
EST -3.7
acyl-Coenzyme A oxidase 2, branched chain Acox2 15p14 -3.7
similar to RIKEN cDNA 4921520P21; DMRTC1 LOC363483 Xq31 -3.4
transmembrane protein 14A Tmem14a 9q13 -3.0
torsin family 1, member B Tor1b 3p12 -3.0
EST     -2.9
polyamine modulated factor 1 binding protein 1 Pmfbp1 19q12 -2.8
RT1 class Ib, locus Aw2 RT1-Aw2 20p12 -2.7
similar to hypothetical protein FLJ20647 RGD1305326 2q43 -2.6
EST     -2.5
solute carrier family 2, member 5 Slc2a5 5q36 -2.5
nuclear protein 1 Nupr1 1q36 -2.4
GNAS complex locus Gnas 3q42 -2.4
apolipoprotein B Apob 6q14 -2.4
spectrin alpha 1 Spna1 13q24 -2.4
protein kinase C, beta 1 Prkcb1 1q36 -2.4
EST     -2.3
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Relation to previously defined QTLs
Of all genes and ESTs with a known chromo-
somal location, which were differentially regu-
lated between the two strains, we identified 
those genes that were located on QTLs know to 
be involved in the development of proteinuria 
in the studied rat strains (5-8). Of all up- and 
downregulated genes, 82 and 33 were located 
on such genomic regions. Within the UAE QTL 
on chromosome 19 (5,6), we identified five up-
regulated, and three downregulated probes. 
Of the five upregulated probes, three recog-
nized hedgehog-interacting protein (Hhip) (5.2 
times). The other two probes were ATP-binding 
cassette sub-family B (MDR/TAP) member 10 
(Abcb10) (1.5 times), and integrin beta 1 (Itgb1) 
(0.9 times). The downregulated genes included 
polyamine modulated factor binding protein 1 
(Pmfbp1, also called ODF3) (-2.8 times), WW 
domain-containing oxidoreductase isoform 2 
(RGD1565791) (1.1 times), and hypothetical 
protein MGC3207 (RGD1307789) (-0.71 times). 
Of these, we validated the expression of Hhip 
and Pmfbp1 by QPCR. Dahl SS rats showed an 
increase in Hhip at all time points, while a down-
regulation of Pmfbp1 was seen. At week 6, lev-
els of Pmfbp1 were undetectable in Dahl SS rats, 
whereas SHR rats showed a stable expression 
throughout the studied time course (Figure 1).
Pathway analysis
Pathway analysis was performed to get insight 
in the biological processes that were represent-
ed by the differentially regulated genes. GOTM 
analysis of the differentially regulated genes in 
time showed that cell-cycle associated genes 
were significantly enriched in the SHR rat, while 
Figure 2. Dynamin expression in rat kidneys. The microar-
ray showed a higher dynamin mRNA expression in 4- and 
6-week-old Dahl SS rats compared to SHR. This was confirmed 
by QPCR (A). At later time points (8 and 10 weeks), dynamin 
upregulation was not significant. There was no clear increase 
in dynamin protein expression in Dahl SS rats (B). Dynamin 
protein was seen in the glomerulus and at the tubular brush 
border (C).
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Table 3. Differential expression of cytoskeleton-related genes
Gene name Symbol RNO Fold change Function
periplakin Ppl 10q12 2.06 intermediate filament binding
filamin, beta Flnb 15p14 0.90 actin binding
dynamin 1 Dnm1 3p11 1.75 actin dynamics regulation
supervillin Svil 17q12 1.39 actin binding
moesin Msn Xq31 1.95 actin filament -- membrane cross-linking
ARP1 actin-related protein 1 homo-
log A (yeast) Actr1a 1q54 0.63 cytoskeleton organization
Rho guanine nucleotide exchange 
factor (GEF) 17 Arhgef17 1q32 1.07 actin cytoskeleton organization and biogenesis
CAP, adenylate cyclase-associated 
protein 1 (yeast) Cap1 5q36 0.79 actin cytoskeleton organization and biogenesis
myosin Ib Myo1b 9q22 0.99 actin binding
myosin IC Myo1c 10q24 0.83 actin binding
tropomyosin 1, alpha Tpm1 8q24 1.16 actin filament capping
parvin, alpha Parva 1q33 1.39 actin cytoskeleton organization and biogenesis
microtubule-associated protein, RP/
EB family, member 1 Mapre1 3q41 1.14 regulation of microtubule polymerization
caldesmon 1 Cald1 4q22 1.07 actin binding
Src homology 2 domain-containing 
transforming protein C1 Shc1 2q34 0.65 actin cytoskeleton organization and biogenesis
thymoma viral proto-oncogene 1 Akt1 6q32 1.44 cell projection organization and biogenesis
actin, beta Actb 12p11 0.62 cytoskeleton organization
echinoderm microtubule associated 
protein like 4 Eml4 6q12 0.98 microtubule stabilization
kinesin light chain 1 Klc1 6q32 0.67 microtubule motor activity
signal-regulatory protein alpha Sirpa 3q36 1.03 actin filament organization
mitogen activated protein kinase 
kinase kinase 1 Map3k1 2q14 0.83 actin filament polymerization
filamin, beta Flnb 15p14 1.07 actin binding
actin related protein 2/3 complex, 
subunit 1B Arpc1b 12p11 0.92 cytoskeleton organization
tropomyosin 4 Tpm4 16p14 1.45 actin binding
A kinase (PRKA) anchor protein 2 Akap2 5q24 0.59 actin filament organization
WD repeat domain 44 Wdr44 Xq12 1.00
plastin 3 (T-isoform) Pls3 Xq14 1.33 actin filament organization
polyamine modulated factor 1 bind-
ing protein 1 Pmfbp1 19q12 -2.81 cytoskeleton organization and biogenesis
spectrin alpha 1 Spna1 13q24 -2.39 cytoskeleton organization
Genes are listed with their chromosomal location and function. Fold changes are indicated as base 2 logaritmic value. A positive 
value indicates upregulation in Dahl SS vs SHR.
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this was not the case in Dahl rats. Cell cycle related genes were also significantly enriched in the 
list of genes that showed a differential expression in time between SHR and Dahl SS strains. 
Pathway analysis showed a relative enrichment 
of genes that were differentially expressed be-
tween the two strains in 49 GO categories. 
Nineteen of these GO categories were related 
to cytoskeletal changes. In a complementary 
approach we used the global test to evaluate 
KEGG pathways, as well as GO categories. This 
analysis also showed that the differences in gene 
regulation between the Dahl SS and SHR could 
in part be explained by regulation of cytoskeletal 
genes (KEGG pathway 04810, P < 0.03, compar-
ative p value 0.17); GO:0005856, cytoskeleton, 
P < 0.05, comparative P value 0.21). The differ-
entially expressed cytoskeletal genes are listed in 
Table 3. 
Expression of dynamin in rat and human 
glomeruli
Dynamin is a cytoskeleton-associated gene that 
we identified as one of the genes that was up-
regulated in the Dahl SS rats compared to the 
SHR rat. Because recent studies showed that 
the actin-remodeling properties of dynamin may 
be important in podocytes (24), we decided to 
further evaluate the expression and distribution 
of dynamin in our model. Evaluation in individ-
ual rats confirmed the upregulation of dynamin 
mRNA expression in 4- and 6-week-old Dahl SS 
rats. At later time points upregulation of dyna-
min mRNA was not statistically significant (figure 
2A). At the protein level, dynamin expression 
Figure 3. Dynamin expression in human kidneys. The protein distribution of dynamin in human tissue (A) was similar to that in 
rats (figure 2C): dynamin was expressed in the glomerulus in a podocyte-like pattern (A, panel 1 and 2); the endothelial cells of 
large vessels were positive, while PTC and intraglomerular vessels did not show immunoreactivity (A, panel 3 and 4). Using digital 
image analysis, the protein expression of dynamin in various acquired proteinuric disease was quantified (B). Dynamin protein 
expression was increased in minimal change disease and in lupus nephritis compared to controls. The expression of cathepsin L 
mRNA was decreased in most acquired proteinuric diseases (C). 
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was observed at the tubular brush border and in glomerular podocytes (Figure 2C). The protein 
expression of dynamin in rat glomeruli was slightly but not significantly elevated in 4-week-old 
Dahl SS rats compared to SHR. At 6 weeks, we could not find a difference in glomerular dynamin 
expression between the two strains (figure 2B).
As in rat kidneys, tubular epithelial brush borders were dynamin-positive in human renal tissue. 
Endothelial cells of larger vessels showed expression of dynamin as well. In human glomeruli, 
dynamin was present in podocytes and occasionally in parietal epithelial cells. Glomerular en-
dothelial cells were not labeled (figure 3A). We observed an increase in dynamin protein expres-
sion in proteinuric kidney diseases, with minimal change disease and lupus nephritis showing a 
statistically significant increase (P < 0.01). Results of the digital image analysis measurements of 
glomerular dynamin expression are depicted in figure 3B.
Recent studies suggest that proteolytic cleavage of dynamin by cathepsin L may underlie the 
development of proteinuria (24). We therefore evaluated the mRNA expression of cathepsin L 
in proteinuric kidney diseases. In most renal diseases studied, we found a downregulation of 
cathepsin L at the mRNA level that was inversely correlated to the extent of proteinuria (r = -0.39, 
P = 0.018; figure 3C).
Table 4. Genes with differential expression in proximal tubular epithelial cells in proteinuric conditions
Model (in vivo, in vitro) Species Protein that evoked response
Method (RT PCR, 
ISH, microarray) Genes regulated Reference
Protein overload after 
uninephrectomy Rat proteinuria RT PCR, in situ PCR
Ang II, ACE, renin 
(downregulated) (40)
Proteinuric diseases Human proteinuria ISH in biopsies HO-1 (41)
PTEC Human HSA RT PCR ET-1, TGF-beta (42)
PTEC, mouse protein  
overload Human, mouse
HSA, mouse 
proteinuria RT PCR Fractalkine (CX3CL1) (43)
Passive heymann nephritis, 
5/6 NX Rat proteinuria RT PCR MCP-1 (44)
PTEC Rat BSA (delipidated) RT PCR MCP-1 (45)
PTEC Rat BSA, transferrin RT PCR MCP-1 (46)
Protein overload proteinuria Rat proteinuria RT PCR MCP-1 (47)
Protein overload proteinuria Rat proteinuria RT PCR MCP-1, osteopontin (ssp1) (48)
Adriamycin nephropathy Rat proteinuria RT PCR whole cortexMCP-1, RANTES (49)







Protein overload proteinuria Rat proteinuria ISH TIMP-1 (52)
PTEC Human serum proteins Fibronectin (53)
PTEC Human albumin Microarray EGF receptor (54)
PTEC – proximal tubular epithelial cell; MCD – minimal change disease; HSA – human serum albumin; BSA – bovine serum 
albumin.
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Proteinuria-induced glomerular gene expression patterns
Increased albumin trafficking through the glomerular filtration barrier within the context of pro-
teinuria may have toxic effects on podocytes. We performed an immunostaining to visualize 
albumin within the glomerulus. As expected, albumin droplets were more often seen in Dahl SS 
rat glomeruli than in those of SHR rats. Co-staining of albumin and the podocyte stress marker 
desmin in Dahl SS tissues revealed that desmin accumulated in a podocyte-pattern in glomeruli or 
segments of glomeruli that showed the most extensive albumin accumulation (Figure 4). 
These observations may support the hypothesis that increased albumin passage through the 
glomerular filtration barrier in Dahl SS rats is associated with podocyte stress. The intraglomerular 
albumin may consequently exert alterations in glomerular gene expression. From the literature we 
compiled a list of 13 genes of which the expression was found to be changed in proximal tubular 
epithelial cells upon proteinuria (Table 4). Using the global test, we found that the expression 
pattern of this group of genes was also significantly different in glomeruli of Dahl SS compared 
to SHR rats (P < 0.03 and P < 0.008 if time was taken as a covariate, Figure 5). If many genes 
are differentially expressed between groups of interest, a random group of genes may also be 
expected to be significantly associated with the difference between the two groups. We there-
fore compared this group of 13 ‘proteinuria-related’ genes to 1,000 randomly selected groups of 
genes of the same size. We found that the group of proteinuria-related genes performed better 
than ~80 percent of the randomly selected groups. This indicates that the association between 
the expression pattern of the group of proteinuria-related genes with the difference between 
Dahl SS and SHR rats is specific.
Discussion
We used microarray technique to obtain more insight in gene expression differences during the 
spontaneous development of proteinuria in the Dahl SS rat. We report the following findings: 
i) we found and validated several genes that are differentially expressed and located within ge-
nomic regions previously identified to be associated with proteinuria; ii) pathway analysis showed 
that differences between the proteinuric and non-proteinuric rat strains are for a large part de-
pendent on cytoskeletal genes; iii) from all genes involved in the regulation of the cytoskeleton, 
we further investigated the upregulation of dynamin expression in glomeruli of the Dahl SS rat 
and in human kidney diseases. iv) genes known to be differentially expressed upon proteinuria in 
tubular epithelial cells are differentially regulated in Dahl SS compared to SHR rats.
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To find genes of interest for the development of 
proteinuria in the Dahl SS rat, we selected dif-
ferentially expressed genes that are located on 
genomic regions previously identified in studies 
by Kreutz and Garrett et al (5-8). In these stud-
ies, a QTL on rat chromosome 19 was shown to 
be of importance for the development of pro-
teinuria in the Dahl SS rat (5,6,9). We found that 
the mRNA expression of hedgehog-interacting 
protein (Hhip) and polyamine modulated factor 
binding protein 1 (Pmfbp1, also named outer 
dense fiber 3, ODF3), located within this genom-
ic region, were significantly up- and downregu-
lated, respectively. Although we confirmed the 
differential regulation of the mRNA transcripts 
in a time course analysis of individual rats, we 
have not been able to study the expression and 
distribution of the respective proteins.
Hedgehogs (Hh) are signaling molecules that 
play a role in tissue morphogenesis through in-
fluence on differentiation and proliferation of 
cells. Hh signaling is initiated by binding of Hh 
to the membrane receptor Patched, which via 
an elaborate pathway results in the transcrip-
tional activation of target genes by Gli proteins 
(25). Hhip is a transcriptional target of Hh signal-
ing and is expressed at the plasma membrane 
of Hh responsive cells where it is able to bind 
hedgehogs, thus preventing binding of hedge-
hogs to Patched (26). In the embryonic kidney, 
sonic Hh is thought to control the expression of 
various genes that play a role in the branching 
morphogenesis (27). Little is known about the 
activity of the Hedgehog signaling pathway in 
the adult kidney. Humphreys et al showed that 
in mice sonic Hh expression is limited to the re-
nal medulla; Indian Hh is expressed in proximal 
Figure 5. Proteinuria-induced gene expression patterns. We 
selected a group of genes of which expression was previously 
found to be induced in the tubulointerstitial compartment 
upon proteinuria. We used the global test to evaluate whether 
the glomerular expression of these genes was altered in pro-
teinuric Dahl SS rats. The glomerular expression of the group 
of genes significantly differed between proteinuric Dahl SS 
rats and SHR (P < 0.03). In the graph, the contribution of the 
individual genes on the test result can be seen. On the x-axis, 
the individual genes are listed. The reference line marks the 
expected expression of the gene if it is not differently regu-
lated (null-hypothesis); the height of the bar indicates the 
relative contribution of the individual gene to the test result; 
the marks indicate the number of standard deviations that the 
bar exceeds the expected (null-hypothesis) height. The graph 
shows a relatively large contribution of ssp1 (osteopontin) 
and fibronectin to the overall test result.
Figure 4. Co-immunostaining of desmin (green) and albu-
min (red) in a section of an 8-week-old proteinuric Dahl 
SS rat. Increased desmin expression is seen mostly in areas 
with extensive albumin accumulation. Desmin (A), albumin 
(B), merge (C).
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tubular epithelial cells, but its presence is dispensable for normal renal development and function 
(Humphreys et al, J Am Soc Nephrol 2006, 665A). Thus, it remains unknown whether increased 
glomerular Hhip expression has an effect on glomerular hedgehog signaling. 
Pmfbp1, also termed outer dense fiber 3 (ODF3), is a coiled-coil protein that was originally identi-
fied in rat spermatozoa. Petersen et al (28) found that pmfbp1 is also expressed in the brain, and 
suggested that the protein is a component of the cytoskeleton. With regard to the organization 
of their cytoskeleton, podocytes show important similarities to neurons (29). It would be of in-
terest to see whether the glomerular mRNA expression of pmfbp1 is indeed of podocyte origin.
Pathway analysis revealed significant overrepresentation of cytoskeletal genes in the group of 
genes with a differential expression between the Dahl SS and SHR. This is not surprising regarding 
the fact that proteinuria is mostly accompanied by profound alterations of the podocyte cyto-
skeleton. Widening and shortening of foot processes leads to loss of the complex cellular archi-
tecture (30,31). The organization of the actin cytoskeleton changes, and an electron dense band 
of filaments is formed at the base of the flattened cells (31). In a previous study, we found that 
the onset of proteinuria at five weeks of age precedes the first signs of foot process effacement 
in Dahl SS rats (15). However, cytoskeleton gene expression differences were already present at 
week 4, and persisted through week 6. We studied several cytoskeletal genes at the mRNA level, 
and found a consistent upregulation of genes involved in actin filament, intermediate filament, 
and microtubule based cytoskeletal networks in Dahl SS compared to SHR rats. 
One of the proteins that has recently been implicated in the podocyte actin cytoskeleton rear-
rangement in proteinuria is the GTPase dynamin (24). We found an upregulation of dynamin 
mRNA in glomeruli of 4- and 6-week-old Dahl SS rats compared to SHR rats of the same age, 
although this difference was not clearly present at the protein level. In patients with acquired 
proteinuric kidney diseases, we did observe an upregulation of dynamin at the protein level. Rei-
ser et al suggested that the cysteine protease cathepsin L is able to cleave and thereby inactivate 
dynamin (24). We found a downregulation of cathepsin L mRNA levels in patients with protein-
uric diseases that was correlated to proteinuria. Taken together, these results may suggest that 
the absence of cathepsin L leads to the increased levels of dynamin protein. However, this pat-
tern – downregulation of cathepsin L in combination with upregulation of dynamin – contrasts 
the previous findings by Reiser et al that cathepsin L activity is increased in LPS and polyamine 
nucleoside-induced nephrotic syndromes in rodents (32). The time frame in which proteinuria 
and foot process effacement develops is much shorter in these experimental models (days), in 
comparison to the spontaneous development of proteinuria in Dahl SS rats (weeks). The differ-
ences in gene and protein regulation in the current study and that of Reiser et al may be a reflec-
tion of this temporal regulation. For example, upregulation of dynamin may be a compensatory 
reaction to proteinuria, similar to our previous observation that certain critical podocyte proteins 
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are upregulated in acquired proteinuric diseases (23). We cannot exclude the possibility that the 
changes in cathepsin L and dynamin mRNA exression are separately influenced by another factor.
We observed that there was little differential regulation over time in the Dahl SS rats in comparison 
to the SHR rats. Pathway analysis of SHR rats indicated that cell-cycle and cytokinesis promoting 
genes were upregulated in the SHR rats compared to Dahl SS rats. In a previous study, we found 
that the glomerular volume per podocyte is increased in Dahl SS rats compared to SHR rats of the 
same age, i.e. there is a relative paucity of podocytes in Dahl SS glomeruli (15). Several studies 
have suggested that a shortage of podocytes may increase the susceptibility of the glomerulus 
to damage. Observational studies in human renal disease have already suggested a link between 
proteinuria and glomerular podocyte number (33). Macconi et al (34) found a similar relation-
ship between relative “podocytopenia” (35) and proteinuria in Munich Wistar Fromter rats. In an 
experimental setting, Wharram et al (36) have studied the effects of podocyte depletion in rats: 
they developed a transgenic rat in which podocytes were depleted in a dose dependent fashion. 
A small percentage of podocyte depletion led to transient proteinuria, whereas removal of over 
twenty percent of podocytes resulted in persistent proteinuria, with increasing extent of glomeru-
lar damage and podocyte loss. We suggest that the lack of cell-proliferation response in Dahl SS 
rats that we observed using microarray analysis may relate to the development of proteinuria.
Furthermore, the observation that the Dahl SS rat showed little differential expression between 
weeks 4 and 6 may indicate that an impaired gene expression response underlies the develop-
ment of proteinuria in the Dahl SS rats. Alternatively, these findings may indicate that the detec-
tion of protein in the urine lags behind the development of proteinuria-related gene expression 
changes in the gomerulus. We wanted to test whether the differential glomerular expression of 
genes between Dahl SS and SHR rats could be related to the increased protein trafficking through 
the glomerular filtration barrier. Gene expression changes upon protein loading are known to 
occur in tubular epithelial cells. Because tubular and glomerular epithelial cells share a common 
embryologic origin, we hypothesized that a similar pattern of gene expression might be present in 
the glomerulus. Our findings using the global test indicate that this may indeed be the case. This 
has interesting, be it speculative, implications. It is increasingly thought that proteinuria confers a 
toxic effect to the tubules, a phenomenon that has been regarded as one of the possible expla-
nations of the link between glomerular damage and tubulo-interstitial injury (11). The similarity 
of proteinuria-induced gene expression pattern in tubules and glomerulus suggests that protein-
uria has a comparable toxic effect on these tissue compartments. This could suggest that the 
increased passage of protein through the glomerular filtration barrier is harmful for podocytes. In 
support of this hypothesis is the observation that desmin protein expression in podocytes, which 
indicates podocyte stress, co-localized with albumin reabsorption droplets in the glomerulus. 
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Morigi et al previously found that exposure of cultured mouse podocytes to human serum albu-
min or IgG causes upregulation of endothelin 1 via activation of NF-κB and Ap1 (37). Also in the 
5/6 nephrectomy model in rats, protein accumulation in podocytes was seen in conjunction with 
de novo podocyte desmin expression and an increased glomerular TGF-beta mRNA expression 
(12). In line with suggestions by these and other authors, the increased accumulation of proteins 
such as IgG and albumin in podocytes may initiate a self perpetuating process of podocyte dam-
age and further proteinuria (38). In a recent study, Nagase et al (39) suggested that the protein-
uria seen in Dahl SS rats might be caused by podocyte damage. Although we cannot disprove this 
hypothesis, our results would also be compatible with a pathogenetic pathway in which podocyte 
injury is a phenomenon secondary to proteinuria.
In conclusion, we have studied the expression of glomerular genes during the development of 
proteinuria in the Dahl rat. Our results warrant further investigation of the role of Hhip and 
Pmfbp1. We found an upregulation of dynamin mRNA and protein expression in rat and human 
proteinuric glomeruli, underscoring the importance of actin-regulating proteins in proteinuric 
diseases. Furthermore, our findings substantiate the hypothesis that the increased passage of 
proteins through the glomerular filtration barrier has a direct toxic effect on the glomerulus. 
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In kidney transplantation, chronic allograft nephropathy (CAN) is the major cause of graft loss. 
Causes of CAN include chronic rejection and chronic cyclosporine A (CsA) nephrotoxicity. It is nec-
essary to differentiate between these two entities in order to apply the appropriate therapeutic 
regimen for the individual patient, but this is hampered by the lack of discriminating functional 
and morphologic parameters. We investigated whether renal cortical mRNA levels for several 
matrix proteins can serve as discriminating parameters.
Methods
Patients with chronic rejection (n = 19) and chronic CsA toxicity (n = 17) were selected by clini-
cal and histologic criteria. Protocol biopsies without histologic abnormalities, taken at 6 months 
after transplantation from patients receiving CsA, were used as controls (n = 6). Total RNA was 
extracted from the renal biopsy tissue, and mRNA levels of transforming growth factor-β (TGF-β) 
and the extracellular matrix (ECM) molecules collagen Iα1, IIIα1, IVα3, decorin, fibronectin, and 
laminin β2 were measured by real-time polymerase chain reaction (PCR).
Results
In both patient groups, the mean collagen IVα3 and fibronectin mRNA levels were significantly 
elevated compared to those in controls, whereas only in CsA toxicity were the laminin β2 and 
TGF-β mRNA levels significantly increased. The increase of laminin β2 and TGF-β mRNA levels was 
significantly higher in the CsA toxicity group than in the chronic rejection group (P < 0.001 and 
P = 0.004, respectively). Receiver-operating characteristic (ROC) curve analysis showed that with 
a 15.6-fold increase in laminin β2 mRNA expression as cut-off point, the presence of CsA toxicity 
could be predicted with 87% sensitivity and 88% specificity.
Conclusion
Renal laminin β2 and TGF-β mRNA levels can be used to differentiate between chronic rejection 
and chronic CsA toxicity in renal transplants. The method of mRNA quantification might be ap-
plicable as an additional diagnostic tool in clinical practice.
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Introduction
Over the past decade, renal transplantation has become a very successful treatment modality 
for end-stage renal disease (ESRD). Due to improvement of immunosuppressive therapy, acute 
rejection episodes can be treated effectively, and the prevalence of early graft loss has diminished 
significantly (1). Long-term graft loss, however, currently forms a major problem in renal trans-
plantation (1-3).
The term chronic allograft nephropathy (CAN) refers to the pathologic changes, including inter-
stitial fibrosis, tubular atrophy, and fibrous intimal thickening, which are found in chronically dys-
functioning kidney transplants (2). Several risk factors for CAN have been recognized, such as the 
number and the severity of acute rejection episodes (4), ongoing chronic rejection, and excessive 
exposure to calcineurin inhibitors such as cyclosporine A (CsA) (2,5). Therefore, the lesions that 
occur in biopsies of patients with CAN may result from either one or a combination of these fac-
tors. Paradoxically, changes induced by chronic rejection are clinically and histopathologically hard 
to distinguish from those caused by the nephrotoxic effects of chronic exposure to CsA, meant 
to prevent chronic rejection. This makes it difficult to determine the optimal dose of the immu-
nosuppressive regimen, in which the beneficial and nephrotoxic effects of CsA are balanced (6).
Some changes observed in routine light microscopy may help reveal the cause of chronic renal 
allograft dysfunction. These include peripheral nodular arteriolar hyalinosis, suggestive of chronic 
CsA toxicity, and transplant vasculopathy (intimal fibrosis, disruption of the lamina elastica in the 
presence of inflammation), suggestive of chronic rejection (7,8). However, these lesions are not 
decisively present in all patients with either of the diagnoses. Furthermore, due to the fact that 
peripheral nodular arteriolar hyalinosis and transplant vasculopathy appear focally in the tissue, 
sampling errors may obscure their presence.
In this study, we describe how differentiation between chronic rejection and chronic CsA toxicity 
may be improved with the aid of molecular techniques, based on the results of a quantitative 
analysis of the renal cortical mRNA levels of several extracellular matrix (ECM) components and 
the ECM-regulating molecule transforming growth factor-β (TGF-β) in two groups of patients 
suffering from either disease entity.
We focused on several molecules that make up the interstitial compartment of the kidney and 
are known to accumulate in renal fibrosis, including collagens I and III, and fibronectin, together 
with the ECM-regulating molecule TGF-β and its potential inhibitor decorin. In recent publica-
tions, attention has been drawn to expression of collagen IVα3 and laminin β2 in the discrimina-
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We reviewed all kidney transplant biopsies performed in our center over the past 20 years, taken 
because of renal function loss beyond 1 year after transplantation. We selected two groups of 
patients: the chronic rejection group and the chronic CsA toxicity group.
The chronic rejection group (n = 19), consisted of patients who received either prednisone and 
azathioprine (n = 6), or prednisone and CsA (n = 13). Of the 13 patients using CsA, seven received 
the Sandimmune formulation and six received the Neoral formulation. These patients, with an 
initially well-functioning kidney transplant, developed a progressive decline in renal function. A 
biopsy was taken 4.8 ± 3.8 years after transplantation, in which transplant vasculopathy (intimal 
fibrosis, intimal inflammation, and disruption of the lamina elastica), transplant glomerulopathy 
(characterized by double contours of the glomerular basement membrane (GBM)) or both were 
present as a histopathologic indication of chronic rejection, as defined by the Banff 97 classifica-
tion (7). Biopsies with peripheral nodular arteriolar hyalinosis, a lesion suggestive of CsA toxicity, 
and biopsies with signs of de novo or recurrent native disease were excluded. Patients suffering 
from diabetes and patients with graft arterial stenosis were excluded.
The chronic CsA toxicity group (n = 17), consisted of patients with an initially well-functioning 
kidney transplant, who developed a progressive decline in renal function only after a switch was 
made from Sandimmune to Neoral; CsA formulations with a relatively low and a relatively high 
bioavailability, respectively. Before the switch, immunosuppression was aimed at CsA 24-hour 
trough levels of 100 g/L by administration of Sandimmune once daily. After the switch, Neoral 
was administered twice daily, aiming at a 12-hour trough level of 150 g/L. Thereby, the mean daily 
CsA dose was increased from 3.2 mg/kg to 3.5 mg/kg (10). Patients who developed a significant 
and progressive decrease in renal function after this switch, in the absence of other features that 
might explain the decline in renal function, were included. Renal biopsies, taken 7.1 ± 3.4 years 
after transplantation and 2.5 ± 1.2 years after the switch from Sandimmune to Neoral, showed 
peripheral nodular arteriolar hyalinosis in 16 of the 17 patients, histopathologically supporting 
the functional selection. Biopsies with histologic features suggestive of chronic rejection or de 
novo or recurrent glomerulonephritis were excluded. Patients suffering from diabetes and pa-
tients with graft arterial stenosis were excluded.
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C4d staining was performed on all biopsy samples. None of the patients in the CsA toxicity group 
showed C4d depositions in their peritubular capillaries, while 26% of the patients in the chronic 
rejection showed diffuse C4d depositions in the peritubular capillaries.
Control group
As controls (n = 6), we used protocol transplant biopsies taken from patients at 6 months after 
transplantation with stable graft function at the time of biopsy. Apart from some cases show-
ing signs of minor nonspecific age-related alterations, none of the biopsies showed any signs of 
rejection or drug toxicity. The glomeruli (at least ten present in the sections for evaluation) did 
not show any abnormalities. Patients in this control group all used CsA as immunosuppressive 
medication.
Clinical data
Clinical data included gender, patient age at time of biopsy, donor age, transplant-origin (cadav-
eric or living donor), number of acute rejection episodes, delayed graft function, time between 
transplantation and biopsy, time between switch and biopsy, mean arterial pressure (MAP), num-
ber of antihypertensive drugs used, use of angiotensin-converting enzyme (ACE) inhibitors, low-
est serum creatinine, serum creatinine at biopsy, proteinuria at time of biopsy, and CsA trough 
levels. We estimated the best endogenous creatinine clearance and creatinine clearance at biopsy 
using the Cockcroft-Gault equation (11). The loss of renal function was defined as the best Cock-
croft clearance minus the Cockcroft clearance at the time of biopsy.
mRNA isolation and cDNA synthesis
Four-micrometer cryostat sections of each biopsy were cut, air dried, and stored at -20°C until use 
for immunohistochemistry. One section was evaluated to localize the cortex, which was there-
after excised from the biopsy. RNA was subsequently extracted, as described previously (12). In 
brief, the tissue was lysed by rigorous mixing after suspension in 500 μL TRIzol® (Invitrogen Life 
Technologies, Carlsbad, CA, USA). After adding 100 μL chloroform, the solution was centrifuged 
at 15,000g for 15 minutes. The RNA was precipitated by addition of 5 μg of glycogen and 250 
μL isopropanol. cDNA synthesis was performed using a reverse transcription (RT) kit (Omniscript 
Reverse Transcriptase) (Qiagen GmbH, Westburg B.V., The Netherlands).
Real-time polymerase chain reaction (PCR)
For several ECM molecules and TGF-β1, forward and reverse primers (Life Technologies BRL and 
Biosource International, Nivelles, Belgium) and TaqMan probes (Biosource International) were 
designed, using Primer Express® 1.5 software (PE Applied Biosystems, Foster City, CA, USA). 
To prevent amplification of genomic DNA, primers or probes were chosen spanning an exon-
intron junction. Primers were located near the 3’ end of the mRNA. The 5’ ends of the Taq-
man probes were 6-carboxy-4,7,2’,7’-tetrachloro-fluorescein (TET)-labeled, except those for 
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH), collagen IVα3, and decorin, which were 
6-carboxy fluorescein (FAM)-labeled. The quencher dye at the 3’ side of the probe was 6-carboxy-
tetramethyl-rhodamine (TAMRA). The sequences of the primers and of the TaqMan probes are 
shown in Table 1.
Real-time PCR was performed using the ABI Prism 7700 sequence detector and software (PE 
Applied Biosystems) (13). Amplification cycles were 95°C for 10 minutes, followed by 40 cycles 
at 95°C for 30 seconds and at 60°C for 60 seconds. Kinetics of the reactions were determined 
using a standard curve. We used the ratio of the levels of the investigated molecule and GAPDH, 
a constitutively expressed gene, to correct for the amount of tissue used for RNA extraction and 
the efficiency of cDNA synthesis. To confirm the suitability of GAPDH as a housekeeping gene, 
we tested the correlation between the expression of two additional housekeeping genes (hypo-
xanthine phosphoribosyl transferase 1 (HPRT1) and β2-microglobulin (B2M)), and that of GAPDH 
in all samples.
Immunofluorescence for C4d
Immunofluorescence staining for C4d was performed on untreated slides using standard proce-
dures as described before (14,15). As the primary antibody, mouse anti-C4d antibody (Quidel, 
San Diego, CA, USA), diluted to 2 ng/mL in phosphate-buffered saline (PBS) and supplemented 
with 1% bovine serum albumin (BSA), was used. The secondary antibody was fluorescein iso-
thiocyanate (FITC)-conjugated goat anti-mouse IgG (Sigma Chemical Co., St. Louis, MO, USA), 
diluted 1:200 in BSA/PBS. The staining was evaluated independently by two of the authors (K.K. 
and M.E.), blinded for the diagnosis of the samples. C4d staining was observed in the peritubular 
capillaries (PTC) in a circumferential pattern. Sporadically, mesangial and GBM areas of the glom-
erulus stained positive. In accordance with scoring methods described in the literature on C4d 
deposition in renal allografts (16,17), biopsies were scored C4d-positive when more than 25% of 
the PTC showed an intense and circumferential 
staining as depicted in Figure 1. In most cases of 
diffuse positive samples all PTC were affected. 
In the few cases of discordant scoring, decision 
was reached by consensus.
Immunohistochemistry
For evaluation of protein expression in the tis-
sue, immunohistochemistry was performed for 
laminin β2 and TGF-β. Four micrometer fro-
zen sections were thawed, air dried, and incu-
bated for 1 hour with mouse monoclonal anti-
laminin β2 antibodies (Developmental Studies 
Figure 1. Immunofluorescence staining for C4d. In some 
chronic rejection samples diffuse circumferential staining 
of peritubular capillaries for C4d was observed (original 
magnification × 400).
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Hybridoma Bank, Iowa City, IA, USA) diluted 1:16 in BSA/PBS, or rabbit polyclonal anti-TGF-β 
(Dako, Glostrup, Denmark), diluted 1:400 in BSA/PBS. The anti-TGF-β antibodies stain both the 
active and latent form of TGF-β. The slides were washed in PBS, and subsequently incubated with 
horseradish peroxidase (HRP)-conjugated antimouse Envision and HRP-conjugated antirabbit En-
vision, respectively (Dako). After 45 minutes of incubation, the slides were washed in PBS and the 
staining was developed with diaminobenzidine (DAB). The color was enhanced by incubating the 
slides in 0.5% CuSO4 solution for 5 minutes. After counterstaining with hematoxylin, the slides 
were dehydrated and mounted. For each staining, all biopsy samples were stained in one session.
Digital image analysis
To quantify the amount of staining for TGF-β and laminin β2, images of the cortical part of the 
biopsies were taken at a 200 magnification using a Zeiss microscope equipped with a Sony DXC-
950P 3 CCD color camera (Sony Corporation, Tokyo, Japan) and further analyzed using KS-400 
image analysis software (version 3.0 for Windows) (Carl Zeiss Vision GmbH, Oberkochen, Ger-
many). The cortical area stained was defined as the amount of staining within the color spectrum 
specific for the enhanced DAB staining, and above a fixed intensity threshold, as described previ-
ously (18). Recording and analysis of the images were performed with fixed settings.
Statistical analysis
Statistical analysis was performed using SPSS 10.0.7 for Windows software. We used log trans-
formed (10log) mRNA levels for analysis. A one-way analysis of variance (ANOVA) with a Bon-
ferroni post hoc correction was used for comparison of differences between groups. Using a 
Table 1. Primer and probe sequences
Molecule (a) Forward primer Reverse primer TaqMan™ probe (b)
GAPDH TGGTCACCAGGGCTGCTT AGCTTCCCGTTCTCAGCCTT 5’-FAM-TCAACTACATGGTTTACATGTTCCAATAT-GATTCCACCAA-TAMRA-3’





















Laminin β2 GGATGAGGCTCGGGACCT CCCGTCCAACTGGGCTG 5’-TET-AGGAATTGGAAGGCACCTATGAG-GAAAATGA-TAMRA-3’
TGF-β1 CCCAGCATCTGCAAAGCTC GTCAATGTACAGCTGCCGCA 5’-TET-ACACCAACTATTGCTTCAGCTCCACGGA-TAMRA-3’
a) GAPDH – glyceraldehyde-3-phosphate dehydrogenase; B2M – β2 microglobulin; HPRT1 – hypoxanthine phosphoribosyl-
transferase 1. (b) TET – 6-carboxy-4,7,2’,7’-tetrachloro-fluorescein; FAM – 6-carboxy fluorescein; TAMRA – carboxy-tetramethyl-
rhodamine.
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receiver-operating characteristic (ROC) curve, we determined the cut-off point of mRNA levels 
with the best combination of sensitivity and specificity that predicted the presence of CsA toxicity. 
Correlations between the mRNA data and the clinical characteristics of the patient groups were 
calculated using Pearson’s correlation test. P < 0.05 was considered statistically significant.
Results
Patient data
The clinical characteristics of the patients and the controls are listed in Table 2. Renal function at 
time of biopsy, donor age, patient age, number of acute rejection episodes, delayed graft func-
tion, the time interval between transplantation and biopsy, MAP, number of antihypertensive 
drugs used, and use of ACE inhibitors did not differ significantly between patient groups. There 
was significantly greater loss of renal function in the chronic rejection group than in the chronic 
Table 2. Clinical characteristics of patients and controls
Group Chronic rejection Chronic CsA toxicity Controls
N 19 17 6
Gender (female) 10 (53%) 4 (24%) 2 (33%)
Number of patients treated with CsA 13 (68%) 17 (100%) 6 (100%)
Patient age (years ± SD) 44 ± 14 49 ± 13 45 ± 6
Donor age (years ± SD) 35 ± 16 44 ± 10 47 ± 17
Living-donor kidney transplants (%) 5 35*
Number of acute rejection episodes 0.8 ± 1.0 0.5 ± 0.6
Delayed graft function (%) 21 18
Time between transplantation and biopsy (years ± SD) 4.8 ± 3.8 7.1 ± 3.4
Time between switch and biopsy (years ± SD) 2.5 ± 1.2
Mean arterial pressure 108 ± 10 106 ± 8
Number of anti-hypertensive drugs used (0/1/2/>3) 2/2/8/7 2/5/5/5
Use of ACE-inhibitors (%) 21 29
Best serum creatinine level (μmol/L ± SD) 113 ± 27 124 ± 25
Serum creatinine at time of biopsy (μmol/L ± SD) 238 ± 83 201 ± 45 118 ± 25
Best creatinine clearance (mL/min ± SD) 74 ± 22* 61 ± 11
Creatinine clearance at time of biopsy (mL/min ± SD) 36 ± 14 40 ± 15 68 ± 14
Loss of renal function (μmol/L ± SD) 38 ± 16† 21 ± 13
Proteinuria at time of biopsy (g/24h ± SD) 2.9 ± 2.6 1.3 ± 1.5
CsA trough levels at time of biopsy (μg/L ± SD) 110 ± 31 114 ± 30
Creatinine clearance was estimated by the Cockcroft-Gault equation. Loss of renal function was defined as the difference 
between the best creatinine clearance and the creatinine clearance at the time of biopsy. * P < 0.05, † P < 0.01



























































































































































































































































































































































































































CsA toxicity group (38 ± 16 mL/min and 21 ± 13 mL/min, respectively) (P < 0.01). There were sig-
nificantly more patients with a living-donor kidney transplant in the CsA toxicity group, compared 
with the chronic rejection group (35% and 5%, respectively) (P = 0.02).
Cortical mRNA levels
GAPDH mRNA levels did not differ between groups (data not shown). Within the chronic rejec-
tion group, mean GAPDH expression did not significantly differ between CsA-using and non-
CsA–using patients. There was a significant correlation between GAPDH mRNA and mRNA of 
the two other housekeeping molecules measured (r = 0.74 and r = 0.92 for B2M and HPRT1, 
respectively) (P < 0.001). Additionally, we tested comparisons between the chronic rejection and 
the CsA toxicity group for all transcripts using β2-microglobulin as the housekeeping molecule. 
This yielded the same results as when GAPDH was used. These findings support the suitability of 
GAPDH as a housekeeping molecule in the experiments.
The mean log transformed mRNA levels of collagen Iα1, collagen IIIα1, collagen IVα3, decorin, fi-
bronectin, laminin β2, and TGF-β are shown in Table 3 and depicted in Figure 2. The mRNA levels 
of collagen IVα3 and fibronectin were higher in both patient groups compared to controls. The 
mRNA levels of laminin β2 and TGF-β were higher in the CsA toxicity groups compared to controls 
(Table 3, Figure 2f and h). The renal mRNA levels of collagen Iα1, IIIα1, and IVα3, decorin, and 
fibronectin were not significantly different between patients with chronic rejection and patients 
with CsA toxicity (Table 3, Figure 2a to e). The renal mRNA levels of laminin β2, TGF-β, and the ra-
tio of TGF-β to decorin were significantly higher in patients with CsA toxicity than in patients with 
chronic rejection (Table 3, Figure 2f and g). After omitting patients who did not use CsA from the 
chronic rejection group, comparative analyses between groups yielded comparable results (Table 
3). In addition, there were no differences in mRNA expression of all molecules analyzed between 
chronic rejection patients who used CsA and those who did not use CsA as immunosuppression 
Table 3. Log-transformed mRNA expression levels
Total chronic rejection 
(Ia)
Chronic rejection using 
CsA (Ib) Chronic CsA toxicity (II) Controls (III) 
Collagen Iα1 0.3 ± 0.2 0.2 ± 0.3 0.2 ± 0.3 0.8 ± 0.2
Collagen IIIα1 0.3 ± 0.2 0.2 ± 0.2 0.3 ± 0.2 0.3 ± 0.1
Collagen IVα3 0.1 ± 0.2† 0.1 ± 0.2† 0.5 ± 0.1† -1.9 ± 0.3
Decorin 0.0 ± 0.2 -0.2 ± 0.2 -0.1. ± 0.2 -0.4 ± 0.2
Fibronectin -0.1 ± 0.2† -0.3 ± 0.2† -0.1 ± 0.2† -1.6 ± 0.2
Laminin β2 0.6 ± 0.1‡ 0.5 ± 0.2‡ 1.1 ± 0.1† -0.1 ± 0.3
TGF-β 0.8 ± 0.1** 0.8 ± 0.2** 1.3 ± 0.1† 0.5 ± 0.2
Ratio TGF-β / decorin 0.8 ± 0.2** 0.8 ± 0.2** 1.4 ± 0.1 0.9 ± 0.2
All values are mean ± SEM. * P < 0.05, I or II vs III; † P < 0.01, I or II vs III; ** P < 0.05, I vs II; ‡ P < 0.01, I vs II. Chronic 
rejection using CsA (1b) – mean log-transformed mRNA levels of the chronic rejection group after omission of patients using 
azathioprine as immunosuppression.
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(collagen Iα1, P = 0.44; collagen IIIα1, P = 0.51; 
collagen IVα3, P = 0.57; decorin, P = 0.07; fibro-
nectin, P = 0.10; laminin β2, P = 0.52; TGF-β, 
P = 0.53). There were no significant differences 
between mRNA expression levels in cadaveric 
transplants and living-donor transplants within 
each patient group.
Immunohistochemistry
We performed immunohistochemical stainings 
to evaluate the tissue expression of laminin β2 
and TGF-β at the protein level (Figure 3). In bi-
opsies of controls, laminin β2 staining was ob-
served in the GBM and in cortical vessels (Figure 
3a). In chronic rejection as well as in CsA toxicity, 
sporadic expression of laminin β2 was seen in 
the tubular basement membrane (Figure 3b and 
c). TGF-β staining was sporadically observed in 
glomeruli and tubuli of controls (Figure 3d). In 
sections of biopsies from patients suffering from 
chronic rejection or CsA toxicity, some tubuli 
showed very intense staining for TGF-β (Figure 
3e and f). There was no relation between this 
sporadic intensive staining and mRNA expres-
sion levels or clinical parameters.
Figure 3. Immunohistochemical stainings for laminin β2 
(A to C) and transforming growth factor-β (TGF-β) (D to 
F). In control tissue laminin β2 staining was observed in the 
glomerular basement membrane and in cortical vessels (A). 
In chronic rejection (B) and cyclosporine A (CsA) toxicity (C), 
expression of laminin β2 was observed in the tubular base-
ment membrane. TGF-β staining was sporadically observed 
in glomeruli and tubuli of controls (D). In chronic rejection 
(E) and CsA toxicity (F), some tubuli showed a very intense 
staining for TGF-β.
Figure 4. Quantification of immunohistochemical staining for laminin β2 and TGF-β. Bars represent mean cortical area per-
centage ± SEM. (A) The amount of laminin β2 staining is slightly higher in the cyclosporine A toxicity (CsAT) group compared to 
the chronic rejection (CR) group, but the difference between groups does not reach statistical significance. (B) TGF-β staining is 
increased in the CsA toxicity group compared to the chronic rejection group. There are no significant differences between groups.
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In both patient groups, the amount of laminin 
β2 staining was increased compared to controls. 
The mean cortical area percentage was slight-
ly higher in the CsA toxicity group than in the 
chronic rejection group (5.7 ± 1.5 and 5.3 ± 1.0, 
mean ± SEM) (Figure 4a). The differences be-
tween groups were not significant. The amount 
of TGF-β staining was higher in patient groups 
than in controls. The mean cortical area percent-
age was higher in the CsA toxicity group than in 
the chronic rejection group (15.8 ± 3.6 and 13.4 
± 2.2, mean ± SEM) (Figure 4b), but this differ-
ence did not reach statistical significance.
ROC curve analysis
ROC curve analysis Figure 5 showed that a 15.6-
fold increase of laminin β2 mRNA levels com-
pared to controls indicates the presence of CsA 
toxicity with 87% sensitivity and 88% specificity. 
The area under the curve was 0.90 (P < 0.001). Similarly, a ninefold increase of TGF-β mRNA levels 
predicts the presence of chronic CsA toxicity with 60% sensitivity and 88% specificity (area under 
the curve 0.76) (P < 0.05).
Correlations
No correlations were found between mRNA levels and age, donor age, number of acute rejection 
episodes, delayed graft function, time between transplantation and biopsy, the time between 
switch and biopsy, loss of renal function, MAP, and use of ACE inhibitors. Only in the chronic 
rejection group, TGF-β mRNA levels and the ratio of TGF-β to decorin mRNA levels correlated 
significantly with laminin β2 mRNA levels (r = 0.56 and r = 0.68, respectively) (P < 0.05).
Discussion
This study was designed to enhance the discrimination between chronic rejection and chronic 
CsA toxicity as a cause of CAN. With current clinical and histologic parameters this distinction is 
difficult to make because of the similarities in clinical presentation and aspecificity of the lesions 
Figure 5. Receiver-operating characteristic (ROC) curve of 
laminin β2 and TGF-β. The fraction of true positive results 
(sensitivity) and false positive results (1-specificity) for laminin 
β2 (solid line) and TGF-β (dashed line) mRNA levels. The area 
under the curve indicates the accuracy of the test: 0.5 is the 
value expected by chance (diagonal line), 1.0 represents the 
ideal predictor. The area under the curves for laminin β2 and 
TGF-β are 0.896 and 0.758, respectively. Using a 15.6-fold 
increase in laminin β2 mRNA levels to those of normal con-
trols as cut-off point, the sensitivity is 87% and the specificity 
88% for the prediction of the presence of chronic cyclosporine 
A toxicity.
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in needle biopsies of patients with CAN. We show that quantification of mRNA levels of laminin 
β2 and TGF-β can be used to distinguish chronic rejection from CsA toxicity, which will help in 
fine-tuning the immunosuppressive regimen. In this way, the beneficial effects of CsA are not 
abrogated by its nephrotoxic side effects (3).
In our center, we had the opportunity to define on functional criteria a patient group that suf-
fered from chronic CsA toxicity, comprising patients who developed a progressive decline in renal 
function after a change in immunosuppressive medication was made leading to a higher CsA 
exposure (10). The appropriateness of these selection criteria was supported by histopathologic 
findings: peripheral nodular arteriolar hyalinosis, regarded as a finding suggestive of CsA toxicity, 
was present in 94% of these patients, and C4d deposition in PTCs, a feature frequently seen in 
chronic rejection (19), was absent in all patients of the CsA toxicity group. An additional selec-
tion criterion for the CsA toxicity group and a further proof of CsA toxicity might have been the 
recovery of renal function after stopping or reducing CsA administration. Unfortunately, these 
data were not available. In the chronic rejection group, 13 out of 19 patients also received CsA. 
However, since the CsA formulation in the majority of these patients had a relatively low bioavail-
ability and administration was applied only once-daily, this group is less likely to have suffered 
from CsA toxicity. In addition, patients in this group had transplant vasculopathy or glomerulopa-
thy, histologic features suggestive of chronic rejection, but they did not show histologic features 
consistent with CsA toxicity. Finally, although there was some heterogeneity in immunosuppres-
sive medication in the chronic rejection group, no differences were found in mRNA data between 
patients using CsA and those who did not use CsA as immunosuppression, and analysis with only 
the group of chronic rejection patients using CsA as immunosuppression yielded the same results 
as the chronic rejection group as a whole. A striking difference in patient characteristics was that 
35% of the CsA toxicity group, but only 5% of the transplants in the chronic rejection group 
were living donor transplants. This might support the opinion that injuries inflicted to cadaveric 
allografts before or during transplantation elicit a predisposition for the development of chronic 
rejection, as has been suggested before (2,20).
The ECM is a meshwork of proteins, in which remodeling continuously takes place by means 
of protein synthesis and degradation. Accumulation of ECM proteins reflects an imbalance of 
this dynamic process, resulting from an increase in protein synthesis, a decrease in protein deg-
radation, or a combination of both. The synthesis of ECM components is enhanced by several 
profibrotic cytokines, including TGF-β. During chronic renal allograft dysfunction, this cytokine 
has been shown to be up-regulated at the mRNA and protein level in the grafts, sera, and periph-
eral blood mononuclear cells of patients taking CsA-based immunosuppression (21,22). TGF-β 
mRNA levels are up-regulated in cultured murine proximal tubular epithelial cells and fibroblasts 
after exposure to CsA (23). Moreover, in rats receiving CsA, administration of anti-TGF-β1 an-
tibodies reduces the extent of histologic damage reminiscent of CsA toxicity (24). Decorin, a 
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low-molecular-weight proteoglycan, can bind and inactivate TGF-β, thereby preventing its pro-
sclerotic action (25). The TGF-β/decorin mRNA ratio may therefore be a better indicator of TGF-β 
activity than TGF-β mRNA levels alone. We found a significant increase of TGF-β mRNA levels and 
of the TGF-β/decorin ratio in CsA toxicity, supporting the notion that CsA has a stimulatory effect 
on TGF-β expression.
Laminin β2 is a normal component of the renal vasculature and the GBM (26). We observed 
an increase in laminin β2 mRNA expression in the CsA toxicity group compared to controls, the 
expression in the CsA toxicity group being also significantly higher than in the chronic rejection 
group. Laminin β2 mRNA expression was also higher in the CsA toxicity group when compar-
ing it to the chronic rejection group with only those patients using CsA included. Only sparse 
information about factors stimulating laminin β2 expression is available. The results of our study 
suggest a direct or indirect stimulatory effect of CsA on laminin β2 expression, yet the underlying 
mechanism is unclear.
We performed immunohistochemistry combined with digital image analysis for laminin β2 and 
TGF-β to evaluate the expression of these molecules at the protein level. The pattern seen at 
the protein level resembled that at the mRNA level (ie, there was a tendency toward a higher 
expression of laminin β2 and TGF-β in the CsA toxicity group than in the chronic rejection group). 
However, differences in protein staining between groups did not reach statistical significance. Fur-
thermore, a correlation between mRNA expression levels and protein deposition was absent. The 
observation that the extent of protein accumulation does not strictly coincide with mRNA levels 
has been described before (27). Additionally, in vivo accumulation of protein is not only deter-
mined by synthesis, but also by degradation of ECM products. Although we did not evaluate the 
mechanism of laminin β2 degradation, the notion that laminin β2 mRNA levels were increased 
in the CsA toxicity group compared to the chronic rejection group, while protein levels were not 
significantly different, might suggest that there is an increased degradation of laminin β2 in CsA 
toxicity. This might be due to the microvascular damage exerted by CsA (8).
Collagen Iα1 and collagen IIIα1 are components of the renal interstitium that are normally pres-
ent in relatively small amounts (28). Accumulation of these molecules has been reported in a vari-
ety of chronic human kidney diseases (29) and CAN (30,31). There was no difference between the 
chronic rejection group and the CsA toxicity group in collagens I and III mRNA levels. We observed 
no differences in the mRNA levels between the patient groups and the control group. This might 
be explained by the possibility that the accumulation of collagens I and III in CAN is a result of an 
early increase in collagen synthesis that might have taken place before the overt damage seen in 
the tissues. Furthermore, it might be that the accumulation of collagens I and III in patients with 
CAN is due to an impaired degradation of these proteins, as has been suggested before (32).
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Collagen IVα3 is a component of both the GBM and the distal tubular basement membrane 
(TBM) (26). In a study by Abrass et al (9), de novo expression of collagen IVα3 protein was re-
ported in the proximal TBM in chronic rejection, but not in CsA toxicity. In our study, we did not 
observe significant differences in collagen IVα3 mRNA expression levels between the two groups. 
Since we used total cortical tissue for mRNA analysis, it is possible that subtle differences of colla-
gen IVα3 mRNA expression in the proximal tubulus epithelium between patient groups remained 
undetected. When we focused only on the chronic rejection group, the collagen IVα3 mRNA 
expression was higher in the C4d+ chronic rejection group than in the C4d– chronic rejection 
group (data not shown). C4d recently has gained much interest as a marker of humoral rejection, 
but there is only sparse information about the relation between C4d and accumulation of ECM 
(33). Future studies would be needed to decipher whether the relation found in our study is of 
pathogenic significance.
In both the chronic rejection and the chronic CsA toxicity group, we observed a significant in-
crease in renal cortical fibronectin mRNA levels in comparison to controls. There were no differ-
ences in the mRNA levels of fibronectin between the chronic rejection and the CsA toxicity group. 
This is in line with previous studies showing an increase in fibronectin mRNA levels in a rat model 
of CsA toxicity (34), and in allograft rejection, both at the mRNA and the protein level (35,36).
One of the advantages of analyzing mRNA profiles may be that alterations in mRNA levels pre-
cede the development or aggravation of tissue damage (37). This holds promise for an earlier rec-
ognition of an unfavorable course after kidney transplantation (38,39). Furthermore, quantitative 
mRNA analysis can be performed rapidly, and requires only small amounts of renal tissue. In the 
future, diagnostic approaches using molecular analysis simultaneously with conventional strate-
gies are likely to be implemented in clinical practice (40). We had the opportunity to compose 
merely on the basis of functional variables two patient groups that represent the extremes of a 
spectrum of causes leading to the development of CAN. Therefore, we studied the presence of 
markers that could discriminate between these two highly selected patient groups. An obvious 
prerequisite for implementation in clinical practice is to test the use of these markers in larger 
nonselected patient groups.
In conclusion, we measured human renal cortical mRNA expression levels of ECM components 
in two well-defined groups of patients suffering from either chronic rejection or chronic CsA 
toxicity. In both patient groups, the mean mRNA levels for collagen IVα3 and fibronectin were 
significantly elevated compared to those in controls, whereas in CsA toxicity the laminin β2 and 
TGF-β mRNA levels were also significantly increased. Most important, we showed that laminin β2 
and TGF-β mRNA levels are significantly higher in patients with CsA toxicity than in patients with 
chronic rejection, and that measurement of these expression levels may help differentiate chronic 
CsA toxicity from chronic rejection. 
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Early Interstitial Accumulation 
of Collagen Type I Discriminates 




Little is known regarding the composition of the interstitial extracellular matrix of kidney al-
lografts with deteriorating function. Collagen I, III, and IV, the collagen IVα3 chain, and the 
laminin β2 chain were investigated in biopsies of allografted kidneys with chronic cyclosporine A 
nephrotoxicity (CsAT) (n = 17), chronic rejection (CR) (n = 12), or chronic allograft nephropathy 
(CAN) (n = 19). α-smooth muscle actin expression was also examined. Normal native kidneys 
were used as control samples (n = 11). Biopsy samples were studied with routine light microscopy 
and immunostaining. The mean interstitial fibrosis scores were significantly higher for the CR and 
CAN groups, compared with the chronic CsAT group. The cortical tubulointerstitial areas of the 
CR and CAN groups, but not the chronic CsAT group, contained more collagen I than did normal 
control samples. Differences were noted even in biopsies with mild fibrosis. Accumulation of col-
lagen III, IV, and IVα3 was increased in all patient groups. Collagen III accumulation was greater in 
the CR and CAN groups than in the chronic CsAT group. Receiver-operating characteristic curve 
analysis demonstrated that collagen I staining had the best discriminatory value in differentiat-
ing CR from chronic CsAT, with a sensitivity of 63% and a specificity of 94% at a cutoff value of 
19%. Laminin β2 staining did not differentiate CR from CsAT. Increased α-smoothh muscle actin 
staining did not differ among the three groups. It was concluded that, during chronic CsAT, col-
lagen III and IV were preferentially accumulated in the tubulointerstitium. Early increases in the 
deposition of collagen I, with collagen III and IV, were more specific for CR. CR seems to elicit a 
more pronounced fibrotic response than does chronic CsAT.
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Introduction
Late loss of allograft function remains a major problem in renal transplantation (1). Kidney al-
lograft failure is usually preceded by a process of chronic transplant dysfunction, which is charac-
terized by a relatively slow but variable rate of decline in GFR, increasing proteinuria, and increas-
es in BP. The pathologic changes in deteriorating grafts are often less specific. The term chronic 
allograft nephropathy (CAN) has been adopted to classify these changes, which include chronic 
obliterative vascular alterations, tubular atrophy, glomerulosclerosis, and interstitial fibrosis (2).
CAN includes both chronic rejection (CR) and chronic calcineurin inhibitor toxicity (2). The nature 
of vascular, glomerular, and interstitial changes in CAN biopsy specimens can sometimes help to 
define more specifically the cause of graft dysfunction. Concentric intimal thickening of arteries 
and arterioles, often accompanied by a moderate degree of mononuclear cell infiltration of the 
vessel walls, and duplication of the glomerular basement membrane are thought to indicate CR. 
Smooth muscle cell necrosis and peripheral nodular medial hyalinosis of arterioles are considered 
hallmarks of cyclosporine A (CsA) nephrotoxicity (CsAT) (3,4).
Extracellular matrix (ECM) accumulates in the cortical interstitium regardless of the cause of 
chronic graft dysfunction, as observed in native kidneys with chronic diseases (4,5). Surprisingly, 
the ECM composition of deteriorating allografted kidneys has rarely been studied. Determination 
of the ECM molecules that accumulate could enhance our understanding of the pathogenesis 
of graft dysfunction and could potentially help define the cause, if disease-specific changes are 
observed. In this study, we investigated whether the ECM composition differs between allografts 
that lose function because of CR and allografts with chronic CsAT. We studied the cortical inter-
stitial ECM composition of kidney allografts of three groups of patients, ie, patients with chronic 




All kidney allograft biopsies that were performed in our center for clinical reasons > 1 year after 
transplantation, in the period between March 1, 1976, and March 1, 2001, were reviewed. Cases 
that had available frozen-tissue samples and that met the criteria defined below were included. 
Patients with graft artery stenosis or diabetes mellitus were excluded. In addition, biopsy samples 
with histologic signs of de novo or recurrent glomerulonephritis or acute rejection were excluded. 
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The group designated the chronic CsAT group (n = 17) consisted of patients who exhibited pro-
gressive declines in allograft function only after a switch was made from a CsA formulation with 
a lower bioavailability (Sandimmune; Sandoz, Basel, Switzerland) to one with a higher bioavail-
ability (Neoral; Novartis, Basel, Switzerland) (6). A brief period of acute rejection in the early post-
transplantation period was allowed and occurred in eight cases. Before the switch, the patients 
used Sandimmune once daily, aiming at a 24 hr trough level of 100 µg/liter, and demonstrated 
stable graft function for a mean of 5.1 ± 3.4 year. After conversion to twice-daily Neoral therapy, 
a higher target 12 hr trough level of 150 µg/liter was adopted. To reach this level, the mean 
CsA dose was increased from 3.2 to 3.5 mg/kg (6). Nephrotoxicity was not observed in the first 
months after conversion but became evident after 12 monts (6). Biopsies were obtained a mean 
of 2.4 ± 1.2 year after switching. None of the studied biopsies in this group exhibited signs of 
chronic allograft glomerulopathy. No positive staining for C4d in the peritubular capillaries (see 
below) was observed. 
The patient group designated the CR group (n = 12) consisted of patients who exhibited pro-
gressive declines in renal allograft function with a calcineurin inhibitor-free immunosuppressive 
regimen. Immunosuppressive therapy consisted of prednisone and azathioprine. All of these pa-
tients initially demonstrated good allograft function (Table 1). Thirty-three percent exhibited C4d 
positivity in their peritubular capillaries. 
A third group of patients received CsA but their allograft biopsies suggested CR as the cause of 
declines in allograft function. This group, designated the CAN group, consisted of patients with 
progressive declines in renal allograft function and biopsy findings suggesting CR, including arte-
rial intimal fibrosis (n = 15) and/or chronic allograft glomerulopathy with glomerular basement 
membrane duplication (n = 4). No temporal relationship existed between the loss of function and 
a switch to Neoral for any of these patients. In this group, 21% of the biopsies were positive for 
C4d deposits in the peritubular capillaries. The control group (n = 11) consisted of specimens 
from normal kidneys obtained in autopsies and from normal kidneys that had not been used for 
transplantation for anatomic reasons. 
Clinical and laboratory data were obtained in chart reviews. The collected data included posttrans-
plantation time, allograft age (donor age plus time after transplantation), systolic and diastolic 
blood pressure, number of antihypertensive medications used, creatinine clearance (as estimated 
with the Cockroft-Gault formula), loss of allograft function, proteinuria, and CsA trough levels at 
the time of biopsy. The loss of allograft function was defined as the difference in the creatinine 
clearance measured before the worsening of allograft function, as assessed by the breakpoint in 
the regression lines of 1/creatinine clearance, and the creatinine clearance measured at the time 
of the index biopsy (7). 
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Light Microscopy
After routine staining, the biopsy specimens were coded and reevaluated with light microscopy. 
An experienced pathologist who was blinded with respect to the instituted immunosuppressive 
regimen scored the histopathologic changes. The Banff 97 classification system for histopatho-
logic scoring of allografted kidneys was used (8). 
Immunostaining
The ECM components that were studied were detected with an indirect immunoperoxidase tech-
nique. Staining for each molecule was performed in one session. The primary antibodies used 
were polyclonal mouse anti-human collagen I, anti-human collagen III, and anti-human collagen 
IV (Harlan Sera-Lab, Sussex, UK) and monoclonal mouse antibodies against the collagen IVα3 
(Wieslab, Lund, Sweden) and laminin β2 (C4) (Developmental Studies Hybridoma Bank, Iowa 
City, IA) chains. The secondary antibody consisted of peroxidase-coupled rabbit anti-mouse IgG 
(Dako, Glostrup, Denmark). Cryostat sections (4 µm) were mounted on glass slides, dried for 1 h, 
and stored at -20°C until used. The tissue was fixed with 4% formalin for 10 min. After block-
ing of endogenous peroxidase by incubation for 30 min with 0.1% H2O2 in phosphate-buffered 
saline, the sections were incubated for 30 min with 5% normal rabbit serum. The sections were 
then incubated with the primary antibody for 1 h, followed by incubation with the secondary 
antibody for 30 min. The sections were incubated for 10 min in a filtered solution of 0.5 mg/ml 
diaminobenzidine and 0.02% H2O2 and were then incubated for 5 min with 0.05% CuSO4 in 
saline solution. Counterstaining with hematoxylin was performed for 15 s. Between all steps, the 
slides were rinsed with phosphate-buffered saline. 
Immunofluorescence staining for C4d was performed on untreated slides, as described previously 
(9). Mouse anti-C4d (Quidel, San Diego, CA) was used as the primary antibody (9). The secondary 
antibody was FITC-conjugated goat anti-mouse Ig (Sigma Chemical Co., St. Louis, MO). Staining 
was independently evaluated by two authors (KK and ME), who were blinded with respect to the 
diagnoses. A previously described scoring method was used (10). 
Image Analysis
After immunostaining, the slides were coded and analyzed in a blinded manner. Digital image 
analysis was performed with a Zeiss microscope equipped with a full-color 3CCD camera (DXD 
950p; Sony Corp., Tokyo, Japan) and KS-400 image analysis software, version 3.0 (Zeiss-Kontron, 
Eching, Germany). This method of digital image analysis has been validated and demonstrated to 
be highly reproducible (11,12). Images of the renal cortex of each biopsy specimen were obtained 
and analyzed with the aid of automated script protocols (macros) developed in our department. 
Recording and analyses of images were performed with fixed settings. The software allowed 
censoring of regions of noninterest. Larger vessels and glomeruli were omitted from the analyses. 
The deposition of each ECM component was determined in each biopsy sample by calculation of 
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the percentage of surface area stained by the indicator dye, relative to the total surface area. The 
degree of deposition was assessed by evaluation of the entire renal cortex, with a minimum of 
five microscopic fields per biopsy sample (at x200 magnification). 
The biopsy specimens that were stained for the laminin β2 and collagen IVα3 chains were also 
directly evaluated for interstitial or tubular expression of those molecules, by two investigators (RB 
and KK) who were blinded with respect to the diagnoses. In the few cases of discordant scoring, 
decisions were reached by consensus. 
Statistical Analyses
Statistical analyses were performed with SPSS for Windows software (SPSS, Inc., Chicago, IL). 
One-way ANOVA was used for comparisons of continuous variables with normal distributions. 
Either a Bonferroni or Games-Howel post hoc procedure was used when appropriate. The Mann-
Whitney U test was used to compare continuous variables that were not distributed normally. 
The data are expressed as mean ± SD or mean ± SEM, as indicated. In a general linear model, 
values were adjusted for differences in the loss of allograft function and creatinine clearance at 
the time of biopsy. Correlations between the degree of deposition of individual ECM components 
and the clinical characteristics of the patients were evaluated with the Pearson correlation test. 
P < 0.05 was considered statistically significant. Using a receiver-operating characteristic curve, 
we determined the cutoff point of the percentage of staining for the various ECM molecules that 
predicted the presence of CR with the best combination of sensitivity and specificity. 
Results
Patient Data
The clinical characteristics of the patients are presented in Table 1. The mean age of the allo-
grafted kidney was lower for the patients with CR, compared with the patients with chronic CsAT 
or CAN. The loss of creatinine clearance was greater for the patients with CR. The time after 
transplantation, BP values, number of antihypertensive drugs prescribed, and creatinine clear-
ance at the time of biopsy were similar among the groups. No difference in CsA trough levels was 
observed between the groups receiving CsA. 
Light-Microscopic Findings
The chronic histopathologic changes that were observed in the biopsy samples in routine light-
microscopic analyses are summarized in Table 2. The mean interstitial fibrosis scores for the CR 
and CAN groups were significantly higher than that for the chronic CsAT group (CR group versus 
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chronic CsAT group, P = 0.011; CAN group ver-
sus chronic CsAT group, P = 0.001). The tubular 
atrophy scores were higher for the CR and CAN 
groups, but the differences did not reach statisti-
cal significance (CR group versus chronic CsAT 
group, P = 0.422; CAN group versus chronic 
CsAT group, P = 0.159). The percentages of 
global glomerulosclerosis did not differ among 
the groups. The mean peripheral arteriolar hya-
Figure 1. Staining areas (mean ± SEM) for collagen I (A) 
and collagen III (B). CsAT, cyclosporine A nephrotoxicity; CAN, 
chronic allograft nephropathy; CR, chronic rejection. *P < 0.05, 
**P < 0.01.
Figure 2. Immunoperoxidase staining for cortical collagen I 
(A and C) and III (B and D). Representative images of a normal 
control sample (left) and a kidney allograft with CR (right) are 
shown.
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line thickening score for the chronic CsAT group was higher than those for the CR and CAN 
groups, as expected from the case definitions. 
ECM Components
First we studied the typical interstitial collagens, ie, collagen types I and III. The mean areas stained 
for these collagens are presented in Figure 1. 
The collagen I-stained areas were significantly 
increased in the CAN and CR groups, compared 
with the control group, but were not increased 
in the chronic CsAT group (mean area ± SEM for 
the CAN, CR, chronic CsAT, and control groups, 
18.0 ± 2.5, 23.2 ± 4.4, 6.5 ± 1.5, and 3.3 ± 
0.6%, respectively). No significant difference 
was observed between the CAN and CR groups.
The areas stained for collagen III were increased 
in all patient groups, compared with the control 
group (mean area ± SEM for the CAN, CR, chron-
ic CsAT, and control groups, 26.8 ± 2.4, 28.9 ± 
2.7, 16.7 ± 2.1, and 6.9 ± 2.2%, respectively). 
However, the areas of staining were significantly 
greater for the CAN and CR groups, compared 
with the chronic CsAT group. The staining ar-
eas did not differ significantly between the CAN 
and CR groups. Figure 2 presents representative 
Figure 3. Staining areas (mean SEM) for collagen IV (A) and 
the collagen IVα3 chain (B). *P < 0.05, **P < 0.01.
Table 1. Clinical characteristics of the patients studied
Clinical Characteristic
Patient Group
CsA toxicity (n = 17) CAN (n = 19) CR (n = 12)
Time after transplantation (yr) 7.1 ± 3.3 5.5 ± 4.1 5.1 ± 4.3
Allograft age (yr) 51 ± 9 42 ± 15 34 ± 12b
BP, systolic (mmHg) 148 ± 19 154 ± 19 157 ± 22
BP, diastolic (mmHg) 86 ± 5 88 ± 9.7 90 ± 12
No. of antihypertensive medications 1.8 ± 1.1 2 ± 1.2 1.9 ± 1.1
Creatinine clearance (ml/min) 38 ± 12 34 ± 15 32 ± 7
Loss of clearance (ml/min) 26 ± 10 39 ± 19 49 ± 23*
Proteinuria (g/24 h) 1.3 ± 1.5 1.9 ± 1.9 4.0 ± 3.3
CsA trough level (µg/ml) 114 ± 30 113 ± 31
Values are mean ± SEM. CsA – cyclosporine A; CAN – chronic allograft nephropathy; CR – chronic rejection. * P < 0.05, com-
pared with chronic CsA toxicity and CAN groups.
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images of immunostaining for collagen I and III 
in an allografted kidney with CR.
Next we studied whether typical basement 
membrane collagen type IV expression was in-
creased to the extent observed in native kidney 
disease (5). The mean areas of staining for colla-
gen IV were significantly increased in all patient 
groups, compared with the control group, to the 
same degree (mean area ± SEM for the CAN, 
CR, chronic CsAT, and control groups, 10.3 ± 
5.1, 13.3 ± 5.6, 12.2 ± 1.4, and 5.9 ± 1.5%, 
respectively) (Figure 3A). We also compared the 
staining areas for the three types of collagen in 
the three groups of patients. In the CAN and CR 
groups, the areas staining for collagen III were 
greater than those staining for collagen IV (CAN 
group, P < 0.001; CR group, P < 0.01) but did 
not differ significantly from those staining for 
collagen I. In the CsAT group, the area staining 
for collagen III was greater than that staining for 
collagen I (P < 0.001), but no significant differ-
ence was observed in comparison with the area 
staining for collagen IV (P = 0.07).
When we studied biopsies with mild intersti-
tial fibrosis (< 25% interstitial expansion), we 
observed a difference in collagen I staining be-
tween the CsAT group and the CR and CAN 
groups combined (CsAT group, 6.5 ± 6%; CAN/
CR group, 15.5 ± 8.7%; P < 0.05). In this sub-
group with mild fibrosis, there was no difference 
in the time that had elapsed since transplantation (CAN/CR group) compared to the time that 
had elapsed since the Neoral switch (CsAT group). Collagen III and IV staining areas did not differ 
between the CsAT group and the CAN/CR subgroup. A meaningful comparison of biopsies with 
greater degrees of interstitial expansion was not possible because of the small numbers.
Because an earlier report suggested that immunostaining for the α3 chain of collagen IV and 
the β2 chain of laminin could differentiate CR from chronic CsAT (13), we also evaluated these 
Figure 4. Box and whisker plots of the median staining ar-
eas for the laminin β2 chain. The boxes contain 50% of the 
values. The upper and lower borders indicate the 25th and 
75th percentiles, respectively. The upper and lower whiskers 
indicate the highest and lowest values, respectively. The black 
lines in the boxes indicate the medians. No significant differ-
ences were observed among the groups (P values from the 
Mann-Whitney test: CsAT group versus CAN, CR, and control 
groups, 0.847, 0.925 and 0.056, respectively; CAN group ver-
sus CR and control groups, 0.868 and 0.172, respectively; CR 
group versus control group, 0.463). 
Figure 5. Box and whisker plots of the median staining ar-
eas for α-smooth muscle actin (SMA). *P < 0.05, **P < 
0.01, compared with control group. 
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molecules. The areas stained for the collagen IVα3 chain were increased in all patient groups, 
compared with the control group, to the same extent (mean area ± SEM for the CAN, CR, chronic 
CsAT, and control groups, 6.7 ± 1.1, 5.3 ± 1.2, 7.8 ± 0.8, and 1.1 ± 0.3%, respectively) (Figure 
3B). The collagen IVα3 chain was expressed in a normal pattern, namely, at the distal tubular 
basement membrane (TBM), in all three patient groups. No interstitial staining or new expression 
at the proximal TBM was noted. In none of the groups did the areas staining for the laminin β2 
chain change significantly, compared with the control group (Figure 4). However, we occasionally 
observed some new abnormal tubular expression in each of the groups (CsAT group, nine biopsy 
samples, 53%; CAN group, eight samples, 42%; CR group, six samples, 50%). The new expres-
sion was mostly confined to atrophic tubules or tubules surrounded by infiltrate, the proximal 
or distal morphologic features of which were difficult to assess. Less than 1% of tubules were 
affected in these samples, except for one sample in the CsAT group, three samples in the CAN 
group, and two samples in the CR group, in which 1 to 10% of tubules exhibited staining. No 
interstitial staining for the laminin β2 chain was observed, except for faint staining in some areas 
of periglomerular fibrosis. 
We investigated whether the observed qualitative and quantitative differences in the interstitial 
ECM composition in kidneys with CR or chronic CsAT were correlated with the numbers of inter-
stitial myofibroblasts present, as assessed with immunohistologic staining for α-smoothh muscle 
actin (SMA). Increases in SMA staining were observed for all patient groups, compared with the 
control group, but no differences were observed among the patient groups (Figure 5). 
Correlations and Receiver-Operating Characteristic Curve Analysis
Among the three groups of patients, we observed no correlation between the areas of staining 
for the various molecules and the clinical variables of loss of allograft function, time after trans-
plantation, allograft age, creatinine clearance, and proteinuria at the time of biopsy. A positive 
correlation (r = 0.379, P = 0.008) was observed between the interstitial fibrosis scores of all bi-
opsy samples combined and the loss of creatinine clearance at the time of biopsy. The interstitial 
Table 2. Light-microscopic features of the allograft biopsies studied
Histological Feature
Patient Group
CSA Toxicity (n = 17) CAN (n = 19) CR (n = 12)
Interstitial fibrosis score 0.58 ± 0.21 1.76 ± 0.19† 1.65 ± 0.25*
Tubular atrophy score 0.69 ± 0.24 1.36 ± 0.22 1.29 ± 0.29
Arterial intimal thickening score 0.77 ± 0.21 1.48 ± 0.19 1.40 ± 0.25
Allograft glomerulopathy score 0.02 ± 0.17 0.25 ± 0.15 0.33 ± 0.19
Peripheral arteriolar hyalinosis score 1.92 ± 0.12‡ 0 ± 0.11 0 ± 0.15
Global glomerulosclerosis (%) 28.0 ± 7.1 32.5 ± 6.4 24.4 ± 8.4
Values are mean ± SEM; Scored according to the Banff 97 classification system; * P < 0.05, compared with chronic CsA toxic-
ity group; † P < 0.01, compared with chronic CsA toxicity group;  ‡ P < 0.01, compared with CAN or CR group
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fibrosis scores of all biopsy samples combined were also correlated with the areas of staining for 
collagen I and III (r = 0.499, P = 0.001, and r = 0.499, P = 0.002, respectively). A general linear 
model was used to adjust for differences in loss of function and creatinine clearance at the time 
of biopsy among the groups. 
Receiver-operating characteristic curve analysis demonstrated that collagen I staining had the 
best discriminatory value in differentiating CR from chronic CsAT, with a sensitivity of 75% and 
a specificity of 88% at a cutoff value of 13% cortical interstitial staining and with values of 63% 
and 94%, respectively, at a cutoff value of 19% staining. The fraction of the area under the curve 
was 0.92 of the total area (P = 0.001). None of the ratios of the mean staining areas for the stud-
ied molecules proved to be useful for discrimination of CR from chronic CsAT. 
Discussion
The aim of this study was to examine the composition of the cortical interstitial ECM of kidney 
allografts with either CR or chronic CsAT. We wondered whether quantitative and/or qualitative 
differences in ECM accumulation occur. Therefore, we quantitatively compared the deposition of 
several ECM molecules. We chose to study the molecules collagen I, III, and IV, because they are 
known to accumulate in the renal cortical interstitium during native kidney disease (5,14). The 
laminin β2 and collagen IVα3 chains were investigated because an earlier report suggested that 
de novo expression of these molecules at the proximal TBM could differentiate CR from chronic 
CsAT (13). 
In this study, we observed quantitative and qualitative differences in the ECM composition of 
kidney allografts with CR or chronic CsAT. Our results demonstrated that collagen I, III, and IV 
accumulated in the renal cortical interstitium during CR. The most prominent increases were ob-
served for collagen I and III. A similar pattern of ECM deposition was observed in the kidneys of 
patients who likely had CR but were receiving CsA. In the kidneys of patients with chronic CsAT, 
however, only collagen III and IV accumulated significantly. 
Regulation of the renal interstitial ECM composition in vivo is complex and encompasses changes 
in ECM biosynthesis and degradation. In normal kidneys, collagen I and III are observed in the 
blood vessels and the interstitium, albeit in small amounts (Figure 2) (15). Collagen IV is a natural 
component of the glomerular basement membrane and TBM, and its α3 chain is normally ob-
served in the basement membranes of glomeruli and distal tubules (15). Laminin is observed in 
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vessel walls and all basement membranes. The β2 chain, however, is observed only in glomeruli 
and vessel walls (16).
Quantitative data on the ECM composition of the cortical interstitium of human allografts with 
chronic CsAT or CR were lacking. A few studies reported increases in collagen III levels in grafts 
with chronic dysfunction but did not compare changes induced by CR and chronic CsAT (17,18). 
A number of in vitro studies have addressed the effects of CsA on the production of ECM mol-
ecules by renal cells. One study reported that CsA stimulated the production of pro-collagen I 
and IV in cultures of murine proximal tubular epithelial cells and the production of pro-collagen I 
in cultures of murine renal fibroblasts (19). Increases in the cortical expression of collagen I and IV 
were observed in vivo in a rat model of CsAT (20). The deposition of collagen III was not assessed 
in that model, however. Other data on collagen production were derived from a study on cultured 
human cells, which demonstrated an increase in collagen III production by renal fibroblasts when 
they were treated with CsA (21). Studies performed with a monkey renal fibroblast cell line (CV1) 
demonstrated that CsA stimulated the synthesis of type III collagen by a pathway leading to ac-
tivation of the COL3A1 promoter and upregulation of COL3A1 mRNA (22). We observed the in-
creased deposition of collagen III and IV in the interstitium of the cortex of human renal allografts 
as a result of chronic CsAT. In contrast to the results of the study performed in rats, we observed 
no significant increase in collagen I deposition. Although we did not observe a correlation be-
tween the time elapsed since the Neoral switch and the degree of collagen I deposition, we can-
not exclude the possibility that, with time, collagen I would also accumulate during long-term 
chronic CsAT. The difference in collagen I staining between the CsAT and CAN/CR subgroups 
with mild fibrosis suggests that CR may stimulate collagen I accumulation earlier than does CsAT.
In our study, we observed greater expansion of the interstitial space in the CR group, compared 
with the chronic CsAT group, as well as more deposition of collagen type III. The difference in 
interstitial fibrosis could not be explained on the basis of differences in clinical variables, because 
no correlations with those variables were observed.
We wondered whether the differences in ECM deposition between CR and chronic CsAT could 
be explained on the basis of a difference in the numbers of myofibroblasts present. SMA is a 
marker of activated myofibroblasts, which are thought to play a major role in the deposition of 
scar tissue (23). Two earlier reports described increases in interstitial SMA staining in deteriorat-
ing human kidney allografts (17,18). In CR, SMA-positive cell numbers were reported to increase 
with increases in the interstitial area fraction and collagen III deposition (18). In our study, we 
did not observe differences in SMA staining among the CR, CAN, and chronic CsAT groups; all 
samples contained more SMA-positive cells than normal. To explain the greater degree of inter-
stitial ECM deposition during CR, compared with chronic CsAT, a higher rate of collagen produc-
tion by myofibroblasts or a lower rate of ECM degradation by tissue metalloproteinases could be 
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hypothesized. Data derived from a primate model of chronic cardiac rejection support the latter 
hypothesis, because it was demonstrated that the progression of myocardial fibrosis was associ-
ated with increased expression of tissue inhibitor of metalloproteinases 1 and 2 (24). 
We also examined the α3 chain of collagen IV and the β2 chain of laminin. Our results are at vari-
ance with a report by Abrass et al (13), which suggested that a pattern of new expression of those 
molecules at the proximal TBM was specific for CR. In that study, CsAT resulted in the interstitial 
deposition of collagen I and III. Our study differs in the definitions of cases, the antibodies used, 
and the mode of analysis. The study by Abrass et al (13) examined patterns of distribution and 
provided no quantitative data on the investigated molecules. According to Abrass et al (13), col-
lagen I and III are not normally observed in the cortical interstitial area and the collagen IVα3 and 
laminin β2 chains are not expressed at the TBM. However, we and others observed that collagen I 
and III are normally present in the renal interstitium, albeit in small amounts (5,15,25-27). We also 
observed that the collagen IVα3 chain is normally expressed at the distal TBM, as noted earlier 
(16,28). This discrepancy may be related to the different antibodies used. In the study by Abrass 
et al (13), allografted kidneys with rejection exhibited acute rejection; although the authors stated 
that their results also applied to allografts with CR, they did not systematically examine that idea 
and no data were presented. The new expression of the collagen IVα3 and laminin β2 chains at 
the proximal TBM observed by Abrass et al (13) might thus very well be related to tubulitis during 
acute rejection. In our study, we observed sporadic new expression of laminin β2 at the TBM in a 
portion of the biopsy samples in each study group, especially in areas of tubular damage. Staining 
for this molecule did not differentiate CR from chronic CsAT. We observed increased expression 
of the collagen IVα3 chain in the CR, CAN, and chronic CsAT groups but no abnormal distribu-
tion pattern. We observed a small nonsignificant increase in collagen I staining for the chronic 
CsAT group, compared with normal control values. It is possible that a small increase in collagen 
I expression by the patients with chronic CsAT, which was below our detection limit, could have 
resulted in the expression pattern observed in the study by Abrass et al (13). 
In conclusion, we observed a more pronounced fibrotic response in the tubulointerstitium, involv-
ing collagen I and III, in allografts with CR, compared with those with chronic CsAT. Early increases 
in the cortical interstitial deposition of collagen I were more specific for CR. Staining for the col-
lagen IVα3 and laminin β2 chains was not useful for the differentiation of CR from chronic CsAT.
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The kidney is essential for the maintenance of the internal milieu of the body. Filtration of blood in 
the glomerulus is an important part of this process: plasma water is filtered, while most proteins 
and cells are retained. Damage to the glomerulus is often accompanied by proteinuria, the pres-
ence of abnormally high amounts of protein in the urine. Proteinuria presumably contributes to 
the progression of renal disease. At the tissue level, progressive loss of kidney function is mirrored 
by replacement of intact nephrons by scar tissue, a process called fibrosis. Once a critical amount 
of functional tissue is lost, the process of fibrosis is uncoupled from the initial cause of injury and 
becomes self-perpetuating.
Eventually, complete loss of kidney function will necessitate renal replacement therapy, for exam-
ple through kidney transplantation. Also kidney grafts are subjected to injurious stimuli that drive 
the development of progressive loss of function. Peritransplant injuries, an immunologically hos-
tile environment, and damage related to donor events contribute to development of progressive 
fibrosis in most renal allografts. Again, the pace of progression may be quickened by proteinuria. 
In this thesis, we focused on two relatively distinct topics: the pathophysiology of proteinuria, and 
the recognition of causes of renal function loss in kidney transplants using a molecular approach. 
In this chapter, the results of the studies described in the previous chapters are summarized and 
placed in a broader perspective.
Proteinuria
A central but still incompletely answered question in renal physiology is how the glomerular filtra-
tion barrier works. Complementary to this is the question what the mechanisms of glomerular 
dysfunction are, in other words, what causes proteinuria. The different layers of the glomerular 
filtration barrier, the endothelium, the glomerular basement membrane (GBM), and the podo-
cytes, are all assumed to contribute to the correct function of the glomerulus. 
Role of podocytes in proteinuria
In recent years there has been much interest in the role of the podocyte in the development 
of proteinuria. Indeed, podocytes show conspicuous changes during proteinuria: their normal 
complex shape is simplified through foot process effacement, and their delicate cytoskeleton is 
condensed at the basal part of the cell (1). This first morphological clue towards a role of podo-
cyte changes in the development of proteinuria was further substantiated by the discovery of the 
genetic base of several congenital or hereditary forms of the nephrotic syndrome. Genes involved 
in the development of these diseases were found to be expressed exclusively in podocytes. This 
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led to the hypothesis that these genes and the proteins that they code for might also be involved 
in the development of acquired forms of proteinuria (2,3). Initial studies seemed to affirm this 
hypothesis: in acquired primary proteinuric diseases such as minimal change disease, FSGS, and 
membranous nephropathy, expression of the podocyte-protein nephrin was decreased (4-6). Ani-
mal studies also pointed towards a decrease in podocyte-associated proteins in proteinuria (7,8). 
However, most of these studies described the expression of single molecules, and only studied 
either mRNA or protein level. We wanted to further investigate the expression of a group of 
podocyte-associated molecules and relate the expression to ultrastructural and clinical parame-
ters. This was the subject of a study described in chapter 2. We studied the glomerular mRNA and 
protein expression of several podocyte-associated molecules in patients with acquired nephrotic 
syndrome, in comparison to that of patients with a non-glomerular type of kidney disease and 
healthy controls. In line with previous studies, we indeed found a decrease in podocyte proteins 
in proteinuric diseases. At the same time, our results suggested that the loss of protein expression 
is not the actual cause of proteinuria: comparison of protein expression levels with the podocyte 
ultrastructure made clear that the decreased protein staining could be explained by the loss of 
the specialized podocyte architecture. Also, mRNA synthesis was not impaired, but was even 
increased in most diseases, suggesting a compensatory reaction of the podocyte to proteinuria. 
A shortcoming of the study presented in chapter 2 may be that support for the hypothesis, that 
the podocytes show a compensatory reaction to proteinuric damage, is merely derived from 
correlations rather than from mechanistic studies. Furthermore, most cases of human acquired 
proteinuric diseases already showed high levels of proteinuria at the time the renal biopsy was 
taken. This limited the evaluation of changes in podocyte ultrastructure and mRNA and protein 
expression in time. To gain insight in the processes at play in the podocyte during the develop-
ment of proteinuria, we used a rat model of proteinuria development, the Dahl salt-sensitive 
(Dahl SS) rat. These animals spontaneously develop proteinuria starting from week 4 to 6 of age, 
and later on show progression to glomerulosclerosis. We were interested in the early phases of 
proteinuria, and studied these rats at different time points between their 2nd and 10th week of 
life. The results of the studies in rats, outlined in chapter 3, were in line with the concept raised 
from the study in patients, ie, the changes in expression of podocyte-associated molecules do not 
precede proteinuria. Instead, despite clear disturbance in glomerular permselectivity as measured 
by urinary albumin and protein excretion at ten weeks of age, expression of most podocyte-
associated molecules was still normal at that time, except for some segmental loss of nephrin 
staining intensity. Podocyte ultrastructural changes, most importantly foot process effacement, 
also notably lagged behind the development of proteinuria. 
The one exception to this general pattern of undisturbed protein expression of studied podo-
cyte-associated molecules was the expression of the glycoprotein podoplanin. We observed a 
segmental loss of podoplanin expression already at four weeks of age – the first time point at 
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which proteinuria could be detected. Others have already related the expression of podoplanin to 
proteinuria. In fact, the name podoplanin has been derived from the fact that loss of this protein 
occurs simultaneously with foot process effacement (pes planus (lat.) – flat feet). Also, injection 
of anti-podoplanin antibodies in rats induces proteinuria (9-11). In our study, the decrease in ex-
pression of podoplanin in proteinuric rats compared to non-proteinuric rats was only seen at the 
protein level. There were no genetic differences between Dahl SS and SHR rats in the podoplanin 
gene that could explain proteinuria, and podoplanin mRNA expression was even increased in 
Dahl SS rats compared to SHR rats. Furthermore, glomeruli from proteinuric Dahl SS rats with and 
without podoplanin loss showed similar podoplanin mRNA expression levels. 
Next to expression in the glomerular podocyte, podoplanin is found in several other cells, includ-
ing alveolar cells, osteoblasts, skeletal muscle, and lympathic endothelial cells (12). Also, a number 
of tumors show expression of podoplanin. Several investigators have described that podoplanin 
is coupled to ezrin, which connects podoplanin to the actin cytoskeleton (13,14). Ectopic expres-
sion podoplanin in cultured cells induces the formation of filopodia (actin-supported cell exten-
sions), a finding that would explain the migratory behavior of podoplanin-positive tumor cells 
(15). Podoplanin exerted this actin-remodeling effect via downregulation of the activity of RhoA, 
a member of the Rho family of GTPases that are involved in the (dis)assembly of actin filaments. 
Whether podoplanin has a similar role in podocytes has not been established yet. We did not 
find differences in ezrin mRNA expression, but this does not rule out a difference in ezrin-podo-
planin interaction at the level of post-translational protein modifications. With respect to actin-
remodeling properties of podoplanin, we did find a trend towards upregulation of RhoA mRNA 
expression in podoplanin-negative glomeruli. This suggests a link between podoplanin expression 
and actin cytoskeleton regulation. In analogy to the role of podoplanin in filopodia formation via 
RhoA downregulation, we hypothesize that a decrease of podoplanin protein expression in the 
podocytes facilitates RhoA-mediated foot process effacement and actin cytoskeleton condensa-
tion. Further evidence that may confirm or disprove such theories will have to come from in-vivo 
manipulation of podoplanin, for example through genetic approaches. Podoplanin knock-out 
mice die of respiratory failure soon after birth (16). Kidney defects or maldevelopment in these 
mice have not been studied. Investigations into the role of podoplanin in the podocyte will ben-
efit from mouse models with a podocyte-specific podoplanin deletion. The Cre-loxP system for 
podocyte-specific gene manipulation is available (17,18), but mice with podoplanin-floxed al-
leles have not been generated yet. It would be of interest to see whether such podocyte-specific 
podoplanin deficient mice develop a normal glomerulus, and whether they show proteinuria or 
increased disease susceptibility. 
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Glomerular gene expression in proteinuria
Besides our study of the expression of well-known podocyte-associated molecules, we also evalu-
ated proteinuria-associated changes in glomerular mRNA expression through a more genome-
wide approach. The results of these experiments are described in chapter 4. We used microarray 
chips to which we hybridized RNA isolated from glomeruli of 4- and 6-week-old Dahl SS and 
SHR rats. These time points were chosen because they flank the period in which the first onset 
of proteinuria is seen. 
For the evaluation of the array results we used several approaches. In recent years, the labs of 
Kreutz et al (19-21) and Garrett et al (22,23) have identified quantitative trait loci (QTLs) that are 
linked to the development of albuminuria in the Dahl SS rat. We evaluated which of the differen-
tially expressed genes between the two rat strains localized to these genome regions. Secondly, 
we used pathway analysis software to evaluate which pathways were represented in the list of 
differentially expressed genes. Furthermore, we compiled a list of genes known to be differen-
tially regulated upon protein loading in renal proximal tubular epithelial cells, and evaluated the 
glomerular expression of these genes using the global test (24).
We identified around 500 genes that were differentially regulated between the two strains, re-
gardless of the time point. Of these, 115 genes were located on the previously defined QTLs. 
We validated the expression of hedgehog interacting protein (Hip, 5.2 times upregulated), and 
polyamine modulating factor binding protein 1 (Pmfbp1, -2.8 times downregulated). Both genes 
are located on the albuminuria QTL on rat chromosome 19.
Pathway analysis indicated an overrepresentation of cytoskeleton-associated genes in the list of 
differentially expressed genes. This may be explained by the fact that proteinuria is known to oc-
cur simultaneously with changes in the cytoskeletal organization of podocytes. During the first 
8 weeks of life of the rats we did not observe widespread differences in the ultrastructure of the 
podocyte foot processes, meaning that already early in the development of proteinuria there is a 
change in podocyte cytoskeleton regulation that is not reflected in morphological alterations. We 
studied the GTPase dynamin in more detail. Recent studies by the Reiser group have indicated 
a role for dynamin in the organization of the podocyte actin cytoskeleton (25). In their studies, 
a cathepsin L-dependent cleavage of dynamin resulted in proteinuria. Our results contrast their 
findings, as we found an increase in dynamin mRNA expression in proteinuric rats, as well as 
an increased dynamin protein expression in proteinuric patients. The models in which dynamin 
was studied differ considerably between our study and that from the group of Reiser. We used 
a model of spontaneous development of proteinuria, while in the animals studied by Reiser and 
colleagues, proteinuria was induced by LPS or puromycin aminonucleoside. This may indicate that 
the regulation of dynamin in diverse proteinuric conditions is different. Similar to the concept 
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discussed in chapter 2, the upregulation of dynamin may reflect a compensatory response to the 
development of proteinuria. 
Furthermore, we found that a group of genes that is differentially expressed upon protein loading 
in proximal tubular epithelial cells is also differentially regulated in glomeruli of proteinuric versus 
non-proteinuric rats. This finding substantiates the hypothesis that increased glomerular protein 
filtration has a toxic effect on the podocyte. In support of this, a double staining of albumin and 
desmin (a podocyte stress marker) showed a colocalization of albumin resorption droplets and 
desmin accumulation in the podocytes.
Further perspectives on proteinuria
Development of proteinuria
In trying to delineate the pathogenesis of proteinuria, the problem is that regardless which com-
ponent of the glomerular filtration barrier is damaged the result is proteinuria. This shows that the 
different components of the glomerular filtration barrier are all indispensable, or are functionally 
interlinked. This functional relationship is obvious. For example, podocytes and endothelial cells 
produce the GBM they rest on; malfunction of either of these cell types may lead to a disturbed 
glomerular filtration that is difficult to trace back to a single cause. Adding more complexity to 
the situation is the fact that the filter may only work properly if not only the static components 
are correctly assembled, but also the glomerulus is perfused under physiologic conditions, as this 
may lead to the in vivo formation of pressure and charge gradients that have a role in glomerular 
permselectivity. This complex interrelationship between different static and functional compo-
nents of the filtration barrier makes it difficult to establish their respective roles in glomerular 
filtration in health and disease. Thus, the question at which site glomerular filtration takes place, 
posed more than 30 years ago by Farquhar in a review on the topic (26), is at present still valid. 
Still, while important parts of the pathogenesis of proteinuria remain uncharted, some pathways 
can be delineated. The perspectives on the different components of the glomerular filtration bar-
rier will be discussed below.
Interplay between proteinuria and foot process effacement
Podocytes are involved in every type of glomerular proteinuria. Clearly, in congenital proteinuric 
diseases podocyte damage is often the cause of proteinuria (see chapter 1). However, the studies 
in this thesis suggest a secondary role for podocytes in acquired proteinuric diseases: Foot pro-
cess effacement only developed after the occurrence of proteinuria (chapter 3); podocyte protein 
expression remained normal in the initial stages of proteinuria (chapter 3), changes in expression 
of most podocyte-associated proteins (except that of podoplanin in the Dahl SS rat) seemed to be 
related to the extent of foot process effacement (chapter 2, 3). Also, a selected number of genes 
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that are expressed in tubular epithelial cells as a consequence of proteinuria also show up in the 
glomerular gene expression profile in proteinuric rats (chapter 4). 
Several studies in the literature support the above findings. Some authors have argued that foot 
process effacement affects the process of glomerular filtration in such a way that proteinuria oc-
curs (27), ie, foot process effacement is the cause of proteinuria. However, most recent studies 
are compatible with foot process effacement as a result of proteinuria. Jarad et al (28) found that 
proteinuria preceded podocyte foot process effacement in a podocyte specific laminin β2 knock-
out mouse model. Kalluri described three different mouse models that show proteinuria without 
initial foot process effacement (29). Van den Berg et al have found that foot process effacement is 
not related to the amount of proteinuria in minimal change disease: patients in remission showed 
a foot process width that was comparable to that in patients with overt proteinuria (30).
Possible causes and consequences of foot process effacement
The exact cause of foot process effacement remains unclear. Also, the role of this process in 
glomerular function is not completely understood. Dysfunctional podocyte proteins, changes in 
GBM composition, protein overload, and (lack of) stimulation by growth factors and cytokines 
have all been related to the development of foot process effacement. Clearly, this is a final com-
mon pathway of podocyte damage. 
From a teleological point of view, several interesting hypotheses have been raised to explain what 
goal foot process effacement could serve: Reiser et al found that podocytes express the co-stimu-
latory molecule CD80. Increased expression of CD80 was found in conjunction with the develop-
ment of proteinuria. This suggested to them that podocytes might have a role in immunological 
danger signaling, and display a stereotypical reaction to such ‘danger signals’. In a review on this 
novel aspect of podocyte function, Reiser and Mundel suggested that foot process effacement 
and the resulting increase in glomerular permeability could have a role in increasing the speed 
with which noxious molecules are cleared from the blood (31,32). However, it is questionable 
whether this theory is valid in situations where, as outlined above, foot process effacement fol-
lows the development of proteinuria.
Another interesting theory (33) suggests that foot process effacement is a way for the glomerulus 
to counteract the increased intracapillary pressure. The different shape of the podocyte, with the 
reinforced cytoskeleton, would then increase stability at the expense of permselectivity. 
The role of the GBM and the endothelium
The glomerular basement membrane supports the endothelial cells and podocytes. The GBM per 
se seems to have only a minor role in glomerular filtration, although it is indispensible for the cor-
rect function of podocytes and endothelial cells. For example, patients with Pierson’s syndrome, 
caused by a mutation in the laminin β2 gene, are proteinuric and show foot process effacement. 
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As discussed in chapter 1, the glomerular filtration barrier is size- and charge selective (34). With 
regard to the charge selectivity, several recent studies have excluded an important contribution of 
heparan sulphate proteoglycans (HSPGs) in the GBM to charge selectivity (35-37).
If HSPGs do not contribute to the charge selectivity, what role do they serve? In embyrogen-
esis, HSPGs have a role in distribution and gradient formation of signaling molecules such as 
hedgehogs. One could speculate that in a similar fashion HSPGs in the GBM have a role in the 
interaction between endothelial cells and podocytes. Indeed, such interaction may be important 
in glomerular filtration: Collino et al have recently shown that stimulation of endothelial cells 
with plasma of women with pre-eclampsia releases factors that subsequently influence podocyte 
homeostasis (38).
Recent studies have shown that the endothelial fenestrations, traditionally thought to be too 
large to contribute to ultrafiltration, may be filled with proteoglycans that could contribute to 
the charge and size selectivity of the glomerulus. With this in mind, it is to be expected that the 
glomerular endothelium has a more important role in glomerular function and dysfunction than 
hitherto acknowledged. A pivotal role of endothelial cells would provide a plausible explanation 
for the proteinuria that is seen in diseases with systemic endothelial dysfunction, such as diabetes 
and pre-eclampsia. Furthermore, it would explain the observation that proteinuria is a risk factor 
for the development of cardiovascular diseases, as both diseases can be traced back to endothe-
lial dysfunction (39).
If indeed the endothelium is an important first barrier to protein, this would mean that in a nor-
mal situation the GBM and podocytes are not exposed to plasma-concentrations of protein. Loss 
of endothelial function would lead to a higher concentration of protein in the GBM and thus at 
the basal cell membrane of the podocyte foot processes. From this perspective, our observation 
of a proteinuria-related gene response in the glomerulus (chapter 4) would be compatible with 
the hypothesis that size selectivity of the glomerulus is located in the endothelium. Indeed, when 
we directly stained frozen slides of Dahl SS and SHR rats with anti-rat-IgG antibodies, we found 
an increased distribution of rat IgG in the GBM and podocytes of the proteinuric Dahl SS rat (re-
sults not shown). This is in line with observations in humans with proteinuric kidney diseases (40). 
In this regard, it is of interest that the Dahl SS rat later develops hypertension, which has been 
regarded as another symptom of endothelial dysfunction (41). Thus, future studies should focus 
on the role of the endothelium in the glomerular filtration barrier. There have been reports of 
genes expressed specifically in glomerular endothelium (42). This offers opportunities to generate 
transgenic mouse models that can be used to dissect the role of the endothelium in glomerular 
filtration.
189proteinuria > further perspectives on proteinuria
Consequences of proteinuria
While the cause of proteinuria remains unclear, the consequences of proteinuria are more clear, at 
least from an epidemiologic point of view: proteinuria is associated with the progression of renal 
disease. This raises the question whether proteinuria solely reflects the damage inflicted upon the 
nephron, which leads to further progression of renal disease, or that proteinuria forms a part of 
the pathogenetic process that underlies progression of renal disease. 
As discussed in chapter 1, reports from the literature on this topic are controversial: some stud-
ies bring support for the possibility that proteinuria causes tubulointerstitial inflammation and 
fibrosis, others dispute such a link. In either scenario, impaired glomerular function precedes 
the development of progressive renal disease. Our findings (chapter 4) are compatible with the 
hypothesis that proteinuria is part of the pathogenetic process that leads to further loss of glo-
merular function, as judged from gene-expression patterns and histological studies. Others have 
described TGF-β and endothelin upregulation in podocytes in response to proteinuria (43,44), 
also pointing towards a deleterious role of proteinuria in glomerular function. 
Once a critical amount of cells and tissue are damaged, loss of glomerular function becomes self-
perpetuative. This vicious cycle seems to be present at two levels in the kidney: At the tissue level, 
loss of nephrons increases the workload for the remaining nephrons, leading to hyperfiltration 
and further damage. At the cellular level, loss of podocytes increases the demands placed on the 
remaining cells. Wiggins et al described a sequence of podocyte hypertrophy, adaptation, and 
decompensation in rats with a relative shortage of podocytes (45). The stress placed on podocytes 





There has been a clear progress in renal transplant survival rate over the years. Especially the first 
year graft-survival rate has increased tremendously through improvements in immunosuppressive 
medication, and monitoring of its administration. Nowadays, failure of renal grafts on the long 
term is the most limiting factor in transplantation. 
Multiple causes may underlie the development of chronic allograft dysfunction, but the eventual 
course is common with respect to clinical and histopathological presentation: there is a slow de-
cline in renal function, mirrored at the histopathological level by the presence of vascular damage, 
tubular atrophy, and interstitial fibrosis. Different causes of chronic allograft dysfunction often 
coexist, thus forming a spectrum of injurious stimuli ranging from the toxicity of excess immuno-
suppressive medications to an ongoing activity of the immune system. An important question is 
how to distinguish the separate causes in patients that present with non-specific clinical and his-
topathological features. The studies described in chapters 5 and 6 aimed to address this question 
using molecular techniques. In chapter 5, we studied the mRNA expression levels of growth fac-
tors and extracellular matrix (ECM) proteins that are important in the development of interstitial 
fibrosis. In chapter 6, we used an immunohistochemical analysis of the composition of interstitial 
fibrosis. These markers were studied using biopsies from renal allografts of patients from two 
well-defined groups, each representing one side of the spectrum of different causes of chronic 
allograft dysfunction: the chronic rejection group and the chronic cyclosporine A toxicity group. 
The composition of the ECM is continuously modified through synthesis and degradation. Previ-
ous experiments have shown that pathophysiological changes could be observed more readily 
at the level of synthesis, through measurement of mRNA expression levels of molecules known 
to be involved in the disease process. As described in chapter 5, differences in mRNA expression 
of laminin β2 and TGF-β could differentiate between chronic rejection and chronic cyclosporine 
A toxicity as a cause of chronic allograft dysfunction. The mRNA expression levels of these pro-
teins were higher in the cyclosporine toxicity group than the chronic rejection group. Analysis of 
laminin β2 and TGF-β mRNA expression levels allows recognition of the actual cause of allograft 
dysfunction with a specificity and a sensitivity of over 85 percent.
In chapter 6, we have shown that the accumulation of collagen I in interstitial fibrotic lesions 
was more pronounced in patients with chronic rejection than that in patients with chronic cyclo-
sporine toxicity. Collagen III and IV accumulated in the interstitial area to similar extent in either 
disease. Others have found that an ectopic production of certain collagen and laminin chains 
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could help differentiate chronic rejection and cyclosporine A toxicity (46). In our studies, we could 
not confirm that such abnormal expression patterns can distinguish between different disease 
entities. 
Besides showing that molecular techniques can have additive value in dissecting the cause of 
clinically non-specific disease processes, the studies in chapter 5 and 6 may give insight in patho-
physiological processes that play a role in transplant rejection. For example, from the results of 
the studies described in chapter 6, we propose that chronic rejection seems to stimulate the accu-
mulation of collagen I more pronounced in comparison to chronic cyclosporine toxicity. However, 
the mRNA expression of collagen I was similar in both diseases, suggesting a role for an impaired 
collagen I degradation process in chronic rejection. The increased laminin β2 mRNA expression in 
chronic cyclosporine A toxicity might point to a stimulatory effect of cyclosporine A production 
on the synthesis of this transcript. Since vascular damage may stimulate laminin β2 production, 
the increase in laminin β2 expression could also reflect a more pronounced vascular damage in 
cyclosporine A toxicity compared to chronic rejection. It should be stated, however, that such 
pathophysiological hypotheses are based only on correlative evidence.
An interesting finding in these studies was that increased mRNA expression does not consistently 
coincide with protein accumulation. Besides differences in protein degradation, changes in mRNA 
processing and regulation as well as variations in the efficiency of mRNA to protein translation 
may account for these differences. It has been shown that even in unicellular eukaryotic organ-
isms such as yeast there is no direct correlation between mRNA expression and protein abun-
dance (47). This again underscores the complexity of regulation of processes such as fibrosis, and 
indicates that some caution in extrapolating result between different levels of organization (i.e. 
mRNA, protein, cellular, and tissue level) is warranted.
The studies described in chapters 5 and 6 were performed in two well-selected populations of 
chronic cyclosporine A toxicity and chronic rejection, representing both ends of the spectrum of 
chronic allograft dysfunction. Although this was helpful in defining a molecular profile that could 
distinguish both causes, the strict selection of patients also forms the main limitation of the study. 
As stated before, in many patients, different causes of allograft dysfunction coexist, and there-
fore we cannot draw conclusions with regard to the usefulness of these markers in non-selected 
patient groups. In the future, the markers studied by us and by others should be tested in larger, 
unselected patient groups.
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Further perspectives on molecular diagnosis of chronic allograft 
dysfunction
What is to be expected from future research of molecular markers in chronic allograft dysfunc-
tion? The search for markers that can identify specific causes of allograft dysfunction, or distin-
guish progressors from non-progressors in an early phase of the disease, will be instrumental 
in better treatment of patients with a renal transplant. Also, further knowledge of the precise 
pathogenesis of allograft dysfunction will be needed to improve the transplant survival rate. Use 
of epidemiologic data may be helpful in selecting which pathogenetic processes to study. These 
topics will be discussed below. 
Microarray studies would seem to be a logical next step in the search for markers of specific 
causes and mechanisms of chronic allograft dysfunction. Several microarray studies have already 
been reported, which have offered important new information with regard to pathophysiological 
processes in acute rejection (48,49). For example, the role of humoral rejection became more ap-
parent in the microarray-based analysis of acute rejection biopsies. However, microarray-assisted 
investigations in chronic allograft dysfunction have so far not brought up new pathophysiological 
concepts. Hotchkiss et al (50) studied expression profiles in biopsies from patients with chronic 
allograft dysfunction with and without arteriolar hyalinosis (suggesting a different pathogenesis), 
but could not find a different expression profile, most likely because the disease had already 
passed to a chronic phase or final common pathway, in which specific causes are obscured by a 
general process of renal deterioration. This shows that molecular markers that identify specific 
causes of allograft dysfunction, or distinguish progressors from non-progressors should be found 
early in the disease process, when specific therapies can still be installed. This leads to another 
problem: a relatively long follow-up time is required to determine early markers that reliably pre-
dict the long-term outcome. During this long follow-up time, immunosuppressive regimens may 
change, and as a result the markers found in these long-term studies may not be applicable for 
the next ‘generation’ of patients. For example, the studies described in chapters 5 and 6 included 
only a few patients that used tacrolimus, while at the moment most transplant centers have 
switched from cyclosporine to tacrolimus as a calcineurin inhibitor. Thus, frequent changes in 
immunosuppressive regimes will impede the evaluation of long-term effects of medication, and 
even more, the evaluation of the usefulness of early molecular markers for long-term prediction 
of transplant course. 
Instead of focusing on the specific characteristics of processes leading to chronic allograft dys-
function, another fruitful strategy could be to identify the pathophysiological processes that 
chronic allograft dysfunction shares with other chronic kidney diseases. Again using microarray, 
Donauer et al found that the expression profiles of native end-stage renal disease kidneys were 
similar to those of transplanted kidneys with chronic allograft dysfunction (51). Also, risk factor 
193transplantation > further perspectives on molecular diagnosis of chronic allograft dysfunction > other lines of investigation
analysis makes clear that not only immunological mechanisms but also non-immunological inju-
ries are of importance for long-term graft survival. Donor age, for example, is one of the most 
important risk factors, accounting for approximately 30 percent of the variation in long-term 
graft survival (52). Together, these microarray experiments and epidemiological data may indicate 
that the pathophysiologic mechanisms that drive the deterioration of kidney grafts are similar 
to those at play in progressive disease of native kidneys. A more extensive comparison of both 
would enhance the insight in the nature of disease progression. 
Other lines of investigation
Because the kidney is transplanted into an immunologically hostile environment, one is inclined to 
think that the processes leading to transplant failure are predominantly immunological in nature. 
The notion that native and transplanted kidneys follow similar final pathways to renal function 
loss shows that this is not necessarily the case, and also illustrates the importance of the use of 
epidemiologic data. In this regard, it is interesting to note that there are considerable differences 
in the reported kidney allograft half-life between continents. In the USA, reported 10-year renal 
allograft survival rates amount to about 40 percent, while in France, 10-year survival rates of 61 
percent were reported (53). Also the allograft survival in the Netherlands is considerably longer 
than that in the USA (M. Mallat and Y. Sijpkens, personal communication). It would be interesting 
to compare on an international level the risk factors of chronic allograft dysfunction in order to 
explain this divergence of long-term survival rates. 
As outlined previously, proteinuria is a risk factor for progression of renal disease in both native 
and transplanted kidneys. Because proteinuria, in contrast to risk factors such as donor age, 
may be to some extent modifiable, it would be interesting to study the role of proteinuria in the 
progression of allograft dysfunction. Post-transplant proteinuria may be caused by certain immu-
nosuppressive drugs (54), and also in the setting of post transplant glomerulopathy. The latter is a 
specific pathophysiological process that is thought to mainly involve humoral rejection (see chap-
ter 1), primarily resulting in endothelial damage (55). The proteinuria that is seen in most cases 
of chronic allograft dysfunction is not necessarily caused by immunological mechanisms. Instead, 
more general mechanisms that are also involved in native glomerular disease and ageing may be 
at play. The glomerular damage seen with increased age is thought to be a podocyte disease: as 
a result of several stress factors, podocytes are lost and cannot be replaced. This is suggested to 
be the starting point of a final common pathway to glomerulosclerosis, and via pathways lined 
out in the introductory chapter on nephron loss (56). Prevention of age-related podocyte damage 
may in part be accomplished by reducing hypertension, preferably with angiotensin II blockers 
that have a kidney- or podocyte-protective effect. Similar to the ‘accelerated senescence’ concept 
proposed by Halloran to explain pathophysiologic processes in transplanted kidneys, glomerular 
aging may also progress faster in transplantation. Attempts to limit other podocyte-damaging 
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factors, for example through blood pressure control using angiotensin II blockers, may thus prove 
beneficial in native and transplanted kidneys alike. 
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Door het afvoeren van afvalstoffen houdt de nier de samenstelling van het bloed, en daarmee 
het vocht dat alle cellen van het lichaam omspoelt, constant. Dit proces vindt plaats in de on-
geveer een miljoen functionele eenheden van de nier, de nefronen. Het eerste onderdeel van een 
nefron is de glomerulus, een kluwen van haarvaatjes. De wand van deze haarvaatjes function-
eert voor het bloed dat er doorheen stroomt als een filter: water, zouten en kleine moleculen 
passeren de bloedvatwand probleemloos, terwijl cellen en eiwitten in het bloedvat achterblijven. 
Per dag wordt er door alle nefronen gezamenlijk ongeveer 180 liter ultrafiltraat of pre-urine ge-
produceerd. Dit ultrafiltraat stroomt vervolgens door naar het tweede onderdeel van het nefron, 
de tubulus. In de tubulus wordt het grootste gedeelte van het ultrafiltraat heropgenomen. Door 
variatie in de mate van opname en door actieve uitscheiding van stoffen reguleert de tubulus de 
precieze samenstelling van de urine, en daarmee ook die van het bloed. 
Een belangrijk probleem dat bij veel nierziekten optreedt is proteïnurie, het verlies van eiwit in de 
urine. Waar normaal gesproken het filter van de nier zeer slecht doorgankelijk is voor eiwitten, 
is bij patiënten met proteïnurie deze selectiviteit verminderd aanwezig en worden er belangrijke 
hoeveelheden eiwit in de urine uitgescheiden. Het eerste deel van dit proefschrift gaat over de 
oorzaak en kenmerken van proteïnurie, met een speciale focus op de rol van een van de celtypes 
in de glomerulus, namelijk de podocyt. 
Het optreden van proteïnurie is gecorreleerd aan het verlies van nierfunctie. Vergaand verlies 
van nierfunctie maakt nierfunctievervangende therapie of niertransplantatie noodzakelijk. De 
levensduur van een niertransplantaat is echter eveneens beperkt. Een belangrijk aspect in deze 
beperking van levensduur is dat zowel activiteit van het immuunsysteem als immuunsuppressie 
schadelijk kunnen zijn voor de nier, zonder dat deze eenvoudig van elkaar zijn te onderscheiden. 
Het tweede deel van het proefschrift is erop gericht met behulp van moleculaire technieken een 
onderscheid te maken tussen verslechtering van nierfunctie ten gevolge van een tekort of juist 
een overdosering van immuunsuppressie.
Proteïnurie
Om de vraag te beantwoorden hoe het komt dat het glomerulaire filter niet goed functioneert, 
dat wil zeggen, hoe proteïnurie ontstaat, volgt hier eerst een beschrijving van de normale bouw 
en werking van de glomerulus. Het glomerulaire filter bestaat uit drie onderdelen. Van binnen 
naar buiten bezien allereerst het endotheel, vervolgens de glomerulaire basaalmembraan en 
tenslotte de glomerulaire epitheelcel of podocyt. Glomerulair endotheel is voorzien van fenestra-
ties en is in zijn geheel bedekt met een glycocalyx, een negatief geladen oppervlak van proteo-
glycanen. Deze glycocalyx draagt mogelijk bij aan de ladingsselectiviteit van glomerulaire filtratie. 
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De glomerulaire basaalmembraan ondersteunt de cellulaire componenten van het filter, maar 
heeft zelf waarschijnlijk slechts een beperkte rol in het filtratieproces. De podocyt tenslotte is de 
epitheelcel van de glomerulus en vormt de buitenbekleding van de capillairen.
Het is gebleken dat beschadiging van elk van de onderdelen van het filter afzonderlijk al leidt tot 
een slechtere filtratiefunctie en proteïnurie. In de afgelopen jaren heeft vooral de podocyt sterk 
in de belangstelling gestaan. De eerste twee studies beschreven in dit proefschrift concentreren 
zich op de rol van de podocyt in proteïnurie.
De podocyt en proteïnurie
De podocyt is een sterk gedifferentieerde cel met een opvallende architectuur: het cellichaam 
bevindt zich in de urineruimte en is met de capillairwand verbonden via talloze uitlopers, ‘voet-
pootjes’ of pedikels genaamd (foot processes). Pedikels van aangrenzende podocyten zijn in 
elkaar vervlochten als de vingers van een hand. Tussen de pedikels is een membraantje uitges-
pannen, het filtratiespleetdiafragma. Al sinds de jaren ‘50 is bekend dat de podocyt opvallende 
veranderingen ondergaat als er proteïnurie bestaat: de fraai vormgegeven pedikels platten af en 
de podocyt verandert van een complex vertakte cel in een simpele platte epitheelcel. Onduidelijk 
was hoe dit proces van obliteratie van epitheelcelpedikels zich verhoudt tot het ontstaan van 
proteïnurie. 
In de afgelopen tien jaar is de moleculaire biologie van de podocyt meer opgehelderd. De meest 
baanbrekende ontdekking was de beschrijving van nefrine, het eiwit dat een belangrijk bestand-
deel vormt van het filtratiespleetdiafragma. Patiënten die geen nefrine maken (zoals patiënten 
met het congenitaal nefrotisch syndroom van het Finse type) hebben al voor de geboorte ern-
stige proteïnurie en moeten veelal in hun eerste levensjaar een niertransplantatie ondergaan 
om in leven te blijven. Sinds de ontdekking van nefrine is een hele reeks van podocyt-specifieke 
eiwitten ontdekt, die van groot belang zijn voor het correct functioneren van de cel (zie figuur 
3 van hoofdstuk 1). Het ontbreken van deze eiwitten, vaak in het kader van zeldzame erfelijke 
aandoeningen, is gerelateerd aan proteïnurie, nierfunctie verlies en uiteindelijk nierfalen. 
Terwijl de zeldzame erfelijke aandoeningen die gepaard gaan met proteïnurie een grote rol heb-
ben gespeeld bij de opheldering van de podocyt biologie, komt proteïnurie het meest voor in 
het kader van op latere leeftijd verworven aandoeningen. De vraag die wij ons in dit proefschrift 
hebben gesteld is of deze podocyt-specifieke eiwitten, evenals in aangeboren nierziekten, een 
belangrijke rol spelen in verworven vormen van proteïnurie. 
In de studies beschreven in hoofdstuk 2 hebben wij geanalyseerd hoe een aantal podocyt-spec-
ifieke eiwitten tot expressie komen in verworven nierziekten. Hiervoor hebben wij biopten van 
patiënten met nierziekten bestudeerd, waarbij wij ons de vraag stelden hoe tijdens proteïnurie 
de podocyt verandert op morfologisch niveau en op eiwit- en mRNA niveau. Het bleek dat de 
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expressie van podocyt-specifieke eiwitten in de glomerulus was verminderd, terwijl de expressie 
van mRNA coderend voor diezelfde eiwitten veelal was toegenomen. Beide processen waren 
gerelateerd aan de mate van obliteratie van epitheelcelpedikels. Deze combinatie van veranderin-
gen wijst mogelijk op een secundaire rol van de bestudeerde podocyt-specifieke eiwitten in het 
ontstaan van proteïnurie in verworven nierziekten. 
Het gebruik van menselijk materiaal brengt als belangrijke beperking met zich mee dat biopten 
pas genomen worden op het moment dat een nierziekte zich al heeft gemanifesteerd. Daardoor 
kan het verloop van podocyt-veranderingen in de tijd niet gevolgd worden. Om beter inzicht te 
krijgen in dit tijdsverloop hebben wij gebruik gemaakt van een diermodel, namelijk de Dahl salt-
sensitive (Dahl SS) rat. Ratten van deze stam ontwikkelen vanaf ongeveer vier tot zes weken na 
geboorte spontaan proteïnurie, wat uiteindelijk uitmondt in het verlies van nierfunctie. In hoofd-
stuk 3 zijn de resultaten beschreven van een analyse van de regulatie van podocyt-specifieke 
eiwitten gedurende de ontwikkeling van proteïnurie in de Dahl SS rat. De resultaten van deze 
studie kwamen overeen met de bevindingen uit hoofdstuk 2: ondanks het bestaan van proteïnu-
rie was er geen vroege verandering in expressie van de meeste podocyt-specifieke eiwitten op 
mRNA en eiwit niveau. Verder bleek ook dat de ontwikkeling van obliteratie van epitheelcelpe-
dikels niet synchroon loopt met de ontwikkeling van proteïnurie: het eerste moment waarop wij 
significante obliteratie waarnamen was tien weken na de geboorte, terwijl wij proteïnurie al na 
vier tot zes weken konden aantonen.
De enige uitzondering op het algemene patroon van onveranderde eiwitexpressie tijdens de 
ontwikkeling van proteïnurie was de expressie van het glycoproteine podoplanine. Dit eiwit bleek 
tegelijkertijd met het ontstaan van proteïnurie in segmenten van de glomerulus sterk verminderd 
tot expressie te komen. Deze veranderingen waren progressief: op latere leeftijd was de afname 
van podoplanine eiwitexpressie meer uitgesproken. Wij konden de veranderingen in podoplanine 
eiwitexpressie niet verklaren door een verandering in mRNA expressie, noch door een genetisch 
verschil tussen de stammen.
Uit andere studies naar de rol van podoplanine is bekend dat expressie van dit eiwit leidt tot 
vorming van zogenaamde filopodia, celuitlopers die een zekere biologische gelijkenis vertonen 
met glomerulaire epitheelcelpedikels. De moleculaire mechanismen die bij de vorming van filopo-
dia een rol spelen zijn gedeeltelijk opgehelderd. Wij hebben geconstateerd dat de processen die 
betrokken zijn bij vorming van filopodia juist tegenovergesteld zijn aan de processen die plaats-
vinden in de glomerulus van de proteïnurische Dahl SS rat. Dit wijst er mogelijk op dat de podocyt 
via vermindering van podoplanine-expressie beschikt over een mechanisme om obliteratie van 
epitheelcelpedikels te bewerkstelligen.
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Glomerulaire genexpressie in proteïnurie
In hoofdstuk 4 wordt de nadruk verlegd van het onderzoeken van bekende genen en eiwitten 
naar het vinden van nieuwe genen die betrokken zijn bij het ontstaan van proteïnurie. Voor deze 
studie hebben wij gebruik gemaakt van een microarray techniek. Met deze techniek kan in een 
experiment de expressie van zo’n 30.000 genen in kaart worden gebracht. Wij hebben deze 
techniek toegepast op dezelfde rattenstammen als die bestudeerd werden voor de experimenten 
beschreven in hoofdstuk 3. Voor de analyse gebruikten wij geïsoleerde glomeruli verkregen op 
tijdstippen juist voor en juist na de ontwikkeling van proteïnurie. 
Uit de microarray analyses bleek, dat zo’n 500 genen verschillend tot expressie komen tussen de 
beide stammen. Ongeveer een kwart van deze genen ligt op chromosoom regio’s die al eerder in 
verband waren gebracht met de ontwikkeling van proteïnurie in de Dahl SS rat. Een aantal van 
de genen die verschillend tot expressie komen hebben wij verder onderzocht. Naast dat wij ons 
gericht hebben op individuele genen is het ook mogelijk groepen van genen, waarvan bekend is 
dat die een bepaalde samenhang hebben, te analyseren. Uit pathway analyses kwam naar voren 
dat al vroeg in de ontwikkeling van proteïnurie genen betrokken bij het cytoskelet verschillend 
tot expressie komen tussen beide stammen. Hoewel dus pas relatief laat na de ontwikkeling 
van proteïnurie herkenbare ultrastructurele veranderingen optreden in de podocyt, is al vroeg 
in de ontwikkeling van proteïnurie de moleculaire aanzet tot verandering van het cytoskelet 
waarneembaar.
Uit de literatuur is bekend dat in tubulus epitheelcellen een profibrotische en proinflammatoire 
reactie opgewekt wordt wanneer deze cellen worden blootgesteld aan hoge concentraties ei-
wit. Wij vroegen ons af of een dergelijke reactie ook in de glomerulus waarneembaar is. Uit de 
literatuur hebben wij een groep genen samengesteld die in tubulusepitheel onder invloed van 
proteïnurie veranderd tot expressie komen. Gebruik makend van de zogenaamde ‘global test’ 
konden wij aantonen dat het expressiepatroon van deze groep genen ook in de glomerulus op 
een zelfde manier verandert. Dit wijst er mogelijk op dat de verhoogde passage van eiwitten door 
de glomerulus schade toebrengt aan de glomerulus en een eerste stap is in de verdere teloorgang 
van de glomerulus.
Proteïnurie is gecorreleerd met achteruitgang van nierfunctie en kan uiteindelijk leiden tot een 
verlies van nierfunctie die dialyse of niertransplantatie noodzakelijk maakt. De chronische proble-
men bij niertransplantatie vormden het tweede onderdeel van dit proefschrift.
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Transplantatie
In de nu ongeveer 40-jarige geschiedenis van niertransplantatie is de levensduur van getrans-
planteerde nieren sterk verbeterd. Deze vooruitgang is met name toe te schrijven aan verbeterde 
immuunsuppressie waardoor afstoting in de eerste fase na transplantatie beter te behandelen is. 
Daarmee zijn de problemen rond niertransplantatie in de loop der jaren verschoven van de acute 
naar de chronische fase: op langere termijn gaat de nierfunctie van een niertransplantaat on-
vermijdelijk achteruit. De gemiddelde overleving van getransplanteerde nieren ligt in Nederland 
rond twaalf jaar, in de Verenigde Staten rond acht jaar. Maar waar er nog altijd verbetering wordt 
behaald in de transplantaatoverleving na een jaar, blijft de lange termijn overleving al jarenlang 
ongeveer gelijk.
De achteruitgang van getransplanteerde nieren op lange termijn wordt geweten aan meerdere 
factoren: beschadigingen opgelopen rondom de operatie (ischemie, reperfusieschade), laaggra-
dige maar steeds aanwezige activiteit van het immuunsysteem en toxische effecten van immuun-
suppressieve medicatie. Al deze mechanismen kunnen, vaak gelijktijdig, bijdragen aan verlies van 
functioneel nierweefsel, en daarmee verlies van nierfunctie. Opmerkelijk is dat deze oorzaken, 
hoe verschillend ze ook zijn, leiden tot een ziektebeeld met vergelijkbare klinische en histolo-
gische kenmerken: de nierfunctie, meestal gemeten als kreatinineklaring, loopt langzaam terug 
en in biopten van getransplanteerde nieren wordt een beeld van tubulusatrofie en ophoping van 
extracellulaire matrix gezien – een proces van verbindweefseling van nefronen.
Moleculaire analyse van lange termijn nierfunctieverlies
De doelstelling van de studies beschreven in hoofdstuk 5 en 6 was om met moleculaire analyses 
beter onderscheid te kunnen maken tussen de verschillende oorzaken die ten grondslag liggen 
aan lange termijn dysfunctie van niertransplantaten. Daarbij hebben wij gebruik gemaakt van 
twee goed gedefinieerde groepen van patiënten met chronische transplantaat dysfunctie. Een 
groep bestond uit patiënten met bewezen nierschade ten gevolge van toxische effecten van 
immuunsuppressieve medicatie (de cyclosporine toxiciteit groep), de andere groep bestond uit 
patiënten met nierschade ten gevolge van een chronische afweerreactie (de chronische rejectie 
groep).
Bij de selectie van markers hebben wij ons gericht op de extracellulaire matrix. De extracellu-
laire matrix verandert voortdurend van samenstelling doordat haar componenten steeds worden 
aangemaakt en afgebroken. Uit vorige studies is gebleken dat het kwantificeren van de aanmaak 
van de extracellulaire matrix een voorspellende waarde kan hebben voor de mate van fibrosering. 
In hoofdstuk 5 hebben wij onderzocht of de mate van mRNA expressie van extracellulaire matrix 
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genen kan helpen onderscheid te maken tussen patiënten met chronische rejectie en die met 
cyclosporine toxiciteit. Wij hebben gevonden dat de mRNA expressie van laminine β2 en TGF-β 
verhoogd is in nierweefsel van patiënten met cyclosporine toxiciteit ten opzichte van dat van 
patiënten met chronische rejectie. De verschillen in mRNA expressie maken een onderscheid tus-
sen beide ziekteprocessen mogelijk met een sensitiviteit en specificiteit van meer dan 85 procent.
In hoofdstuk 6 hebben wij met behulp van immunohistochemie en digitale beeldanalyse de mo-
leculaire samenstelling van de renale extracellulaire matrix bestudeerd. Wij hebben gevonden dat 
een aantal componenten van de extracellulaire matrix, te weten collagenen III en IV, in gelijke 
mate voorkomen in chronische rejectie en cyclosporine toxiciteit. De expressie van collageen I was 
echter hoger in chronische rejectie ten opzichte van cyclosporine toxiciteit, in een mate die een 
redelijk betrouwbaar onderscheid tussen beide ziekteprocessen mogelijk maakte.
Naast dat deze studies behulpzaam zouden kunnen zijn in het onderscheiden van ziekteproces-
sen, kunnen ze ook gebruikt worden om meer inzicht te krijgen in de ontstaanswijze van deze 
aandoeningen. Chronische rejectie gaat gepaard met een sterkere ophoping van collageen I in 
de extracellulaire matrix. Tegelijkertijd was de mRNA expressie van collageen I niet verhoogd in 
biopten van patiënten met chronische rejectie. Dat zou erop kunnen wijzen, dat de afbraak van 
deze collageen keten verminderd plaatsvindt. Laminine β2 mRNA komt verhoogd tot expressie 
bij cyclosporine toxiciteit. Aangezien laminine in de vaatwand voorkomt zou deze verhoogde 
expressie kunnen passen bij een vaatwandbeschadiging ten gevolgen van cyclosporine, hetgeen 
in overeenstemming is met het bestaan van arteriolaire hyalinose als histologisch kenmerk van 
cyclosporine toxiciteit. Niettemin moet worden opgemerkt dat dergelijke hypothesen berusten op 
correlaties, niet op een direct bewijs.
Een belangrijke beperking van de studies in hoofdstuk 5 en 6 wordt gevormd door de manier 
waarop de patiëntengroepen zijn geselecteerd. Zoals eerder aangegeven kan verlies van nier-
functie na transplantatie veroorzaakt worden door een groot aantal mechanismen die meestal 
gelijktijdig optreden. Uit het spectrum van patiënten met een chronisch verlies van nierfunctie 
na transplantatie zijn alleen de uitersten – de groep patiënten met chronische afstotingen en die 
met juist een toxisch overschot aan immuunsuppressie – geselecteerd. De patiënten van wie de 
nierfunctie is achteruitgegaan door een combinatie van deze en andere factoren zijn in de analy-
ses van hoofdstuk 5 en 6 buiten beschouwing gelaten. Om te zien of de gevonden moleculaire 
markers ook daadwerkelijk toepasbaar zijn in de patiënten die zich niet in de uitersten van het 
spectrum bevinden zullen de markers eerst getest moeten worden in een grotere en ongeselect-
eerde patiëntenpopulatie.
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In de hierboven beschreven studies hebben wij gezocht naar markers die kunnen bijdragen in 
het onderscheiden van specifieke ziekteprocessen. Om dit onderscheid te kunnen vertalen in 
een betere manier van behandeling is het noodzakelijk dat deze markers relatief vroeg in het 
ziekteproces worden geanalyseerd. Daarin schuilt mogelijk een toekomstig probleem: omdat 
de ontwikkelingen in immuunsuppressieve medicatie nog altijd doorgaan wisselt de medicatie 
waaraan patiënten in de eerste fase na transplantatie zijn blootgesteld met enige regelmaat. 
Patiënten die nu in de chronische fase na niertransplantatie zijn hebben daarom vaak een andere 
vorm van immuunsuppressie gehad dan de huidige generatie patiënten met een niertransplanta-
at. Het is daarom de vraag of de markers gevonden in de huidige chronische patiënten populatie 
toepasbaar zijn bij toekomstige patiënten.
Verder is het van belang te constateren dat de processen die leiden tot achteruitgang van nier-
functie na transplantatie niet allemaal van immunologische aard zijn. Niet-immunologische fac-
toren zijn evenzeer van belang en bijvoorbeeld donorleeftijd verklaart al zo’n 30 procent van de 
variatie in het beloop na transplantatie. De mechanismen waardoor nierfunctieverlies optreedt 
in niertransplantaten zijn dan ook niet wezenlijk verschillend van die mechanismen waardoor in 
‘natieve’ nieren de nierfunctie verloren gaat. Een centraal proces is de zogenaamde hyperfiltratie: 
zodra, onverschillig door welke reden, een kritisch aantal nefronen verloren is gegaan, neemt de 
belasting van de overgebleven nefronen zodanig toe (hyperfiltratie), dat dit op zichzelf schadelijk 
is en leidt tot een verder verlies van nefronen. Zo vormt een specifiek ziekteproces het beginpunt 
van een stereotiep proces van verder nierfunctieverlies dat is losgekoppeld van de oorspronkelijke 
oorzaak. 
Een van de factoren die samenhangen met progressie van nierziekten is proteïnurie. Anders dan 
andere risico- of progressiefactoren (zoals bijvoorbeeld leeftijd of, in transplantatie, HLA-mis-
matching) is proteïnurie beïnvloedbaar. Een betere kennis van de pathofysiologische mechanis-
men van proteïnurie kan dus betekenis hebben voor de behandeling van nierziekten in zowel 







Figure 2. Organization of the 
podocyte cytoskeleton. A cross 
section through a capillary loop 
shows that the capillary is sur-
rounded by podocyte foot pro-
cesses. At the base of the capillary, 
contractile mesangial cell filaments 
are attached (a). A schematic view 
from above shows that the foot 
processes sprout perpendicular 
to the major processes. The cyto-
skeleton of the major processes is 
composed of microtubuli, to which 
the actin-based cytoskeleton of 
the foot processes is attached 
(b). In (c) and (d) the lateral view 
capillary wall is depicted, corre-
sponding to the w-x and y-z line 
in (b), respectively. Adapted from 
(14), used with permission from 
The American Physiological Society 
and the author.
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Figure 3. Molecular organization of the podocyte foot process. Two podocyte foot processes with the bridging slit diaphragm 
are depicted, resting on the glomerular basement membrane (GBM). The central part of the foot process is the actin cytoskeleton 
(indicated in the left foot process with grey dots), which is reinforced by synaptopodin and α-actinin-4, and has contractile prop-
erties as a result of myosin fibers (M). Connected to the cytoskeleton are several molecules that reside in the negatively charged 
apical membrane, including podocalyxin (PC) via NHERF2 (N) and ezrin (Ez), and podoplanin (not depicted). At the basal mem-
brane, the actin cytoskeleton is connected to the GBM via dystroglycan (linking utrophin (U) to agrin), and the integrin-complex 
(integrin, talin-paxillin-vinculin (TPV), integrin linked kinase (ILK), focal adhesion kinase (FAK)). The slit diaphragm is composed 
of nephrin, NEPH-proteins, P-cadherin, and FAT, and the slit diaphragm domain contains several molecules that play a role in 
the anchoring and signaling of the slit diaphragm (TRPC6, podocin, CD2AP (CD), β-catenin (cat), and ZO-1 (Z)). The podocyte 
has several receptors, including the angiotensin II receptor AT1. See text for further details. Adapted from (505) and (506), with 
permission from Elsevier, Lippincott Williams & Wilkins, and the author.
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Figure 4. Transplant glomerulopathy. Transplant glomeru-
lopathy is seen in chronic rejection. This glomerular lesion is 
characterized by a duplication of the glomerular basement 
membrane (inset).
Figure 5. C4d deposition. In chronic humoral rejection, the 
complement split product C4d remains covalently bound to 
endothelial cells. This picture shows widespread deposition of 
C4d in peritubular capillaries.
Figure 6. Arteriolar hyalinosis. Nodular depositions of hyaline 
material are seen in the media of arterioles, indicating the 
presence of chronic CNI toxicity.
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Figure 2. Staining pattern of nephrin, podocin, podocalyxin, and CD2-associated protein (CD2AP) in normal and diseased 
human kidney sections. Nephrin (A), podocin (B), and podocalyxin (C) show a podocyte-like staining pattern in normal glomeruli 
as visualized by an immunohistochemical diaminobenzidine staining. The staining pattern of nephrin is more dispersed than that 
of podocin and podocalyxin, which show a fine glomerular basement membrane (GBM)-like line along the capillary loops of 
the glomerulus. CD2AP, visualized with immunofluorescence, shows a GBM-like staining pattern (D). In diseased situations, the 
staining for nephrin (E; minimal change disease), podocin (F; focal segmental glomerulosclerosis [FSGS]), and podocalyxin (G; 
FSGS) is less intense, and nephrin and podocin stainings show a more granular staining pattern. CD2AP staining shows no clear 
differences between control (D) and diseased tissue (H; diabetic nephropathy). Magnification x 400.
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Figure 4. Immunohistochemistry of podocyte proteins. Despite marked proteinuria, 10-week-old Dahl SS rats showed normal 
expression of α-actinin-4, α3 integrin, α-dystroglycan, ezrin, nephrin, podocin, podocalyxin, synaptopodin, and WT1. Original 
magnification: x 400.
Figure 5. Podoplanin protein expression in Dahl SS glomeruli was progressively lost in a focal and segmental fashion. Loss of 
podoplanin protein expression was first seen in 4-week-old Dahl SS rats and increased thereafter. In contrast, podoplanin protein 
expression remained normal in SHR rats throughout the time course of the study. The upper row of images in A shows podoplanin 
staining in Dahl SS rats at the indicated time points and in a 10-week-old SHR rat. The lower row of images in A shows desmin 
staining in Dahl SS rats at the indicated time points and in a 10-week-old SHR rat. Starting at 6 weeks, desmin expression was 
visible in the extramesangial areas of Dahl SS glomeruli. Expression level increased with age. No change in desmin expression 
was observed in aging SHR rats. Sequential sections of the kidney of a 10-week-old Dahl SS rat stained with anti-rat podoplanin 
antibodies, anti-podocin antibodies, and with PAS show that loss of podoplanin is not related to morphological alterations 
observed by light microscopy or to alterations in podocin expression (B). Nephrin expression was diminished sporadically in 
segmental parts of glomeruli, but only in 10-week-old Dahl SS rats (C). Original magnification: x 400.
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Figure 7. Podoplanin (red) and desmin 
(green) were costained in kidney sections 
from 8-week-old Dahl SS rats. Normal glom-
eruli show desmin expression in renal blood 
vessels and glomerular mesangium and podo-
planin expression in podocytes. Desmin and 
podoplanin did not colocalize (A). In glomeruli 
that showed segmental loss of podoplanin ex-
pression, increased desmin expression was 
observed in the podoplanin-negative areas (B). 
Original magnification: x 630.
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Figure 4. Co-immunostaining of desmin (green) and albu-
min (red) in a section of an 8-week-old proteinuric Dahl 
SS rat. Increased desmin expression is seen mostly in areas 
with extensive albumin accumulation. Desmin (A), albumin 
(B), merge (C).
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Figure 3. Immunohistochemical stainings for laminin β2 (A to C) and transforming growth factor-β (TGF-β) (D to F). In 
control tissue laminin β2 staining was observed in the glomerular basement membrane and in cortical vessels (A). In chronic 
rejection (B) and cyclosporine A (CsA) toxicity (C), expression of laminin β2 was observed in the tubular basement membrane. 
TGF-β staining was sporadically observed in glomeruli and tubuli of controls (D). In chronic rejection (E) and CsA toxicity (F), some 




Figure 2. Immunoperoxidase staining for cortical collagen I (A and C) and III (B and D). Representative images of a normal 
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